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Preface 
 
The work reported in this thesis is focused on three main projects that underpin 
my research activity during the PhD program. The topics discussed, despite unrelated 
each other, share a common feature: all of them regard unconventional and not yet 
drugged targets or diseases. Consequently, my effort has been the discovery of 
molecules of therapeutic relevance in order to satisfy current challenges in medicinal 
chemistry and improve the number of available candidates for addressing unmet 
medical need. 
During the first two years and a half of my PhD I carried out my research activity 
at Università del Piemonte Orientale (UPO), where I primarily worked on the 
discovery of small molecules that targeting the Store-Operated Calcium Entry 
machinery and on the discovery of indoleamine 2,3-dioxygenase 1 inhibitors. Then, 
I moved to the University of California San Diego (UCSD) at Skaggs School of 
Pharmacy and Pharmaceutical Sciences where I had the opportunity to join for six 
months the Prof. C. Ballatore’s research group, as a visiting PhD student. During this 
experience I worked on the development of heparan sulfate enhancers for the 
treatment of hereditary multiple exostoses.  
Parts of this thesis have been reported in the literature and have been co-written 
by the author of this thesis: 
- Riva, B. #; Griglio, A. #; Serafini, M.; Sanchez, C.; Aprile, S.; Di Paola, R.; 
Gugliandolo, E.; Alansary, D.; Biocotino, I.; Lim, D.; Grosa, G.; Galli, U.; 
Niemeyer, B.; Sorba, G.; Canonico, P.L.; Cuzzocrea, S.; Genazzani, A.; Pirali, T. 
Pyrtriazoles, a novel class of Store-Operated Calcium Entry modulators: discovery, 
biological profiling and in vivo proof-of-concept efficacy in acute pancreatitis. J. 
Med. Chem. 2018, 61, 9756-9783. 
Contents 
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- Griglio, A.; Torre, E.; Serafini, M.; Bianchi, A.; Schmid, R.; Coda Zabetta, G.; 
Massarotti, A.; Sorba, G.; Pirali, T.; Fallarini, S. A multicomponent approach in the 
discovery of indoleamine 2,3-dioxygenase 1 inhibitors: synthesis, biological 
investigation and docking studies. Bioorg. Med. Chem. Lett. 2018, 28, 651-657. 
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1.1. The Store-Operated Calcium Entry 
1.1.1. The origin of the “capacitative calcium entry” 
hypothesis  
Calcium is an intracellular second messenger that plays a fundamental role in the 
human organism. The vast array of functions mediated by Ca2+ includes gene 
expression, cell proliferation, differentiation and apoptosis. Cytosolic [Ca]2+ is very 
low (100-200 nM) compared to extracellular [Ca]2+ (2-5 mM). Calcium is stored in 
intracellular organelles (endoplasmic reticulum, sarcoplasmic reticulum and Golgi 
apparatus) and in the presence of specific signals is able to diffuse through the cell 
membranes and enter the cytoplasm. Consequently, the increase of cytoplasmic 
[Ca]2+ levels can be a result of two different mechanisms: the release of intracellular 
organelles-Ca2+ stores or the influx of extracellular [Ca]2+ through [Ca]2+ permeable 
ion channel located to the plasma membrane.1  
The Store-Operated Calcium Entry (SOCE) is a unique mechanism that combines 
these two phenomena. Indeed, given that Ca2+-pumps and exchangers are located on 
both plasma and intracellular organelles membranes to extrude Ca2+ from the 
cytosol, it would be expected that the intracellular organelle pool would be soon 
depleted. It was already back in 1986 that Jim Putney, a pioneer of the cross-talk 
between the endoplasmic reticulum (ER) and the plasma membrane, formalized the 
hypothesis that a phenomenon known as “capacitative calcium entry” would exist 
that allows entry through the plasma membrane to refill the depleted organelles.2 The 
key experiment to exemplify capacitative calcium entry, or Store-Operated Ca2+ 
Entry (SOCE), as it is referred to nowadays, is depicted in Figure 1. In brief, 
emptying of the ER/SR store leads to opening of a plasma membrane channel 
through which Ca2+ can flow back in the cell. These two processes can be dissected 
by adding Ca2+ to the extracellular solution after the intracellular stores are depleted. 
Chapter 1 
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Nevertheless, the exact molecular mechanism behind this phenomenon has been 
elusive for a long time. 
 
 
Figure 1. Representative trace of Store-Operated Calcium Entry (SOCE). 
1.1.2. Orai and STIM: the key players of the process 
During the last decade the principal components of SOCE were identified and 
consist of Ca2+-sensors on the ER membrane (STIM proteins) and plasma membrane 
Ca2+-channels (Orai channels).3 
STIM proteins are single-span membrane proteins, highly conserved across 
species. Two members of the family have been described, STIM1 and STIM2, of 
which the former appears more expressed.4  
Orai channels reside on the plasma membrane channel and three members of the 
family (Orai1, Orai2, and Orai3) have been identified, with Orai1 being the most 
abundant.5 Structural information on Orai and STIM proteins is relatively scarce. 
Only the crystal structure of Orai1 from Drosophila melanogaster, which shares 73% 
sequence identity with human Orai1 within its transmembrane region, has been 
described at 3.35 Å resolution.6 
Moreover, it is important to stress that other crucial proteins participate in the 
SOCE process, including the transient receptor potential canonical channels 
(TRPC).7 
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After the discovery of the key molecular components of SOCE mechanism 
intense efforts were pursued in order to understand how STIM and Orai interact each 
other. Now it is well known that emptying of calcium from the endoplasmic 
reticulum causes a conformational change in STIM. After oligomerization and 
translocation to the plasma membrane, STIM interacts with Orai and causes the 
opening of the channel with subsequent calcium influx and a current known as ISOC 
(Figure 2).8 
 
 
 
Figure 2. Scheme illustrating the mechanism and the molecular choreography of SOCE. 
Taken from Ma, G. et al. Nat. Commun. 2015, 6, 1-14. 
1.1.3. The pathophysiologic role of SOCE 
Capacitative calcium entry, mediating the ISOC current,
9 is not solely a 
replenishment mechanism, but also encodes cellular signals per se, regulating 
cytokine production, gene expression, cell growth, proliferation, differentiation and 
even cell death. Therefore, dysfunctions in this cellular event are implicated in a vast 
range of human disorders including allergy,10 thrombosis,11 cancer,12 inflammatory 
bowel disease13 and acute pancreatitis14, pointing to SOCE as a druggable target for 
developing novel therapies. 
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The Store-Operated Ca2+ Entry is an important Ca2+ influx pathway in many non-
excitable cells (immune cells, platelets and skeletal muscles) while it plays a minor 
role in other cell types. 
Among the several diseases characterized by a hyperactivation of SOCE 
mentioned before there is acute pancreatitis. This disease is caused by the 
intracellular premature activation of pancreatic pro-enzymes, packaged into 
zymogen granules inside the acinar cells. Briefly, what happens is that excessive 
Ca2+ release from intracellular stores is followed by excessive entry of Ca2+ from the 
interstitial fluid and subsequent pro-enzymes activation which results in necrosis and 
inflammation. Recently, Gerasimenko et al. have shown that the pharmacological 
blockage of SOCE in vitro protects against palmitoleic acid ethyl ester (POAEE)-
induced necrosis of pancreatic acinar cells.14 Yet, it has been reported that GSK-
7975A and CM128 were protective in three separate models of chemically-induced 
acute pancreatitis demonstrating that the use of SOCE inhibitors could be a potential 
strategy to treat this disease which is life-threating and currently lacks effective 
treatment.15 
Importantly, very recently, mutations in genes encoding STIM or Orai proteins 
have been related with the development of rare genetic disorders. In particular, loss-
of-function genes mutations (LoF) cause a form of severe combined 
immunodeficiency (SCID). By contrast, gain-of-function mutations (GoF) are 
responsible for other three rare diseases: tubular aggregate myopathy (TAM), York 
platelet syndrome and Stormorken syndrome.16 TAM can be re-conducted to GoF 
mutations in either STIM1 and Orai1, and is clinically characterized by variable 
combinations of myalgias, cramps and muscle stiffness.17 York platelet syndrome 
sees blood dyscrasias as the main phenotype and has, so far, only been associated to 
STIM1 mutations.18 Importantly, families with these disorders have been described 
in Italy.19 While the mutations have different clinical presentations, quality of life of 
patients is always severely hampered. Lastly, Stormorken syndrome is a mixture of 
Introduction 
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the first two diseases and associates the myopathic signs described for TAM to mild 
bleeding tendency due to platelet dysfunction.20 All the described disorders related 
to gain-of-function and loss-of-function mutations are currently without therapy and 
therefore a pharmacological modulation of SOCE mechanism can be a potential tool 
to treat these rare diseases. 
1.1.4. Pharmacological modulation of SOCE over the years: 
an overview 
As mentioned above, aberrant activity of SOCE has been associated with a wide 
range of human diseases including immune deficiency, neurodegeneration, muscular 
and cardiovascular disorders as well as cancer progression and rare genetic diseases.  
Specific pharmacological manipulation of SOCE has been challenging over the 
years. For a long time, non-selective agents such as 2-APB,21 CAI 22 and SKF-
9636514 23 have been the primary experimental tools to modulate SOCE. Over the 
years, much interest has been directed at a series of 3,5-bistrifluoromethyl pyrazole 
derivatives, disclosed by Abbott in 2000.24 Specifically, BTP2 (Pyr2, YM-58483) is 
a potent inhibitor, but it has pleiotropic effects on both Orai and TRPC channels.25 
Subsequently, other pyrazoles, identified as Pyrs, have been reported. Among them 
Pyr3, a previously suggested selective inhibitor of TRPC3,26 was shown to inhibit 
both TRPC3- and Orai1-mediated Ca2+ entry. By contrast, two compounds, Pyr6 and 
Pyr10, are able to distinguish to a certain degree Orai and TRPC-mediated Ca2+ 
entry.27 While the initial interest was mainly the discovery of experimental tools to 
gain insights into the role played by SOCE, drug development programs in this 
direction are currently underway.28 In this context, second-generation agents have 
been described with different characteristics in terms of mechanism of action and 
selectivity profile, including Synta66,29 RO2959,30  GSK-7975A31 and the Amgen 
antibody mAb 2C1.132 (Figure 3). 
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Figure 3. Chemical structures of SOCE modulators. 
A growing number of small molecules have been developed so far; however, a 
key limitation in the search for SOCE modulators has been to identify molecules that 
display selectivity together with potency and lack of toxicity. As a result, to date, 
only few compounds have achieved human clinical trials: CM2489 and CM4620 
developed by CalciMedica, RP3128 and RP4010 discovered by Rhizen 
Pharmaceutical and PRCL-02 from PRCL Research Inc. (Table 1). Unfortunately, 
none of them has reached regulatory approval and the advent of novel modulators 
would certainly increase the chances of clinical benefit. 
Interestingly, in silico screening of an FDA-approved drug library has recently 
led to the discovery of five compounds that can potentially serve as leads for future 
development of SOCE inhibitors.28d 
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Name Structure Company Phase Pathology Note 
CM2489 Undisclosed CalciMedica 1 
Moderate to 
severe plaque 
psoriasis 
- 
CM4620 Undisclosed CalciMedica 2 
Acute 
pancreatitis 
- 
RP3128 Undisclosed 
Rhizen 
Pharmaceuticals 
I/IIa Asthma 
Terminated due 
to recruitment 
delays 
RP4010 Undisclosed 
Rhizen 
Pharmaceuticals 
I/Ib 
Relapsed or 
refractory non-
Hodgkin’s 
lymphoma 
- 
PRCL-02 Undisclosed PRCL Research Inc. 1 Plaque psoriasis - 
 
Table 1. SOCE inhibitors in clinical trials. 
Finally, it is important to stress that most of the reported inhibitors in the literature 
(IC50 < 10 µM) display an amide moiety as a common feature in their chemical 
structure. This suggests the hypothesis that the amide linkage could represent a 
pharmacophore for SOCE modulation. Moreover, as it has been speculated that the 
inhibitor GSK-7975A interacts with Orai1, many of the promising molecules 
discovered so far that possess the amide moiety may act in a similar way. 
Nevertheless, further investigations are necessary in order to investigate the exact 
mechanism of action of known SOCE inhibitors.28d 
Besides negative modulators, SOCE potentiating agents have been reported. 2-
APB is a well-known, though not so selective, effector of SOCE, but it may either 
enhance or inhibit the current depending on concentrations,33 while MDEB, another 
borinate compound, has only a potentiating ability on ISOC (Figure 3).
34  
In summary, none of the SOCE modulators available today has widely exceeded 
the selectivity issue and has been approved for clinical purposes; consequently, the 
quest for new and selective agents remains mandatory.  
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1.2. Tryptophan catabolism 
1.2.1. IDO1, IDO2 and TDO: a bird’s eye view  
Tryptophan (Trp) is an essential amino acid that plays an important role in protein 
synthesis and in neurotransmitter serotonin and neurohormone melatonin 
biosynthesis. The major route for Trp catabolism in humans is represented by the 
kynurenine pathway (KP). In this context, the first and rate-limiting step consists of 
the oxidation of L-tryptophan (L-Trp) to N-formyl-L-kynurenine (NFK) which is 
catalysed by three different enzymes belonging to dioxygenases family: indoleamine 
2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2) and tryptophan 
2,3-dioxygenase (TDO). 
IDO1, the well-known member, is an intracellular heme-containing enzyme 
expressed in a vast array of tissues including brain, placenta, stomach, liver, gut, lung 
and cells within the immune system. It recognizes a broad range of substrates (i.e. L-
tryptophan, D-tryptophan, tryptamine, melatonin, serotonin) and it is functionally 
active as monomer. 1 
IDO2 has been recently discovered and share 43% homology at the amino acid 
level with its isoform IDO1. Nevertheless, its physiological role remains unclear.1-2 
TDO functions as an homotetramer and it is predominately expressed in the liver 
although it has also been found in the brain. Its functions include the regulation of 
systemic Trp levels as well as liver Kyn levels. In contrast to IDO1, TDO is 
enantiomer specific, indeed it only catalyzes L-Trp.3 
 
 
 
 
 
Chapter 1 
24 
1.2.2. Targeting tryptophan metabolism for cancer 
immunotherapy 
The tryptophan to kynurenine catabolic pathway plays a pivotal role in both innate 
and adaptive immunity control. IDO’s immunoregulatory effects are mainly 
mediated by dendritic cells (DCs) and involve both Trp deprivation and Kyn 
production, which act on IDO1+ DCs, thus rendering an otherwise stimulatory DCs 
capable of regulatory effects, as well as on T lymphocytes. As a result, IDO1+ DCs 
mediate multiple effects on T cells, including inhibition of proliferation, apoptosis, 
and differentiation towards a regulatory phenotype.4 More in detail, Trp deprivation 
promotes activation of the kinase general control non-derepressible 2 (GCN2) which 
causes inhibition of T-effector cells proliferation. Moreover, reduction of Trp levels 
leads to blockage of master amino acid-sensing kinase (GLK1) and suppression of 
mammalian target of rapamycin complex 1 (mTORC1) with subsequent increase of 
T-effector cells apoptosis. On the other side, increased kynurenines lead to aryl 
hydrocarbon receptor (AhR) activation, a transcription factor involved in cancer 
progression, and increase in immunosuppressive T-regulatory cells (Figure 1).5  
 
Figure 1. Schematic representation of the mechanisms by which IDO1 mediates immune 
escape in tumour microenvironment. Taken from Brochez, L. et al. Eur. J. Cancer. 2017, 
76, 167-182. 
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Actually, IDO1 does not merely degrade Trp and produce Kyn, but it also acts as 
a signal-transducing molecule.6 In particular, its signalling function relies on the 
presence of two immunoreceptor tyrosine-based inhibitory motifs (ITIMs). When 
phosphorylated, ITIMs act as docking sites for distinct molecular partners, that can 
either prolong IDO1's half-life, promoting long-term immunoregulatory effects 
(tyrosine phosphatases, SHPs), or reduce IDO1's half-life (SOCS3 protein), 
favouring inflammatory responses.7  
There is a growing body of evidence supporting that IDO1 plays a crucial role in 
pathological immune escape.3,8 Notably, in cancer, IDO1 contributes to 
immunosuppression in tumour microenvironment and its overexpression is 
correlated with tumour progression, invasiveness and reduced overall survival.3 
Indeed, IDO1 has been shown to be highly expressed in tumours and Ido1 knock-out 
tumour-bearing mice, compared with wild type mice, have lower levels of 
spontaneous metastasis, smaller tumour volume and increased survival time. Most 
importantly, high expression of IDO1 is associated with poor prognosis in various 
human tumours.9 It has been largely demonstrated in animal models that IDO1 
inhibition can break an acquired immune tolerance, significantly increasing the 
immunological responses induced by various chemotherapeutic drugs and 
immunotherapeutic agents.10 
Additionally, scientific evidences that demonstrate TDO overexpression in many 
cancers (i.e. melanomas, brain and breast tumours) have been recently emerging. 
Indeed, in vitro and in vivo studies underline the role played by TDO in promoting 
tumour cell survival and in immune escape mechanism. Most significantly, tumour 
cells can catabolize Trp via TDO instead or in addition to IDO1, suggesting that 
specific inhibition of IDO1 may not be adequate to counteract a decrease in 
tryptophan levels. 
Accumulating proofs indicate that IDO2 mediates autoimmune responses as it is 
expressed in B cells and has a role in modulating autoantibody production. 
Moreover, despite the relationship between IDO2 and cancer has not yet extensively 
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studied, the association between pancreatic adenocarcinoma and gastrointestinal 
cancer and IDO2 overexpression together with IDO1 and TDO has been reported.5b, 
11  
1.2.3. The landscape of IDO/TDO inhibitors  
As mentioned above, IDO1, IDO2 and TDO are emerging as druggable targets in 
cancer immunotherapy as there is a growing body of evidence supporting their 
crucial role in oncological immune escape.3,8 As a result, it is not surprising that the 
well-known enzyme IDO1 has been center-stage as a druggable target in the last 10 
years with great hopes. Indeed, it has been largely demonstrated that IDO1 inhibition 
can break an acquired immune tolerance, synergizing with chemotherapy, 
radiotherapy or other immunotherapeutic agents.10e  
In 2006 the X-ray crystal structure of human IDO1 complexed with 4-PI (a weak 
IDO1 inhibitor) has been solved by Sugimoto et al. suggesting the existence of two 
hydrophobic pockets, named pocket A and pocket B, in the catalytic site of the 
enzyme (Figure 2).  
 
Figure 2. Depiction of the IDO1 active site (PDB code 4PKS): pocket A (turquois), pocket 
B (orange) and the iron binding site (magenta). Taken from Röhrig, U.F. et al. J. Med. 
Chem. 2015, 58, 9421.9437. 
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Since then, several other papers have provided additional structures of the enzyme 
in complex with inhibitors.12 Nevertheless, among the thousands of compounds 
reported in the scientific and patent literature as IDO inhibitors, only five molecules 
to date have reached human clinical trials and no IDO1 inhibitor has been approved, 
confirming that the translation from bench to bedside in IDO inhibition is proving to 
be a big challenge.13 Besides indoximod 14, epacadostat 15 and GDC-0919 16 
(structure not disclosed), very recently PF-06840003 17 and BMS-986205 18 
(structure not disclosed) have entered clinical trials (Figure 3). Unfortunately, the 
recent report at the 2018 ASCO Annual Meeting revealed that epacadostat failed to 
show a clinical benefit in combination to pembrolizumab in unresectable or 
metastatic melanoma.19 In this respect, two nodal points can be associated on the 
reason of the failure: first, the difficulty in the identification of good markers to 
stratify patients that will respond better from IDO inhibition; secondly, recent data 
have shown that IDO2 and TDO mediate natural and acquired resistance to IDO1 
inhibitors. 
 
Figure 3. Chemical structures of IDO1 inhibitors entered onto clinical trial. 
While IDO1 inhibition has been deeply explored, TDO inhibitors pipeline has 
been investigated to a far lesser extent. The indole LM10, a TDO inhibitor developed 
in 2011 by Dolusi et al., displayed a good anti-tumour activity in a preclinical model 
together with good solubility and good bioavailability. 20 However, further 
investigations are required before undergoing clinical trials (Figure 4). The crystal 
structure of human TDO (hTDO) has been recently elucidated making in silico-
guided design of novel inhibitors reliable.21 Indeed, two additional molecules were 
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developed between 2015 and 2016 and include N1-benzyl-1H-naphtho[2,3-
d][1,2,3]triazole-4,9-diones 1 disclosed by Wu et al. and a 3-(indol-3-yl)pyridine 
compound (structure not disclosed) developed by Pfizer, with an IC50 of 30 nM and 
27 nM, respectively (Figure 4).22-23 
Little is still known about targeting the newcomer enzyme, IDO2. In 2012 during 
a screening of a small library of molecules already approved by the Food and Drug 
Administration (FDA) tenatoprazole drug demonstrated to be highly selective for 
IDO2 inhibition while no effect at ≥ 100 µM for IDO1 or TDO has been seen (Figure 
4).24 
 
Figure 4. (A) Chemical structures of most promising TDO inhibitors. (B) Chemical structure 
of tenatoprazole drug. 
Inhibition of IDO2, alongside increasing the efficacy and durability of IDO/TDO 
inhibition in tumours that over-express the enzyme, would also reduce autoimmune 
side-effects associated with immunotherapy, as this enzyme supports autoantibody 
production in B cells.25 However, intense efforts need to be pursued in both the 
searching for TDO and IDO2 inhibitors. 
Interestingly, dual IDO1/TDO inhibitors are appearing in the landscape as shown 
by compound RG70099 developed by Roche.26 Overall, evidences clearly suggest 
that combi-IDO/TDO inhibitors may represent a promising strategy in order to limit 
acquired resistance to IDO1 blockade and reduce autoimmune side effects of 
immunotherapy.  
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1.3. Hereditary multiple exostoses 
1.3.1. Heparan sulfate structure and biosynthesis 
Heparan sulfate (HS) is a glycosaminoglycan (GAG) present in cell surface and 
extracellular matrix heparan sulfate proteoglycans (HSPGs). The HSPG family 
includes membrane-anchored proteoglycans syndecans and glypicans, the secreted 
extracellular matrix proteoglycans agrin, perlecan and type XVIII collagen and the 
secretory vesicle proteoglycan serglycin. Proteoglycans (PGs) consist of a core 
protein, and one or more glycosaminoglycans (GAGs) side chains attached to 
specific serine residues. GAGs are long unbranched negatively charged 
heteropolysaccharides that consist of alternating residues of an uronic acid and an 
amino sugar. The amino sugar can be N-acetylated or N-sulfated glucosamine 
(heparan sulfate) or N-acetylgalactosamine (chondroitin/dermatan sulfate) while the 
uronic acid consist of glucuronic (GlcA) or iduronic acid (IdoA).1 The first step in 
HS synthesis is the formation of a linkage tetrasaccharide which is composed of a 
xylose, two galactose residues and glucuronic acid. Then chain polymerization 
begins with N-acetyl-D-glucosamine (GlcNAc) addition and proceeds with 
sequential and addition of glucuronic acid (GlcA) and GlcNAc carried out by an 
enzyme complex composed of Ext1 and Ext2. Xylose addiction to a serine residue 
in the PG core is carried out in the endoplasmic reticulum while the following steps 
in HS biosynthesis take place in the Golgi apparatus. The first GlcNAc residue is 
added to the linkage tetrasaccharide by Extl3. The nascent HS chains then undergo 
a series of structural modification including sulfation at different position and 
glucuronic acid epimerization leading to chains characterized by high structural 
complexity and biological specificity (Figure 1).2 
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Figure 1. Heparan sulfate structure and assembly. Taken from Sarrazin, S. et al. Cold 
Spring Harb Perspect Biol. 2011, 3, 1-33. 
1.3.2. Heparan sulfate functions in health and disease 
HS plays an essential role in regulating cellular functions such as cell growth, 
adhesion, angiogenesis, and blood coagulation by binding to a large number of 
proteins, including growth factors, signaling proteins, integral membrane receptors, 
chemokines, and extracellular matrix proteins. At least 300 heparan sulfate binding 
proteins (HSBPs) have been identified so far with differences in terms of affinity, 
specificity and function.   
Perlecan, agrin and type XIII collagen present in the matrix of basement 
membranes help define matrix structure and organisation and provide a substratum 
for cell migration. It has been reported that HSPGs are found in secretory vesicles 
where they control several activities including the maintenance of the active state of 
proteases and the packaging of granular contents. Again, granule proteoglycans 
regulate biological functions such as coagulation, wound repair and host defence 
after vesicles secretion. Moreover, they can protect cytokines, grown factors and 
chemokines against proteolysis by binding to them. HSPGs present in the cell surface 
can act as receptors regulating distribution and activity of its ligand and as 
coreceptors by modifying the activation threshold or the duration of signalling by 
different tyrosine kinase-type growth factor receptors (Figure 2). These various 
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activities depend on recognition of the HS chains through HS-binding domains 
present in the various protein ligands, including fibroblast growth factors (FGFs), 
vascular endothelial growth factors (VEGFs), bone morphogenetic proteins (BMPs). 
Finally, they cooperate with different cell adhesion receptors by facilitating a 
plethora of function ranging from cell-cell interactions to cell motility.1 
It has been reported that HSPGs are involved in pathological conditions. Changes 
in HS composition have been associated with tumour cell transformation and 
invasiveness. Furthermore, HS has also been implicated in the development of 
neurodegenerative diseases (i.e. prion, Alzheimer’s, and Parkinson’s disease). 
Viruses and bacteria possess HSBPs consistent with the known role that these 
complex polysaccharides play in infection.2a,3 Finally, a decrease in HS levels has 
been related to the development of hereditary multiple exostoses (HME), a rare 
genetic pediatric disorder.4 The pathology of this disease will be described in detail 
in the next paragraph. 
 
 
Figure 2. Pictorial representation of the vast array of functions mediated by HSPGs. Taken 
from Sarrazin, S. et al. Cold Spring Harb Perspect Biol. 2011, 3, 1-33. 
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1.3.3. Hereditary multiple exostoses: pathogenesis, clinical 
presentation and perspectives 
Hereditary multiple exostoses, also known as multiple osteochondromas (MO), is 
an autosomal dominant disorder that results from heterozygous loss-of-function 
mutations in EXT1 or EXT2. 1 in every 50,000 children worldwide are affected by 
this relatively rare pediatric disease.5 Heterozygosity diminishes the capacity of cells 
to make heparan sulfate. Indeed, EXT deficiency causes truncation of the HS chains 
and consequent decrease in HS levels in plasma and various tissues. HME is 
characterized by the formation of multiple bony spurs or lumps, known as exostoses 
or osteochondromas, next to long bones, ribs and vertebrae and other skeletal 
elements. Patients with HME present shortened stature, bowing and shortening of 
forearm elements, changes in angulations of the knee and fingers, and limb-length 
inequalities. Because of their multiple locations, considerable size and great number, 
the exostoses cause several complications with the advance of the disease. These 
include joint ankylosis, skeletal deformities, impingement of muscle, blood vessels 
and nerves and conversion to malignant chondrosarcoma especially during 
adulthood (2-3%).6 Matsumoto et al. demonstrated that another common 
complication of the disease is represented by scoliosis.7  
Currently, the most common treatment for HME patients consists of surgical 
removal of osteochondromas which results in the correction of major skeletal 
defects. In some cases osteochondromas are impossible to resect because of 
dangerous or delicate localization within the body. Symptomatic pain that appears in 
patients is controlled by the use of palliative drugs.8 At present no pharmacological 
treatment has been developed for reducing the number or growth of exostoses. 
Nevertheless, it has been recently demonstrated that chondrogenesis requires 
bone morphogenetic protein (BMP) signalling and that Ext1-mutant mice display 
enhanced BMP signalling that leads to osteochondromagenesis.9  
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Promisingly, Sinha and co-workers showed that the use of LDN-193189, a BMP 
signalling antagonist, effectively reduced osteochondroma growth in Ext1-mutant 
mice10 providing a therapeutic approach for MHE (Figure 3). 
 
 
Figure 3. Chemical structure of BMP antagonist LDN-193189. 
 
In summary, further efforts are needed in order to identify novel approaches to 
develop drugs for treating the disease. 
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2.1. Outline of the thesis  
This thesis illustrates three different projects on which I focused my research 
activity during the PhD program: the development of Store-Operated Calcium Entry 
modulators, the discovery of indoleamine 2,3-dioxygenase 1 inhibitors for anticancer 
therapy and the search for small molecules enhancers of heparan sulphate as 
candidate therapeutics for the treatment of hereditary multiple exostoses.  
Chapter 3 describes the discovery, by a click chemistry approach, of a new class 
of molecule able to fine-tune the Store-Operated Calcium Entry mechanism. 
Interestingly, both enhancers and inhibitors of the process have been reported.  
Chapter 4 presents an isocyanide-based multicomponent approach to the rapid 
and versatile generation of imidazothiazole compounds as IDO1 inhibitors.  
Chapter 5 introduces the discovery, by a virtual screening approach, of a novel 
scaffold for IDO1 inhibition and the in silico-driven synthesis of a series of 
structurally related analogues.  
Chapter 6 reports my research activity in the development of HS enhancers that 
took place at University of California San Diego (UCSD) under the supervision of 
Prof. Carlo Ballatore. Specifically, it illustrates the design, synthesis, structure 
activity relationship (SAR) study and physicochemical properties evaluation of N-
aryl-2-aminothiazoles as potential leads for the treatment of HME disease. 
Finally, Chapter 7 sums up and highlights future developments in each field.  
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3.1. Introduction 
As mentioned in Chapter 1.1.4., alteration of the SOCE machinery is related to 
the development of a vast array of diseases ranging from cancer to rare diseases. 
Therefore, this cellular event has been suggested to be druggable target for 
developing novel therapies.1 However, despite the increasing number of molecules 
discovered so far, only few compounds have progressed to the clinic and none of 
them has obtained the FDA approval, primarily owing to their drawbacks in terms 
specificity and selectivity.2 It follows that there is a need to increase the range of 
available compounds. 
A rational design of SOCE modulators is at present complicated since structural 
information on Orai and STIM proteins is very poor (See Chapter 1.1.2).3 In this 
context, Prof. Pirali’s research group started from the observation that the arylamide 
substructure appears to be an essential pharmacophoric feature for SOCE modulation 
and almost all the inhibitors reported in the literature share this structural 
redundancy.2 Thus, before I started the PhD program, a click chemistry approach had 
been pursued in order to investigate whether the arylamide displayed by known 
SOCE modulators could be isosterically replaced by the 1,4-disubstituted 1,2,3-
triazole ring. To this aim, starting from known pyrazole derivatives, namely BTP2 
and Pyr compounds, they isosterically substituted the amide moiety with the triazole 
ring (Figure 1).4-7 Giving that the trifluoromethyl groups in the C3 and C5 positions 
of the pyrazole ring or, alternatively, the ethyl carboxylate group in the C4 position 
are necessary for the inhibitory activity they were kept fixed, while the portion 
beared by the triazole ring, which appears to contribute to selectivity, was 
extensively varied. A library of seventy-nine candidates was designed, synthesized 
and biologically evaluated for their ability to modulate SOCE (Figure 1). Within this 
series, a hit compound, namely 1S, was identified as a promising inhibitor of SOCE. 
Strikingly, two enhancers of the process (2T and 3G, Figure 1) were discovered, 
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affording experimental tools to further explore the (patho)physiological role of 
capacitative calcium entry. Yet, they represent the first SOCE enhancers that do not 
display a borinate substructure (See Chapter 1.1.4).8 
 
Figure 1. Scheme representing the strategy performed for the discovery of SOCE 
modulators and the chemical structures of SOCE inhibitor 1S and enhancers 2T and 3G. 
However, Prof. Pirali’s laboratory decided to focus its attention on the hit 1S, as 
inhibitors have immediate therapeutic applications. Thanks to the collaboration with 
Prof. Genazzani’s group, compound 1S activity was evaluated. 1S displays an IC50 
value for inhibition of SOCE of 0.6 ± 0.1 μM in Hek cells compared to 0.5 ± 0.1 of 
Pyr3 and 0.3 ± 0.1 of Pyr6, the reference substances (Figure 2A). Cytotoxicity was 
measured evaluating viability of cells after 24 h treatment via the MTT assay. 
Viability of cells treated with Pyr3 at 10 µM was 28.6 ± 0.4%, compared to 70.3 ± 
5.8% of Pyr6 and 84.0 ± 1.0% of 1S (Figure 2B). Gratifyingly, compound 1S is the 
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less cytotoxic and affects cell viability at concentration 100-fold the IC50 for SOCE 
inhibition.  
 
Figure 2 (A) Concentration-response curves of 1S, Pyr3 and Pyr6 in Hek cell line;(B) MTT 
assay of Pyr3, Pyr6 and 1S. 
As it has been reported that Pyrs may also affect other channels, Genazzani’s 
laboratory tested the activity of 1S on voltage-operated channels, TRPV1 and 
TRPM8 channels that have been shown previously to be affected by SOCE 
inhibitors. Promisingly, it does not have an effect on voltage-dependent channels, 
although it inhibits TRPV1 channels.  
Finally, given that the ester group in 1S might be susceptible to hydrolysis, they 
decided to examine whether the corresponding carboxylic acid 61 retained activity. 
To this aim, during the research experience as a PhD student in Prof. Pirali’s 
laboratory, I synthesized compound 61. Unfortunately, it is not active, demonstrating 
that the ester group is necessary for the inhibition of SOCE (Figure 3).  
 
Figure 3. Chemical structure of 1S corresponding carboxylic acid 61. 
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Therefore, in collaboration with Prof. Grosa, we decided to investigate the 
hydrolytic stability of 1S in mouse plasma. The residual substrate after 30 minutes 
of 0% confirms that the ethyl ester underwent fast hydrolysis. Consequently, this 
result suggests that 1S might not be good lead compound for systemic use.  
3.2. Aim of the work 
In order to improve the hydrolytic stability of the hit compound 1S and eventually 
increase its potency and selectivity during my PhD I have performed a focused SAR 
study. Toward this aim, three portions of the molecule have been switched: the 
central triazole ring core, the ethyl ester group in the C4 position of the pyrazole ring 
and the carboxylic moiety on the terminal aryl ring. All the synthesized molecules 
have been evaluated as SOCE inhibitors. Moreover, the selectivity of selected 
compounds and the hydrolytic and metabolic stability have been investigated. 
Finally, efficacy in two different diseases characterized by aberrant SOCE activity, 
TAM and acute pancreatitis, has been proven.  
3.3. Results and discussion 
3.3.1. Chemistry 
First of all, in order to investigate whether the triazole ring behaved merely as an 
isostere of the amide group or played a role in the interaction with the SOCE 
machinery, 1S analogues displaying both the direct (6) and inverse (12) amide were 
synthesized, according to Scheme 1.  
The synthesis of the pyrazolic precursors 3 and 9 was accomplished following the 
route depicted in Scheme 1. The carboxylic acid 3 was obtained by condensing the 
commercially available oxobutyrate 4 with 4-hydrazinylbenzoic acid 5 (Scheme 1A). 
Amine 9, instead, was synthesized in two steps: condensation reaction followed by 
reduction of the aromatic nitro group (Scheme 1B). 
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Then the amines (2 and 9) and the carboxylic acids (3 and 8) were coupled, while 
protecting and deprotecting the additional carboxylic group.  
 
 
Scheme 1. Modification of the triazole moiety of compound 1S, direct and inverse amides. 
(a) K2CO3, benzyl bromide, dry DMF, rt, 16 h, 47%; (b) EtOH, THF, rt, 3 h, 93%; (c) EDCI, 
DIPEA, DMAP, dry CH2Cl2, rt, 16 h, 84-94%; (d) H2, 5% Pd/C, MeOH, rt, 1 h, 55-72%; (e) 
TEA, benzyl bromide, DMF, MeOH, H2O, rt-100 °C, 16 h, 36%; (f) DMF, reflux, 2 h, 96%; 
(g) H2, 5% Pd/C, EtOAc, rt, 2 h, 94%. 
 
The corresponding 1,5-disubstituted triazole (14) has also been synthesized using 
a ruthenium-based catalyst (Scheme 2). To this aim, the required azide 13 was 
obtained by diazotation-azidation of aniline 9. 
 
Scheme 2. Modification of the triazole moiety of compound 1S, 1,5-disubstituted triazole. 
(a) NaNO2, NaN3, HCl, H2O, rt, 1 h, 78%; (b) Cp*RuCl(cod), microwaves, DMF, 90 °C, 
10 min, 39%;  
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Then, the ethyl ester portion of 1S was modified. In particular, intermediate 15 
was transesterified (16, 17), reduced to amine (18, 19), converted into azide (20, 21) 
and clicked with commercially available 3-ethynylbenzoic acid to give the final 
methyl ester 22 and isopropyl ester 23 (Scheme 3).  
  
 
Scheme 3. Modification of the ester moiety of compound 1S, methyl and isopropyl esters. 
(a) Conc. H2SO4, MeOH or 2-propanol, reflux, 32 h, 81-90%; (b) H2, 5% Pd/C, EtOAc, rt, 
2 h, 91-94%; (c) NaNO2, NaN3, HCl, H2O, rt, 3 h, 62-87%; (d) Sodium ascorbate, 
CuSO4•5H2O, t-BuOH, H2O, rt, 16 h, 54-55%. 
Alternatively, intermediate 13 was hydrolized to 24, coupled with different 
alcohols (25-30) and clicked with 3-ethynylbenzoic acid, leading to a series of 
structurally different esters (31-36) (Scheme 4). 
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Scheme 4. Modification of the ester moiety of compound 1S, second series of esters. 
(a) NaOH, H2O, acetone, rt, 3 h, 60%; (b) EDCI, DMAP, TEA, dry CH2Cl2, rt, 16 h, 47-
68%; (c) Sodium ascorbate, CuSO4•5H2O, t-BuOH, H2O, rt, 16 h, 53-80%. 
Moreover, the ethyl ester of intermediate 9 was reduced in the presence of LiAlH4, 
converted into azide 37 and clicked with 3-ethynylbenzoic acid to give the final 
primary alcohol 38 (Scheme 5A).  
Yet, intermediate 24 was coupled with isopropylamine and then clicked with 3-
ethynylbenzoic acid, yielding the secondary amide 40 (Scheme 5B).  
 
Scheme 5. Modification of the ester moiety of compound 1S, primary alcohol and 
secondary amide. 
(a) LiAlH4, dry THF, rt, 6 h, 80%; (b) NaNO2, NaN3, HCl, H2O, rt, 3 h, 92%; (c) Sodium 
ascorbate, CuSO4•5H2O, t-BuOH, H2O, rt, 16 h, 83-87%; %; (d) Isopropylamine, EDCI, 
HOBt, TEA, dry CH2Cl2, rt, 16 h, 59%. 
Chapter 3 
52 
The ethyl ester of compound 1S was reacted with aqueous ammonia to give the 
primary amide 41 (Scheme 6).  
 
Scheme 6. Synthesis of compounds 41 and 42. 
(a) Conc. NH4OH, 90 °C, 3 h, 63%; (b) Methansulfonamide, EDCI, TEA, DMAP, dry 
CH2Cl2, rt, 16 h, 71%. 
Last, we investigated whether the carboxylic moiety of compound 1S was tolerant 
to substitution with acyl methansulfonamide 42 (Scheme 6), methyl ester 55, methyl 
ketone 56, primary amide 57, primary alcohol 58, sulfonamide 59 and hydroxamic 
acid 60 (Scheme 7). To this aim, the corresponding alkynes 44, 46, 48, 50, 52 were 
prepared by a Sonogashira coupling and deprotection (Scheme 8 A-E) while alkyne 
54 was synthesize by coupling reaction using O-(trimethylsilyl)hydroxylamine and 
deprotection (Scheme 8F). 
While the described compounds have been patented 9 other promising analogues 
have been synthesized, but they are not disclosed in this thesis for patentability 
reason. 
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Scheme 7. Modification of the carboxylic moiety of compound 1S. 
(a) Sodium ascorbate, CuSO4•5H2O, t-BuOH, H2O, rt, 16 h, 42-80%. (b) TBTA, 
Cu(OAc)2, sodium ascorbate, THF, H2O, rt, 16 h, 42%. 
 
 
 
 
Scheme 8. Synthesis of alkynes. 
(a) Ethynyltrimethylsilane, DIPEA, CuI, Pd(PPh3)2Cl2, toluene, 100 °C, 6 h, 48- 99%; (b) 
TBAF, CH3COOH, THF, 0 °C, 1 h, 98%; (c) ethynyltrimethylsilane, TEA, CuI, 
Pd(PPh3)2Cl2, THF, 50 °C, 6 h, 98%; (d) K2CO3, MeOH, rt, 30 min-1 h, 49-98%; (e) 
Oxalyl chloride, conc. NH4OH, THF, DMF, rt, 30 min, 98%.(f) TBAF, THF, 0 °C, 30 min 
– 1h, 70-79%; (g) ethynyltrimethylsilane, PPh3, Pd(OAc)2, TEA, 94 °C, 1 h, 65%; (h) O-
(Trimethylsilyl)hydroxylamine, TEA, EDCI, dry CH2Cl2, rt, 4 h. 
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3.3.2. Biological evaluation 
The synthesized analogues were screened in the laboratory of Prof. Genazzani for 
activity on Store-Operated Ca2+ Entry in Hek cells, via calcium imaging experiments 
using Fura-2 as a fluorimetric dye. In brief, a multi-plate reader approach was 
employed in which intracellular stores of Hek cells were emptied with t-BhQ (50 
µM) in the presence of the compounds (at 10 µM). Calcium was then re-added to the 
extracellular medium and intracellular levels determined. The results are displayed 
in Table 1. These included their effect at a concentration of 10 μM, cell viability via 
the MTT assay at 10 μM and determination of the IC50s for the inhibition of SOCE 
for the most active compounds in Hek cells. Pyr3 and Pyr6 were used as reference 
substances. 
 
Cpd Structure 
Residual 
SOCE activity 
(% of control) 
% viability 
@ 10 µM 
SOCE 
inhibition 
IC50 (µM) 
Pyr3 
 
8.9 ± 0.6 28.6 ± 0.4 0.5 ± 0.1 
Pyr6 
 
10.3 ± 3.0 70.3 ± 5.8  0.3 ± 0.1 
1S 
 
12.8 ± 2.2 84.0 ± 1.0 0.6 ± 0.1 
6 
 
> 90% ND ND 
12 
 
63.5 ± 3.2 65.9 ± 5.3 ND 
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Cpd Structure 
Residual 
SOCE activity 
(% of control) 
% viability 
@ 10 µM 
SOCE 
inhibition 
IC50 (µM) 
14 
 
> 90% ND ND 
22 
 
7.9 ± 1.8 69.2 ± 2.5 ND 
23 
 
3.5 ± 0.3 87.2 ± 5.8 3.1 ± 1.3 
31 
 
17.5 ± 1.6 93.6 ±4.6 4.4 ± 1.2 
32 
 
> 90% ND ND 
33 
 
> 90% ND ND 
34 
 
> 90% ND ND 
35 
 
10.5 ± 1.4 82.2 ± 4.3 ND 
36 
 
> 90% ND ND 
38 
 
> 90% ND ND 
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Cpd Structure 
Residual 
SOCE activity 
(% of control) 
% viability 
@ 10 µM 
SOCE 
inhibition 
IC50 (µM) 
40 
 
> 90% ND ND 
41 
 
> 90% ND ND 
42 
 
> 90% ND ND 
55 
 
> 90% ND ND 
56 
 
> 90% ND ND 
57 
 
72.1 ± 2.5 ND ND 
58 
 
> 90% ND ND 
59 
 
83.6 ± 4.1 ND ND 
60 
 
6.4 ± 5.7 67.5 ± 5.0 ND 
 
Table 1. Effect of 1S analogues on Store-Operated Ca2+ Entry, IC50 values and cytotoxicity 
in Hek cells. ND = not determined 
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3.3.3. SAR study 
From the data obtained, the first observation is that the triazole ring does not 
merely behave as an isostere of the amide group but plays a pivotal role in the 
modulation of SOCE. Indeed, when substituted with both its direct and the inverse 
amide (6 and 12), a decrease in activity surprisingly occurs, validating this series of 
compounds as an entirely novel class of SOCE modulators. Moreover, the 1,4-
disubstituted triazole ring can not be replaced with the 1,5-disubstituted analogue 14.  
Second, the methyl ester 22 and the isopropyl ester 23 are more active compared 
to the ethyl ester 1S, the pentan-2-yl ester 31 inhibits SOCE to the same extent, while 
the other synthesized esters (32-36) lose the ability to act on SOCE. Furthermore, 
the ethyl ester can not be replaced by a primary alcohol (38) or by an amide (40, 41).  
Finally, the carboxylic group moiety is not tolerant to the substitution with other 
functionalities (42, 55-59), except for the hydroxamic acid 60, which is endowed 
with remarkable activity, but significantly affects cell viability at 10 µM. 
A summary of the SAR is reported in the Figure below.  
 
Figure 4. Summary of the SAR study of Pyrtriazole compounds. 
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3.3.4. Hydrolytic stability, metabolism and selectivity 
Given that the ester group in 1S was susceptible to hydrolysis and the 
corresponding carboxylic acid resulted inactive, we decided to investigate the 
hydrolytic stability of 1S esters, selected according to their activity on SOCE (22, 
23, 31, 35), in mouse plasma. As it can be seen (Table 2) the short linear esters (1S 
and 22) and the (benzyloxy)carbonyl 35 underwent fast hydrolysis, suggesting that 
they might not be good lead compounds for systemic use. Conversely, the branched 
esters 23 and 31 showed an overall good stability in plasma, with a residual substrate 
after 30 minutes of 87.7 and 97.8%, respectively.  
 
Cpd structure 
Plasma stability 
(residual substrate) 
1S 
 
0% 
Pyr3 
 
20.4% 
22 
 
6.5% 
23 
 
87.7% 
31 
 
97.8% 
35 
 
0% 
 
Table 2. Hydrolytic stability of selected 1S analogues in plasma mouse. 
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Given that the plasma stability of Pyr3 was poor (20.4% residual substrate after 
30 min), 23 and 31 appeared as major improvements in this respect. 
Therefore, we decided to evaluate their metabolism in mouse liver homogenates. 
In mouse liver S9 fractions (MLS9), their hydrolytic stability was confirmed with 
the residual substrate after 1 hour being 81.3% and 73.7% for 23 and 31, respectively. 
We next investigated the in vitro oxidative metabolism of the two compounds by 
performing incubations in the presence of NADPH. Alternatively, given the presence 
of a carboxyl acid moiety, the formation of acylglucuronide metabolites was assessed 
by incubating the compounds in mouse liver microsomes (MLM) activated by 
UDPGA. Overall, hydrolysis of the ester function was the main metabolic pathway 
in liver metabolism, as no significant differences in residual substrate were observed 
in the presence or absence of NADPH or UDPGA. However, minute amounts of 
other metabolites (<1%) were detected and characterized by mass spectrometry 
analysis. Compound 31 underwent oxidative hydroxylation at the pentan-2-yl chain, 
giving the metabolite 31-OH (Figure 5). Moreover, both the carboxyl functions of 
compounds 23 and 31 were susceptible to the formation of acylglucuronide 
metabolites (23-G and 31-G; Figure 5). Finally, no traces of glucuronide conjugates 
of metabolite 61 were detected in the incubations. 
 
Figure 5. In vitro metabolic pathways for compounds 23 and 31. 
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Last, the selectivity of 23 and 31 in respect to voltage-operated calcium channels, 
TRPV1 and TRPM8 channels has been evaluated. Gratifyingly, as it can be observed 
in Figure 6, neither 23 or 31 had an effect on these channels. This therefore makes 
these two compounds stand out compared to Pyr3 and Pyr6, in terms of selectivity 
stability and cytotoxicity. 
 
Figure 6. Characterization of the selected compounds. Histograms show the effect of 23 or 
31 on the peak amplitude in primary cultures of mouse cerebellar granule cells and in Hek 
cells over-expressing TRPV1 or TRPM8. Values are mean ± SEM of 600 cells from 30 
plates on four separate experimental days. 
3.3.5. Ex vivo evaluation of 23 and 31 on muscle biopsies 
from patients affected by TAM 
Based on the data obtained about compound 23 in human embryonic kidney Hek 
cells (cell model used for the screening of all compounds reported, Figure 7A), we 
evaluated the effect of this molecules in in vitro and ex vivo models of TAM. 
TAM is a rare genetic disease in which either Orai or STIM are mutated with gain 
of-fuction mutations and lead to an increased Ca2+-entry mainly in muscle and 
platelets (See Chapter 1.1.3).  
To support this hypothesis, by calcium imaging approach, we demonstrated, that 
23 (10 μM) was able to restore Ca2+ entry  to control levels both in a Hek cells 
Pyrtriazoles, a novel class of Store-Operated Calcium Entry modulators: discovery, 
biological profiling and in vivo proof-of-concept efficacy in SOCE-related diseases 
 
61 
transfected with an Orai1 gain-of-function mutation (Hek Orai1 C290G, Figure 7B) 
and in cells transfected with non-mutated protein (not shown). Moreover, to further 
support the possibility that the modulation of this mechanism may represent an 
efficient pharmacological approach in TAM disease, we decided to investigate 
whether 23 could counter-act the effect of the same Orai1 mutation (C290G) in a 
muscle biopsy from a patient affected by tubular aggregate myopathy. As it can be 
observed in Figure 7C, in the patient biopsy, Ca2+-entry triggered by store depletion 
was significantly increased compared to Ca2+-entry in a control patient not affected 
by the disorder. Treatment with 10 µM 23 led to a significant decrease of SOCE, 
reaching levels similar to the unaffected patient. Furthermore, the same protocol 
described above was performed for compound 31 (not shown), since compounds 23 
and 31 display similar potency and stability. Promisingly, also compound 31 proved 
to be effective both in in vitro and ex vivo models of TAM. These data, as a whole, 
represent the proof-of-concept that symptoms from GoF mutations of STIM or Orai 
can be corrected via this pharmacological approach. 
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Figure 7. (A) Effect of 23 on Hek wild-type cells; (B) effect of 23 on mutated embryonic 
kidney (Hek Orai1 C290G) cells (C) effect of 23 on a muscle biopsy from a patient bearing 
the Orai1 C290G mutation.  
 
3.3.6. In vivo evaluation of 31 in an animal model of acute 
pancreatitis 
Besides evaluating our SOCE inhibitors in the aforementioned genetic diseases, 
in collaboration with Prof. Cuzzocrea, we opted to verify the potential use of 31 in 
acute pancreatitis. 
First, to verify its tolerability, we investigated its toxicity after a single dose (40 
mg/Kg) for 14 days, monitoring mortality, body weight, clinical signs of distress and 
histological alterations of major organs (brain, heart, liver, lung, kidney, lung, 
stomach and ileum) in accordance to the OECD guideline for acute toxicity. None 
of the 6 treated animals showed any alterations. 
We next performed a pharmacokinetic analysis to further characterize the 
compound. The half-life of 31 was 1.3 hours, with a Cmax of 640 μg/L after 1 hour. 
The clearance was 17 L/h/Kg, with a volume of distribution of 32 L/Kg. Despite the 
surprisingly high volume of distribution, the plasma concentrations reached (approx. 
1.2 µM) led us to believe that it might have exerted a therapeutic effect and decided 
therefore to perform proof-of-principle in vivo experiment. It has been demonstrated 
that GSK-7975A and CM128 were protective against POAEE-induced necrosis of 
pancreatic acinar cells in three separate models of chemically-induced acute 
pancreatitis, including the model that uses cerulein. Indeed, a clinical trial has been 
initiated on CM4620, another SOCE inhibitor. Given that this is an acute disorder, 
we reasoned that 31, with a half-life of hours, might have been suitable. 31 was given 
twice (40 mg/Kg, n = 10) by intraperitoneal injection, 30 and 150 minutes after the 
first cerulein injection. As shown in Figure 8, the histological scores were 
significantly ameliorated by treatment with 31. This was evident in the 
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haematoxylin/eosin stainings, when evaluating oedema and inflammation and when 
determining neutrophil infiltration via MPO staining. 
 
 
 
Figure 8. Evaluation of compound 31 in a model of acute pancreatitis.  
(A) H&E sections of pancreatic tissues were assessed at 200X magnification over ten 
separate fields for severity of pancreatitis. (B) Evaluation of edema, inflammatory 
infiltration and apoptosis was performed with a three point scoring system (edema-0: 
absent or rare, 1: in the interlobular space, 2: in the intralobular space, 3: the isolated-
island shape of pancreatic acinus; inflammation-0: absent, 1: mild (infiltration in ducts), 2: 
moderate (infiltration in parenchyma < 50%), 3: severe (infiltration in parenchyma > 50%); 
parenchyma apoptosis-0: absent, 1: focal (<5%), 2: and/or sublobular (<20%), 3: and/or 
lobular (>20%)). Analysis were performed in a blinded manner. (C) MPO activity. 
Data represent the mean ± standard error of the mean (SEM) of 10 mice for each group. 
***p < 0.001; **p < 0.05 versus Sham; ##p < 0.05; #p < 0.5 versus cerulein. 
 
 
 
B 
 
A 
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3.4. Conclusions 
In conclusion, we have discovered a novel class of agents that are able to modulate 
Store-Operated Ca2+ Entry and starting from a promising hit we have performed a 
SAR study. While almost all the SOCE inhibitors reported to date share an arylamide 
moiety, the modulators described by us display a 1,4-diaryl-1H-1,2,3-triazole ring. 
We selected two structural analogues (23 and 31), according to SOCE inhibition, 
cytotoxicity and extent of hydrolysis, for further investigations on metabolic stability 
and selectivity. These analogues display IC50s in the low micromolar range and are 
specific on SOCE compared to the channels evaluated in the present study (voltage-
operated, TRPV1 and TRPM8). Moreover, these compounds appeared suitable as 
lead compounds for systemic use as they were relatively stable. Indeed, slow 
hydrolysis of the ester function was the main metabolic pathway both in mouse 
plasma and liver, with minute formation of the oxidative (23) or glucuronidated (23 
and 31) metabolites. The ex vivo experiments demonstrated that 23 and 31 may have 
a value in the therapy of tubular aggregate myopathy, a disease characterized by 
gain-of-function mutations in either STIM or Orai. This conclusion has promped our 
lab to develop via a commercial service (PolyGene Transgenics, CH) a knock-in 
animal model (KI-STIM1I115) that bears one of the most frequent mutations in Italy, 
STIM1 (I115F). The characterization showed that the litters are viable and 
heterozygous animals (tested at 1 and 3, 6 and 12 months) display muscle weakness, 
as observed in rotarod and treadmill tests. Furthermore, the murine muscles exhibit 
contraction and relaxation defects as well as dystrophic features, and functional 
investigations display an increased Ca2+ influx in myotubes. Once concluded the 
characterization of this transgenic mouse model, one of our best negative modulators 
will be evaluated in vivo, to further strengthen the possibility that Pyrtriazoles have 
the potential to become a viable strategy in the treatment of TAM.  
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On the other hand, the in vivo study performed on 31 showed that half-life was 
1.3 hours and a twice-administration of the compound significantly ameliorated 
cerulein-induced pancreatitis, in the absence of signs of toxicity. Yet, the high 
volume of distribution and the short half-life in vivo might suggest that further 
refinements are necessary and indeed these are already being investigated by our 
research group. 
Overall, the described compounds hold great promise to both get insights into the 
biological role of SOCE and pave the way for the treatment of human disorders 
arising from imbalanced calcium homeostasis. 
3.5. Experimental section 
General Methods. Commercially available reagents and solvents were used as 
purchased without further purification. When needed, solvents were distilled and 
stored on molecular sieves. Column chromatography was performed on silica gel 
Merck Kieselgel 70-230 mesh ASTM. Thin layer chromatography (TLC) was 
carried out on 5 cm × 20 cm plates with a layer thickness of 0.25 mm (Merck silica 
gel 60 F254). When necessary, TLC plates were visualized with aqueous KMnO4 or 
with aqueous Pancaldi solution. Melting points were determined in open glass 
capillary with a Stuart scientific SMP3 apparatus. All the target compounds were 
checked by IR (FT-IR Thermo-Nicolet Avatar), 1H and 13C NMR (Jeol ECP 300 
MHz), and mass spectrometry (Thermo Finningan LCQ-deca XP-plus) equipped 
with an ESI source and an ion trap detector. Chemical shifts are reported in parts per 
million (ppm).  
3.5.1. Chemistry 
Benzyl 3-aminobenzoate, (2). 
3-Aminobenzoic acid (1.00 g, 7.29 mmol) was dissolved in dry DMF (20 mL). Then 
anhydrous K2CO3 (1.11 g, 8.15 mmol) was added followed by dropwise addition of 
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benzyl bromide (0.87 mL, 7.29 mmol). The resulting mixture was stirred at room 
temperature for 16 h, then diluted with aqueous saturated Na2CO3 solution and 
extracted with ethyl acetate (x3). The combined organic phases were washed with 
brine, dried over sodium sulfate and concentrated. The crude material was purified 
by column chromatography using petroleum ether/ethyl acetate 98:2 and then 
petroleum ether/ethyl acetate 9:1 as eluent to give compound 2 (777 mg, 3.42 mmol, 
47%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3): δ = 7.55 (d, J = 7.7 Hz, 1H), 
7.50-7.35 (m, 6H), 7.21 (t, J = 7.7 Hz, 1H), 6.84 (d, J = 7.7 Hz, 1H), 5.38 (br s, 2H), 
3.91 (s, 2H). MS (ESI): m/z: 228 [M + H]+.  
4-(4-(Ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)benzoic acid, (3). 
To a solution of 4-hydrazinylbenzoic acid (1 g, 6.58 mmol) in EtOH (10 mL), THF 
(2 mL) was added and the reaction mixture was cooled at -8 °C under nitrogen 
atmosphere. Then (E)-ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate 
(1.28 mL, 6.58 mmol) was added dropwise. After stirring at room temperature for 3 
h the mixture was filtered under vacuum and rinsed with heptane to give compound 
3 (2 g, 6.10 mmol, 93%) as a dark white solid. 1H NMR (300 MHz, DMSO-d6): δ = 
8.36 (s, 1H), 8.14 (d, J = 7.5 Hz, 2H), 7.71 (d, J = 7.5 Hz, 2H), 4.36 (q, J = 7.1 Hz, 
2H), 1.33 (t, J = 7.1 Hz, 3H). MS (ESI): m/z: 329 [M + H]+.  
3-(4-(4-(Ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-
yl)benzamido)benzoic acid, (6). 
Step 1: To a solution of compound 2 (0.53 g, 2.33 mmol) in dry CH2Cl2 (13 mL), 
EDCI (0.73 g, 3.61 mmol), DIPEA (0.74 g, 5.74 mmol), DMAP (23.4 mg, 0.19 
mmol) and compound 3 (0.63 g, 1.91 mmol) were added in order. The reaction was 
stirred at room temperature for 16 h. Then, CH2Cl2 is added and the organic phase 
was washed with 3N HCl (x4), dried over sodium sulfate and evaporated to afford 
ethyl 1-(4-((3-((benzyloxy)carbonyl)phenyl)carbamoyl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate (1.18 mg, 2.19 mmol, 94%) as a white 
solid. 1H NMR (300 MHz, CDCl3): δ = 8.46 (s, 1H), 8.14-8.03 (m, 3H), 8.00 (d, J = 
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8.3 Hz, 2H), 7.84 (d, J = 7.7 Hz, 1H), 7.46 (d, J = 8.3 Hz, 2H), 7.42-7.29 (m, 5H), 
5.32 (s, 2H), 4.39 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H). MS (ESI): m/z: 536 
[M - H]-.  
Step 2: Ethyl 1-(4-((3-((benzyloxy)carbonyl)phenyl)carbamoyl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate (500 mg, 0.93 mmol), Pd/C (5 wt%, 
150 mg, 0.07 mmol of Pd) and MeOH (5 mL) were added in order under hydrogen 
atmosphere and the resulting mixture was stirred for 1 h at room temperature. Then, 
the reaction was filtered under vacuo over a pad of celite, rinsed with ethyl acetate 
and evaporated. The crude material was subjected to column chromatography using 
petroleum ether/ethyl acetate 4:6, petroleum ether/ethyl acetate 2:8 and ethyl acetate 
(+0.1% HCOOH) to give compound 6 (228 mg, 0.51 mmol, 55%) as a white solid. 
mp 281-282 °C dec. 1H NMR (300 MHz, CD3OD): δ = 8.39 (s, 1H), 8.20 (s, 1H), 
8.13 (d, J = 8.1 Hz, 2H), 7.99 (d, J = 7.9 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.65 (d, 
J = 8.1 Hz, 2H), 7.49 (t, J = 7.9 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 
Hz, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 167.7, 165.2, 160.3, 143.0, 141.8, 
139.8, 136.8, 132.5 (q, J = 38.2 Hz), 132.0, 129.5, 129.4, 126.8, 125.0, 124.9, 121.3, 
119.7 (q, J = 260.3 Hz), 117.1, 61.7, 14.5. IR (KBr): ṽ = 3271, 2990, 2663, 2534, 
1661, 1242, 1137, 709, 564 cm-1. MS (ESI): m/z 448 [M + H]+. 
3-((Benzyloxy)carbonyl)benzoic acid, (8). 
To a solution of isophthalic acid (1.66 g, 10 mmol) in MeOH (20 mL) and water (2 
mL) TEA (1.40 mL, 10.1 mmol) was added. The reaction was stirred at room 
temperature overnight. Then, DMF (25 mL) was added followed by dropwise 
addiction of benzyl bromide (1.31 mL, 11 mmol) and the resulting mixture was 
heated at 100 °C for 16 h. Aqueous saturated NaHCO3 solution was added and the 
reaction was extracted with ethyl acetate (x2). The collected organic phases were 
washed with brine, dried over sodium sulfate and evaporated. The crude material 
was purified by column chromatography using petroleum ether/ethyl acetate 7:3 and 
petroleum ether/ethyl acetate 6:4 (+0.1% HCOOH) as eluent to give compound 8 
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(922 mg, 3.60 mmol, 36%) as a white solid. 1H NMR (300 MHz, CDCl3): δ = 8.80 
(s, 1H), 8.42-8.30 (m, 2H), 7.57 (t, J = 5.2 Hz, 1H), 7.49-7.34 (m, 5H), 5.46 (s, 2H). 
MS (ESI): m/z: 257 [M + H]+.  
Ethyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (9). 
Ethyl acetate (30 mL), Pd/C (5 wt%, 0.9 g) and compound 62 (3.00 g, 9.12 mmol) 
were added in order under hydrogen atmosphere. After stirring at room temperature 
for 2 h the resulting mixture was filtered under vacuo over a pad of celite, rinsed with 
ethyl acetate and evaporated to give compound 9 (2.56 g, 8.57 mmol, 94%) as a 
yellow solid. 1H NMR (300 MHz; CDCl3): δ = 8.06 (s, 1H), 7.17 (d, J = 8.5 Hz, 2H), 
6.72 (d, J = 8.5 Hz, 2H), 4.37 (q, J = 7.1 Hz, 2H), 3.19 (br s, 2H), 1.39 (t, J = 7.1 Hz, 
3H). MS (ESI): m/z: 300 [M + H]+.  
3-((4-(4-(Ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-
yl)phenyl)carbamoyl)benzoic acid, (12). 
Step 1: Ethyl 1-(4-(3-((benzyloxy)carbonyl)benzamido)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate was synthesized as previously reported 
for the preparation of compound 6 in step 1, starting from compound 8 (350 mg, 1.17 
mmol) and compound 9 (290 mg, 0.97 mmol).  The crude material was purified by 
column chromatography using petroleum ether/ethyl acetate 9:1, petroleum 
ether/ethyl acetate 8:2 and petroleum ether/ethyl acetate 7:3 as eluent yielding ethyl 
1-(4-(3-((benzyloxy)carbonyl)benzamido)phenyl)-5-(trifluoromethyl)-1H-pyrazole-
4-carboxylate (527 mg, 0.98 mmol, 84%) as a yellow solid. 1H NMR (300 MHz, 
CDCl3): δ = 9.01 (s, 1H), 8.50 (s, 1H), 8.26-8.01 (m, 3H), 8.00 (d, J = 8.3 Hz, 2H), 
7.51-7.23 (m, 7H), 5.30 (s, 2H), 4.31 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H). 
MS (ESI): m/z: 538 [M + H]+.  
Step 2: The title compound was synthesized as previously reported for the 
preparation of compound 6 in step 2, starting from ethyl 1-(4-(3-
((benzyloxy)carbonyl)benzamido)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-
carboxylate (165 mg, 0.31 mmol). The crude material was subjected to column 
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chromatography using petroleum ether/ethyl acetate 4:6, petroleum ether/ethyl 
acetate 2:8 and petroleum ether/ethyl acetate 9:1 (+ 0.1% HCOOH) to give 
compound 12 (98 mg, 0.22 mmol, 72%) as a white solid. mp 269.5-270.5 °C dec. 1H 
NMR (300 MHz, CD3OD): δ = 8.62 (s, 1H), 8.25-8.23 (m, 2H), 8.16 (s, 1H),7.95 (d, 
J = 8.9 Hz, 2H), 7.65 (t, J = 7.6 Hz, 1H), 7.47 (d, J = 8.9 Hz, 2H), 4.37 (q, J = 7.4 
Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 167.4, 165.7, 
160.9, 142.6, 141.1, 135.6, 134.7, 133.0, 132.6, 132.1 (q, J = 38.2 Hz), 131.8, 129.5, 
129.1, 127.1, 121.1, 120.4 (q, J = 276.4 Hz), 116.6, 61.6, 14.5. IR (KBr): ṽ = 3335, 
1655, 1540, 1243, 1136, 845, 736 cm-1. MS (ESI): m/z 448 [M + H]+. 
Ethyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (13). 
To a suspension of compound 9 (2.60 g, 8.70 mmol) in water (40.7 mL) 37% HCl 
aqueous solution (3.3 mL) was added. The resulting mixture was cooled at 0 °C and 
a solution of NaNO2 (0.57 g, 8.26 mmol) in water (3.9 mL) was added. After 10 min 
a solution of NaN3 (0.64 g, 9.85 mmol) in water (3.9 mL) was added and the reaction 
was left to reach room temperature and stirred for 1 h. The mixture was worked up 
by dilution with ethyl acetate and washing with water (x1). The organic layer was 
dried over sodium sulfate and evaporated yielding compound 13 (2.20 g, 6.77 mmol, 
78%) as a pale red oil. 1H NMR (300 MHz, CDCl3): δ = 8.08 (s, 1H), 7.39 (d, J = 
8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.1 Hz, 
3H). 13C NMR (75 MHz, CDCl3): δ = 160.9, 142.6, 141.9, 135.9, 133.6 (q, J = 39.0 
Hz), 127.4, 119.6, 119.1 (q, J = 269.1 Hz), 116.9, 61.4, 14.1.  IR (KBr) ṽ = 3406, 
3221, 2987, 2415, 2096, 1713, 1560, 1510, 1355, 1286, 1148, 971, 848, 558, 404 
cm-1.  
3-(1-(4-(4-(Ethoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-1H-
1,2,3-triazol-5-yl)benzoic acid, (14). 
To a solution of compound 13 (100 mg, 0.31 mmol) and commercially available 3-
ethynylbenzoic acid (44.9 mg, 0.31 mmol) in DMF (1.7 mL) Cp*RuCl(cod) (11.7 
mg, 0.1 mmol) was added. The reaction tube was flushed with nitrogen, capped and 
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heated at 90 ºC for 10 min in microwave (CEM Discover SP) to give compound 14 
(57 mg, 0.12 mmol, 39%) as an amorphous yellow solid. 1H NMR (300 MHz, 
CDCl3): δ = 8.25 (s, 1H), 8.05-7.98 (m, 2H), 7.54-7.43 (m, 3H), 7.28-7.26 (m, 2H), 
6.85 (d, J = 7.9 Hz, 2H), 4.37 (q, J = 7.3 Hz, 2H), 1.35 (t, J = 7.3 Hz, 3H). 13C NMR 
(75 MHz, DMSO-d6): δ = 169.5, 165.4, 144.2, 139.7, 134.9 (q, J = 41.2 Hz), 133.7 
(2C), 132.0, 131.8, 131.4, 131.0, 129.8, 129.3, 126.7, 121.5, 119.8, 118.7 (q, J = 
280.8 Hz), 114.5, 62.6, 14.2. IR (neat): ṽ = 3281, 2920, 2851, 1719, 1684, 1296, 
1246, 1150, 1039, 753, 679 cm-1. MS (ESI): m/z 472 [M + H]+.  
Ethyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (15). 
To a solution of (4-nitrophenyl) hydrazine hydrochloride (1.99 g, 10.5 mmol) in 
DMF (20 mL) compound 10 (2.15 mL, 11.04 mmol) was added. The resulting 
mixture was stirred at reflux for 2 h. Then, diethyl ether was added and the organic 
layer was washed with water (x2), dried over sodium sulfate and evaporated to give 
compound 15 (3.32 g, 10.08 mmol, 96%) as a deep yellow solid. 1H NMR (300 MHz; 
CDCl3): δ = 8.39 (d, J = 8.8 Hz, 2H), 8.16 (s,1H), 7.66 (d, J = 8.8 Hz, 2H), 4.38 (q, 
J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). MS (ESI): m/z: 330 [M + H]+. 
Methyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (16). 
Compound 15 (500 mg, 1.52 mmol) was solubilized in MeOH (15 mL) and 
concentrated H2SO4 (950 µL) was added dropwise. The mixture was stirred at reflux 
for 16 h, then volatile was removed under vacuo. Ethyl acetate was added and the 
organic phase was washed with aqueous saturated NaHCO3 solution (x1), dried over 
sodium sulfate and evaporated, affording compound 16 (388 mg, 1.23 mmol, 81%) 
as a yellow solid. 1H NMR (300 MHz, CDCl3): δ = 8.38 (d, J = 8.8 Hz, 2H), 8.16 (s, 
1H), 7.65 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H). MS (ESI): m/z 316 [M + H]+. 
Isopropyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (17). 
The title compound was synthesized as previously reported for the preparation of 
compound 16, starting from compound 15 (516 mg, 1.57 mmol) and using 2-
Pyrtriazoles, a novel class of Store-Operated Calcium Entry modulators: discovery, 
biological profiling and in vivo proof-of-concept efficacy in SOCE-related diseases 
 
71 
propanol as solvent (15 mL).  After evaporation, compound 17 was collected (484 
mg, 1.41 mmol, 90%) as a yellow oil. 1H NMR (300 MHz; CDCl3): δ = 8.35 (d, J = 
8.8 Hz, 2H), 8.12 (s, 1H), 7.63 (d, J = 8.8 Hz, 2H), 5.21 (ept, J = 6.3 Hz, 1H), 1.31 
(d, J = 6.3 Hz, 6H).  MS (ESI): m/z: 344 [M + H]+. 
Methyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (18). 
The title compound was synthesized as previously reported for the preparation of 
compound 9, starting from compound 16 (354 mg, 1.11 mmol). The crude material 
was filtered under vacuo over a pad of celite, rinsed with ethyl acetate and evaporated 
to give compound 18 (297 mg, 1.04 mmol, 94%) as a pale yellow solid. 1H NMR 
(300 MHz; CDCl3): δ = 8.06 (s, 1H), 7.16 (d, J = 8.4 Hz, 2H), 6.70 (d, J = 8.4 Hz, 
2H), 3.89 (s, 3H). MS (ESI): m/z: 286 [M + H]+. 
Isopropyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, 
(19). 
The title compound was synthesized as previously reported for the preparation of 
compound 9, starting from compound 17 (486 mg, 1.42 mmol). The crude material 
was filtered under vacuo over a pad of celite, rinsed with ethyl acetate and evaporated 
to give compound 19 (404 mg, 1.29 mmol, 91%) as a yellow oil. 1H NMR (300 MHz; 
CDCl3): δ = 8.00 (s, 1H), 7.06 (d, J = 6.7 Hz, 2H), 6.61 (d, J = 6.7 Hz, 2H), 5.15 
(ept, J = 6.1 Hz, 1H), 4.78 (br s, 2H), 1.26 (d, J = 6.1 Hz, 6H). MS (ESI): m/z: 314 
[M + H]+. 
Methyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (20). 
The title compound was synthesized as previously reported for the preparation of 
compound 13, starting from compound 18 (276 mg, 0.97 mmol). After evaporation, 
compound 20 was recovered (261 mg, 0.84 mmol, 87%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3): δ = 8.05 (s, 1H), 7.36 (d, J = 8.3 Hz, 2H), 7.08 (d, J = 8.3 Hz, 
2H), 3.85(s, 3H).  
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Isopropyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (21). 
The title compound was synthesized as previously reported for the preparation of 
compound 13, starting from compound 19 (362 mg, 1.16 mmol). The crude material 
was purified by column chromatography using petroleum ether/ethyl acetate 8:2 as 
eluent, yielding compound 21 (224 mg, 0.72 mmol, 62%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3): δ = 8.07 (s, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 
2H), 5.22 (ept, J = 6.0 Hz, 1H), 1.34 (d, J = 6.0 Hz, 6H). 
1-(4-Azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, (24).  
To a solution of compound 13 (1.00 g, 3.07 mmol) in THF (10 mL) and water (10 
mL) NaOH (0.25 g, 6.15 mmol) was added and the resulting mixture was stirred at 
room temperature for 8 h. Then, ethyl acetate was added and the organic phase was 
washed with 3N HCl (x1) and brine (x1), dried over sodium sulfate and evaporated, 
yielding compound 24 (0.55 g, 1.84 mmol, 60%) as a white solid. 1H NMR (300 
MHz, CDCl3): δ = 8.20 (s, 1H), 7.43 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 8.8 Hz, 2H). 
MS (ESI): m/z 298 [M + H]+. 
General procedure for the synthesis of compounds 25-30 
To a solution of compound 24 (131 mg, 0.44 mmol) in dry CH2Cl2 (2.88 mL) EDCI 
(92 mg, 0.48 mmol), TEA (67 µL, 0.48 mmol), DMAP (5.37 mg, 0.05 mmol) and 
the corresponding alcohol (1.1 eq) were added in order. The resulting mixture was 
stirred at room temperature for 16 h. CH2Cl2 was added and the organic phase was 
washed with 3N HCl (x3), dried over sodium sulfate and evaporated. Purification by 
column chromatography using petroleum ether/ethyl acetate 98:2, petroleum 
ether/ethyl acetate 95:5 as eluent yielded compounds 25-30. 
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Characterization of compounds 25-30. 
Pentan-2-yl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, 
(25).  
White solid; yield 47% (76 mg, 0.21 mmol); mp 129-130 °C dec. 1H NMR (300 
MHz, CDCl3): δ = 8.07 (s, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 2H), 
5.14 (sex, J = 6.3 Hz, 1H), 1.78-1.63 (m, 1H), 1.52-1.60 (m,1H), 1.36-1.18 (m, 5H), 
0.92 (t, J = 7.2 Hz, 3H).  
Isopentyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (26).  
Yellow oil; yield 68% (110 mg, 0.30 mmol). 1H NMR (300 MHz, CDCl3): δ = 8.09 
(s, 1H), 7.40 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 4.34 (t, J = 6.6 Hz, 2H), 
1.72-1.63 (m, 3H), 0.96 (d, J = 6.6 Hz, 6H).  
(E)-3,7-Dimethylocta-2,6-dien-1-yl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-
pyrazole-4-carboxylate, (27) 
Yellow oil; yield 48% (91 mg, 0.21 mmol). 1H NMR (300 MHz, CDCl3): δ = 8.10 
(s, 1H), 7.40 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 5.44 (t, J = 6.9 Hz, 1H), 
5.08 (t, J = 6.9 Hz, 1H), 4.82 (d, J = 6.9 Hz, 2H), 2.11-2.08 (m, 4H), 1.80 (s, 3H), 
1.67 (s, 3H), 1.60 (s, 3H).  
Pyridin-4-ylmethyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-
carboxylate, (28).  
White solid; yield 48% (82 mg, 0.21 mmol); mp 149-150 °C. 1H NMR (300 MHz, 
CDCl3): δ = 8.60 (d, J = 5.8 Hz, 2H), 8.14 (s, 1H), 7.37 (d, J = 8.8 Hz 2H), 7.29 (d, 
J = 5.8 Hz, 2H), 7.11 (d, J = 8.8, 2H), 5.33 (s, 2H).  
Benzyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (29). 
White solid; yield 60% (101 mg, 0.26 mmol); mp 136-137 °C. 1H NMR (300 MHz, 
CDCl3): δ = 8.13 (s, 1H), 7.60-7.23 (m, 7H), 7.13 (d, J = 8.5 Hz, 2H), 5.36 (s, 2H). 
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2-Morpholinoethyl 1-(4-azidophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-
carboxylate, (30). 
Yellow oil; yield 55% (98 mg, 0.24 mmol). 1H NMR (300 MHz, CDCl3): δ = 8.09 
(s, 1H), 7.40 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H), 4.43 (t, J = 5.8 Hz, 2H), 
3.82 (t, J = 4.11 Hz, 4H), 2.73 (t, J = 5.8 Hz, 2H), 2.55 (t, J = 4.11 Hz, 4H).  
(1-(4-Azidophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanol, (37).   
Step 1: To a solution of compound 9 (166 mg; 0.55 mmol) in dry THF (4 mL) LiAlH4 
(20.9 mg, 0.55 mmol) was added at 0 °C and under nitrogen atmosphere. The 
reaction was left to reach room temperature. After 6 h the reaction was quenched 
with ethyl acetate and then with saturated aqueous solution of sodium sulfate. The 
mixture was filtered over a pad of celite and rinsed with ethyl acetate. The organic 
phase was washed with water and dried over sodium sulfate and evaporated. The 
crude material was purified with chromatography column using petroleum 
ether/ethyl acetate 7:3 as eluent to give (1-(4-aminophenyl)-5-(trifluoromethyl)-1H-
pyrazol-4-yl)methanol (113.3 mg, 0.44 mmol, 80%) as a yellow solid. 1H NMR (300 
MHz, CDCl3): δ = 7.69 (s, 1H), 7.17 (d, J = 7.9 Hz, 2H), 6.69 (d, J = 7.9 Hz, 2H), 
4.73 (s, 2H). MS (ESI): m/z 258 [M + H]+.  
Step 2: The title compound was synthesized as previously reported for the 
preparation of compound 13, starting from (1-(4-aminophenyl)-5-(trifluoromethyl)-
1H-pyrazol-4-yl)methanol (107 mg, 0.42 mmol).  After evaporation, compound 37 
was recovered (109.4 mg, 0.39 mmol, 92%) as a yellow oil. 1H NMR (300 MHz, 
CDCl3): δ = 7.74 (s, 1H), 7.40 (d, J = 7.1 Hz, 2H), 7.10 (d, J = 7.1 Hz, 2H), 4.72 (s, 
2H). 
1-(4-Azidophenyl)-N-isopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide, 
(39).  
To a solution of compound 24 (407.5 mg, 1.37 mmol) in dry CH2Cl2 (4 mL) EDCI 
(315.6 mg, 1.65 mmol), TEA (420 µL, 3.02 mmol), HOBt (222.5 mg, 1.65 mmol) 
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and isopropyl amine (141 µL, 1.65 mmol) were added in order. The resulting mixture 
was stirred at room temperature for 16 h. CH2Cl2 was added and the organic phase 
was washed with aqueous saturated NH4Cl solution (x1), dried over sodium sulfate 
and evaporated. Purification by column chromatography using petroleum ether/ethyl 
acetate 8:2 and petroleum ether/ethyl acetate 7:3 as eluents yielded compound 39 
(272 mg, 0.80 mmol, 59%) as a white solid. 1H NMR (300 MHz, CD3OD): δ = 7.93 
(s, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.5 Hz, 2H), 4.14 (ept, J = 6.3 Hz, 
1H), 1.23 (d, J = 6.3 Hz, 6H). 
3-(1-(4-(4-Carbamoyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-1H-1,2,3-
triazol-4-yl)benzoic acid, (41).  
Compound 1S (50 mg, 0.10 mmol) was suspended in 33% aqueous ammonium 
hydroxide solution (1.4 mL) in a screw-capped tube. The reaction was stirred at 90 
°C for 3 h. Then, the solvent was removed under vacuo and the crude material was 
subjected to column chromatography using ethyl acetate as eluent to give compound 
41 (28 mg, 0.06 mmol, 63%) as a white solid. mp 160-161 °C dec. 1H NMR (300 
MHz, CD3OD): δ = 9.11 (br s, 1H), 8.17 (d, J = 8.5 Hz, 2H), 8.12 (s, 1H), 8.07 (s, 
1H), 7.95 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 7.1 Hz ,1H), 7.69 (d, J = 7.1 Hz, 1H), 7.59 
(s, 1H), 7.35 (t, J = 7.1 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ = 172.3, 163.0, 
147.4, 143.1, 138.1, 136.2, 134.7 (q, J = 38.6 Hz), 132.3, 131.0, 130.0, 129.1, 128.8, 
128.7, 128.6, 126.7, 121.2, 121.1, 118.7 (q, J = 259.6 Hz). IR (neat): ṽ = 3188, 2853, 
2634, 1913, 1577, 1421, 1133, 1035, 973, 846, 754 719, 658, 532, 505 cm-1. MS 
(ESI): m/z 443 [M + H]+. 
Ethyl 1-(4-(4-(3-((methylsulfonyl)carbamoyl)phenyl)-1H-1,2,3-triazol-1-
yl)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, (42).  
To a solution of compound 1S (100 mg, 0.21 mmol) in dry CH2Cl2 (2 mL), EDCI 
(80 mg, 0.42 mmol), TEA (87 μL, 0.63 mmol), DMAP (2.4 mg, 0.02 mmol) and 
methansulfonamide (40 mg, 0.42 mmol) were added in order under nitrogen. The 
reaction was stirred at room temperature for 16 h. Then, CH2Cl2 is added and the 
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organic phase was washed with aq. sat. NH4Cl, dried over sodium sulfate and 
evaporated. The crude material was purified by column chromatography using ethyl 
acetate and ethyl acetate/methanol 9:1 as eluents to afford compound 42 (82 mg, 0.15 
mmol, 71%) as a white solid. mp 209-210 °C. 1H NMR (300 MHz, CD3OD): δ = 
9.02 (s, 1H), 8.57 (s, 1H), 8.21-8.14 (m, 3H), 8.03 (d, J = 7.9 Hz, 2H), 7.73 (d, J = 
7.9 Hz, 2H), 7.45 (t, J = 8.2 Hz, 1H), 4.36 (q, J = 6.6 Hz, 2H), 1.38 (t, J = 6.6 Hz, 
3H). 13C NMR (75 MHz, acetone-d6): δ = 173.9, 160.5, 148.1, 142.5, 139.1, 138.1, 
133.1 (q, J = 40.3 Hz), 130.5, 129.9, 129.8, 128.9, 128.1, 127.8, 126.7, 120.6, 119.3, 
118.4 (q, J = 281 Hz), 117.1, 61.1, 40.3, 13.6. IR (KBr): ṽ = 3093, 2982, 1731, 1649, 
1523, 1357, 1243, 1148, 959, 848 cm-1. MS (ESI): m/z 549 [M + H]+. 
Methyl 3-ethynylbenzoate, (44). 
Step 1: To a solution of methyl 3-bromobenzoate (2 g, 9.30 mmol) in toluene (50 
mL) DIPEA (6.5 mL, 37.2 mmol), CuI (0.32 g, 1.67 mmol), Pd(PPh3)2Cl2 (0.39 g, 
0.56 mmol) and ethynyltrimethylsilane (5.25 mL, 37.2 mmol) were added in a 
Schlenk apparatus. The reaction was stirred at reflux for 6 h under nitrogen 
atmosphere. Then, the mixture was filtered over a pad of celite and rinsed with ethyl 
acetate. The organic phase was washed with water (x1), dried over sodium sulfate 
and evaporated. The crude material was purified by column chromatography using 
petroleum ether and petroleum ether/ethyl acetate 95:5 as eluents to give methyl 3-
((trimethylsilyl)ethynyl)benzoate as a brown oil (1.95 g, 8.30 mmol, 89%). 1H NMR 
(300 MHz; CDCl3): δ = 8.10 (s, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.59 (d, J = 7.7 Hz, 
1H), 7.32 (t, J = 7.7 Hz, 1H), 3.88 (s, 3H), 0.22 (s, 9H).  
Step 2: Methyl 3-((trimethylsilyl)ethynyl)benzoate (0.60 g, 2.55 mmol) was 
dissolved  in THF (6 mL). The mixture was cooled at 0 °C and CH3COOH (175 µL, 
3.06 mmol) and TBAF (3.06 mL, 3.06 mmol) were added. The reaction was stirred 
at 0 °C for 1 h. The volatile was removed under vacuo, ethyl acetate was added and 
the organic layer was washed with water (x1). After drying over sodium sulfate and 
evaporation of the solvent, the crude material was purified by column 
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chromatography using petroleum ether and petroleum ether/ethyl acetate 95:5 as 
eluents to give compound 44 (0.40 g, 2.50 mmol, 98%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3): δ = 8.17 (s, 1 H), 7.96 (d, J = 6.5 Hz, 1H), 7.67 (d, J = 6.5 Hz, 
1H), 7.40 (t, J = 6.5 Hz, 1H), 3.92 (s, 3H), 3.12 (s, 1H). MS (ESI): m/z: 161 [M + 
H]+. 
1-(3-Ethynylphenyl)ethanone, (46). 
Step 1: To a solution of 1-(3-bromophenyl)ethanone (2 g, 10.05 mmol) in THF (20 
mL) TEA (2.1 mL, 15.07 mmol), CuI (7.62 mg, 0.04 mmol), Pd(PPh3)2Cl2 (141.08 
mg, 0.20 mmol) and ethynyltrimethylsilane (2.78 mL, 20.09 mmol) were added in a 
Schlenk apparatus. The reaction was stirred at 50 °C for 6 h under nitrogen 
atmosphere. Then, the mixture was filtered under vacuo and rinsed with ethyl acetate. 
The volatile was then removed under vacuo and the crude material was purified by 
column chromatography using petroleum ether/ethyl acetate 98:2 as eluents to give 
1-(3-((trimethylsilyl)ethynyl)phenyl)ethanone as a brown oil (2.13 g, 9.85 mmol, 
98%). 1H NMR (300 MHz; CDCl3): δ = 7.96 (s, 1H), 7.78 (d, J = 7.7 Hz, 1H), 7.56 
(d, J = 7.7 Hz, 1H), 7.28 (t, J = 7.7 Hz, 1H), 3.02 (s, 3H), 0.24 (s, 9H).  
Step 2: 1-(3-((Trimethylsilyl)ethynyl)phenyl)ethanone (1.84 g, 8.52 mmol) was 
dissolved  in MeOH (18 mL) and K2CO3 (2.96 g, 21.4 mmol) was added. The 
reaction was stirred for 1 h. The volatile was removed under vacuo, ethyl acetate was 
added and the organic layer was washed with water (x1). After drying over sodium 
sulfate and evaporation of the solvent, the crude material was purified by column 
chromatography using petroleum ether/ethyl acetate 95:5 as eluent to give compound 
46 (1.20 g, 8.33 mmol, 98%) as a yellow solid. 1H NMR (300 MHz, CDCl3): δ = 
8.01 (s, 1H), 7.88 (d, J = 7.6 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.37 (t, J = 7.6 Hz, 
1H), 3.13 (s, 1H), 2.56 (s, 3H). MS (ESI): m/z: 145 [M + H]+. 
3-Bromobenzamide, (62). 
3-Bromobenzoic acid (2 g, 9.95 mmol) was dissolved in THF (20 mL) and oxalyl 
chloride (1.74 mL, 19.90 mmol) and DMF (62 µL) were added. After stirring at room 
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temperature for 2 h, conc. NH4OH (12 mL) was added. The reaction was stirred for 
additional 30 min and then was evaporated, affording compound 62 (2.11 g, 9.75 
mmol, 98%) as a white solid. 1H NMR (300 MHz; CD3OD): δ = 8.04 (s, 1H) 7.84 
(d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H). 
3-Ethynylbenzamide, (48). 
Step 1: 3-((Trimethylsilyl)ethynyl)benzamide was synthesized as previously 
reported for the preparation of compound 44 in step 1, starting from compound 47 
(1.30 g, 6.02 mmol). The crude material was subjected to chromatography column 
using petroleum ether/ethyl acetate 7:3 and petroleum ether/ethyl acetate 5:5 as 
eluents, yielding 3-((trimethylsilyl)ethynyl)benzamide (0.63 g, 2.91 mmol, 48%) as 
a brown oil. 1H NMR (300 MHz; CDCl3): δ = 7.88 (s, 1H), 7.76 (d, J = 7.9 Hz, 1H), 
7.60 (d, J = 7.9 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 0.26 (s, 9H).  
Step 2: 3-((Trimethylsilyl)ethynyl)benzamide (0.63 g, 2.89 mmol) was dissolved  in 
THF (13 mL). The mixture was cooled at 0 °C and TBAF (3.47 mL, 3.47 mmol) was 
added. The reaction was stirred at 0 °C for 30 min. The volatile was removed under 
vacuo, water was added and the aqueous layer was extracted with ethyl acetate (x3). 
The organic phase was dried over sodium sulfate and evaporated. The crude material 
was purified by column chromatography using petroleum ether/ethyl acetate 5:5 as 
eluent to give compound 48 (0.33 g, 2.25 mmol, 79%) as a yellow solid. 1H NMR 
(300 MHz, CDCl3): δ = 7.91 (s, 1 H), 7.80 (d, J = 7.7 Hz, 1H), 7.64 (d, J = 7.7 Hz, 
1H), 7.43 (t, J = 7.7 Hz, 1H), 3.13 (s, 1H). MS (ESI): m/z: 146 [M + H]+. 
(3-Ethynylphenyl)methanol, (50). 
Step 1: In a Schlenk apparatus (3-bromophenyl)methanol (1.5 g, 8.02 mmol), TEA 
(7.5 mL), PPh3 (42.02 mg, 0.16 mmol), Pd(OAc)2 (18.01 mg, 0.08 mmol) and 
ethynyltrimethylsilane (2.23 mL, 16.04 mmol) were added. The reaction was stirred 
at 94 °C for 1 h under nitrogen atmosphere. Then, the mixture was filtered under 
vacuo and rinsed with ethyl acetate. The organic phase was washed with water (3x) 
and dried over sodium sulfate. The volatile was then removed under vacuo and the 
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crude material was purified by column chromatography using petroleum ether/ethyl 
acetate 95:5 and petroleum ether/ethyl acetate 9:1 as eluents to give (3-
((trimethylsilyl)ethynyl)phenyl)methanol as a brown oil (1.07 g, 5.25 mmol, 65%). 
1H NMR (300 MHz; CDCl3): δ = 7.96 (s, 1H), 7.26 (d, J = 7.2 Hz, 1H), 7.18 (d, J = 
7.2 Hz, 1H), 6.98 (t, J = 7.2 Hz, 1H), 4.50 (s, 2H), 0.21 (s, 9H). 
Step 2: The title compound was synthesized as previously reported for the 
preparation of compound 46 in step 2, starting from (3-
((trimethylsilyl)ethynyl)phenyl)methanol (1.07 g, 5.25 mmol). The crude material 
was subjected to chromatography column using petroleum ether/ethyl acetate 95:5 
and petroleum ether/ethyl acetate 9:1 as eluents, yielding compound 50 (0.34 g, 2.52 
mmol, 49%) as a yellow oil. 1H NMR (300 MHz, CDCl3): δ = 7.42 (s, 1H), 7.32 (d, 
J = 6.2 Hz, 1H), 7.22-7.11 (m, 2H), 4.56 (s, 2H), 3.01 (s, 1H). MS (ESI): m/z: 133 
[M + H]+. 
3-Ethynylbenzenesulfonamide, (52). 
 Step 1: 3-((Trimethylsilyl)ethynyl)benzenesulfonamide was synthesized as 
previously reported for the preparation of compound 44 in step 1, starting from 
compound 51 (0.50 g, 2.12 mmol). The crude material was subjected to 
chromatography column using petroleum ether/ethyl acetate 95:5 and petroleum 
ether/ethyl acetate 8:2 as eluents, yielding 3-
((trimethylsilyl)ethynyl)benzenesulfonamide (0.53 g, 2.09 mmol, 99%) as a brown 
oil. 1H NMR (300 MHz; CDCl3): δ = 8.02 (s, 1H), 7.85 (d, J = 7.6 Hz, 1H), 7.64 (d, 
J = 7.6 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 0.25 (s, 9H). 
 Step 2: The title compound was synthesized as previously reported for the 
preparation of compound 46 in step 2, starting from 3-
((trimethylsilyl)ethynyl)benzenesulfonamide (0.53 g, 2.11 mmol). After 
evaporation, ethyl acetate wad added and the organic phase was washed with HCl 
3N, dried over sodium sulfate and evaporated. The crude material was subjected to 
chromatography column using petroleum ether/ethyl acetate 7:3 as eluent, yielding 
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compound 52 (0.34 g, 1.88 mmol, 89%) as a yellow oil. 1H NMR (300 MHz; 
CD3OD): δ = 8.03 (s, 1 H), 7.87 (d, J = 7.7 Hz, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.53 
(t, J = 7.7 Hz, 1H), 3.67 (s, 1H). MS (ESI): m/z: 182 [M + H]+. 
3-Ethynyl-N-hydroxybenzamide, (54). 
To a solution of 3-ethynylbenzoic acid (99 mg, 0.68 mmol) in dry CH2Cl2 (1 mL), 
TEA (94 µL, 0.68 mmol), EDCI (143 mg, 0.68 mmol) and O-
(trimethylsilyl)hydroxylamine (99.6 mg, 0.68 mmol) were added in order under 
nitrogen atmosphere. After 4 h, the reaction was finished. The volatile was removed 
under vacuo and the crude material was dissolved in THF (3.2 mL). The mixture was 
cooled at 0 °C and TBAF (0.68 mL, 0.68 mmol) was added. The reaction was stirred 
for 1 h at 0 °C and then ethyl acetate was added. The organic phase was washed with 
HCl 3N (1x), dried over sodium sulfate and evaporated. The crude material was 
purified by column chromatography using ethyl acetate and ethyl acetate/methanol 
8:2 as eluents, yielding compound 54 (76.6 mg, 0.48 mmol, 70%) as a white solid. 
1H NMR (300 MHz; CD3OD): δ = 7.84 (s, 1H), 7.73 (d, J = 7.7 Hz, 1H), 7.59 (d, J 
= 7.7 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 3.56 (s, 1H). MS (ESI): m/z: 162 [M + H]+. 
General procedure for the preparation of compounds 22-23, 31-36, 38, 40, 55-
59. 
To a suspension of azide (0.29 mmol, 1 eq) in water (570 µL) and t-BuOH (570 µL) 
alkyne (0.29 mmol, 1 eq) was added. Then, 30 µL of aqueous solution of sodium 
ascorbate 1M and copper sulfate pentahydrate (0.0029 mmol, 0.01 eq) were added 
and the mixture was maintained under vigorous stirring overnight. Ice was added and 
the precipitate was filtered and rinsed with water and heptane. Purification by silica 
gel column chromatography afforded compounds 22-23, 31-36, 38, 40, 55-59. 
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3-(1-(4-(4-(Methoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-1H-
1,2,3-triazol-4-yl)benzoic acid, (22).  
The title compound was synthesized following the general procedure, starting from 
compound 20 (260 mg, 0.84 mmol) and 3-ethynylbenzoic acid (123 mg, 0.84 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 4:6 and petroleum ether/ethyl acetate 1:9 as eluents to afford 
compound 22 (210 mg, 0.46 mmol, 55%) as a white solid. mp 228-229 °C dec. 1H 
NMR (300 MHz, DMSO-d6): δ = 9.57 (s, 1H), 8.56 (s, 1H), 8.33 (s, 1H), 8.26-8.19 
(m, 3H), 7.97 (d, J = 6.9 Hz, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.62 (t, J = 6.9 Hz, 1H), 
3.86 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 161.2 (2C), 147.5, 143.0, 139.1, 
138.1 (2C), 132.4 (q, J = 39.5 Hz), 130.9, 129.8, 129.7, 128.5, 126.8, 121.2 (2C), 
120.9, 119.4 (q, J = 268.3 Hz), 116.6, 52.9. IR (KBr): ṽ = 3511, 2958, 1724, 1688, 
1524, 1261, 1039, 846, 759, 554 cm-1. MS (ESI): m/z 458 [M + H]+. 
3-(1-(4-(4-(Isopropoxycarbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-
1H-1,2,3-triazol-4-yl)benzoic acid, (23). 
The title compound was synthesized following the general procedure, starting from 
compound 21 (83 mg, 0.24 mmol) and 3-ethynylbenzoic acid (35.8 mg, 0.24 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 6:4 and petroleum ether/ethyl acetate 4:6 as eluents to afford 
compound 23 (63 mg, 0.13 mmol, 54%) as a white solid. mp 250-251 °C dec. 1H 
NMR (300 MHz, DMSO-d6): δ = 9.58 (s, 1H), 8.55 (s, 1H), 8.33 (s, 1H), 8.27-8.05 
(m, 3H), 7.97 (d, J = 7.6 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.64 (t, J = 7.6 Hz, 1H), 
5.15 (ept, J = 6.3 Hz, 1H), 1.32 (t, J = 6.0 Hz, 6H). 13C NMR (75 MHz, DMSO-d6): 
δ = 167.4, 159.9, 146.9, 142.4, 138.7, 137.5, 131.6 (q, J = 39.3 Hz), 130.3, 129.3, 
129.2, 129.1, 128.0 (2C), 126.2, 120.7 (2C), 118.8 (q, J = 244.3 Hz), 116.8, 69.4, 
22.0. IR (KBr): ṽ = 3479, 2924, 1716, 1689, 1524, 1298, 1149, 1033, 845, 759 cm-1. 
MS (ESI): m/z 486 [M + H]+. 
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3-(1-(4-(4-((Pentan-2-yloxy)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-
yl)phenyl)-1H-1,2,3-triazol-4-yl)benzoic acid, (31).  
The title compound was synthesized following the general procedure, starting from 
compound 25 (66.6 mg, 0.18 mmol) 3-ethynylbenzoic acid (26.5 mg, 0.18 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 8:2 and petroleum ether/ethyl acetate 5:5 as eluents to afford 
compound 31 (72 mg, 0.14 mmol, 80%) as a white solid. mp 198-199 °C. 1H NMR 
(300 MHz, CDCl3) δ = 8.60 (s, 1H), 8.40 (s, 1H), 8.28 (d, J = 7.3 Hz, 1H), 8.15 (d, 
J = 7.6 Hz, 2H), 8.00 (d, J = 7.6 Hz, 2H), 7.77-7.57 (m, 3H), 5.19 (sex, J = 4.2 Hz, 
1H), 1.82-1.67 (m, 1H), 1.67-1.53 (m, 1H), 1.51-1.40 (m, 1H), 1.35 (d, J = 6.0 Hz, 
3H), 1.30-1.22 (m, 1H), 0.96 (t, J = 7.0 Hz, 3H). 13C NMR (75 MHz, DMSO-d6) δ = 
167.6, 160.6, 147.4, 143.0, 139.3, 138.0, 132.6 (q, J = 40 Hz), 132.3, 131.0, 130.0, 
129.7, 128.6, 126.7, 121.3, 121.2, 121.1, 119.3 (q, J = 269.0 Hz), 117.3, 72.2, 37.9, 
20.2, 18.6 14.3. IR (KBr): ṽ = 2960, 2873, 2670, 1716, 1523, 1249, 1033, 845, 759, 
683 cm-1. IR (KBr): ṽ = 2960, 2873, 2670, 1716, 1523, 1249, 1033, 845, 759, 683 
cm-1. MS (ESI): m/z 514 [M + H]+ 
3-(1-(4-(4-((Isopentyloxy)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-
1H-1,2,3-triazol-4-yl)benzoic acid, (32). 
The title compound was synthesized following the general procedure, starting from 
compound 26 (80.4 mg, 0.22 mmol) and 3-ethynylbenzoic acid (32.1 mg, 0.22 
mmol). The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 7:3 and petroleum ether/ethyl acetate 4:6 as eluents to afford 
compound 32 (66 mg, 0.13 mmol, 58%) as a white solid. mp 217-218 °C. 1H NMR 
(300 MHz, acetone-d6): δ = 9.29 (s, 1H), 8.65 (s, 1H), 8.27-8.22 (m, 4H), 8.02 (d, J 
= 7.1 Hz, 1H), 7.85 (d, J = 8.2 Hz, 2H), 7.62 (t, J = 7.1 Hz, 1H), 4.36 (t, J = 6.1 Hz, 
2H), 1.82-1.77 (m, 1H), 1.65 (q, J = 6.1 Hz, 2H), 0.95 (d, J = 6.1 Hz, 6H). 13C NMR 
(75 MHz, DMSO-d6): δ = 167.6, 160.9, 147.3, 143.0, 139.2, 138.0, 132.5, 132.2 (q, 
J = 36 Hz), 130.9, 130.2, 129.7, 128.6, 126.7, 121.2 (2C), 121.0, 119.2 (q, J = 250.0 
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Hz), 116.9, 64.1, 37.4, 25.0, 22.8. IR (KBr): ṽ = 2958, 2873, 1732, 1689, 1524, 1299, 
1252, 1151, 1033, 845, 759 cm-1. MS (ESI): m/z 514 [M + H]+. 
(E)-3-(1-(4-(4-(((3,7-Dimethylocta-2,6-dien-1-yl)oxy)carbonyl)-5-
(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-1H-1,2,3-triazol-4-yl)benzoic acid, 
(33).  
The title compound was synthesized following the general procedure, starting from 
compound 27 (53 mg, 0.12 mmol) and 3-ethynylbenzoic acid (17.9 mg, 0.12 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 3:7 and petroleum ether/ethyl acetate 1:9 as eluents to afford 
compound 33 (38 mg, 0.06 mmol, 54%) as a white solid. mp 198-199 °C. 1H NMR 
(300 MHz, acetone-d6): δ = 9.30 (s, 1H), 8.66 (s, 1H), 8.28-8.25 (m, 3H), 8.21 (s, 
1H), 8.07 (d, J = 7.4 Hz, 1H), 7.85 (d, J = 8.5 Hz, 2H), 7.65 (t, J = 7.4 Hz, 1H), 5.49 
(t, J = 7.1 Hz, 1H), 5.12 (t, J = 7.1 Hz, 1H), 4.85 (d, J = 7.1 Hz, 2H), 2.13-2.04 (m, 
4H), 1.79 (s, 3H), 1.65 (s, 3H), 1.60 (s, 3H).  13C NMR (75 MHz, acetone-d6): δ = 
166.6, 160.4, 147.5, 142.7, 142.5, 139.4, 138.2, 132.3 (q, J = 40.1 Hz), 131.5, 131.4, 
131.1, 129.9, 129.4, 129.3, 128.0, 126.8, 123.8, 120.1, 119.6, 119.4 (q, J = 279.4 
Hz), 118.3, 117.1, 61.7, 39.4, 26.4, 25.6, 16.9, 15.7. IR (KBr): ṽ = 3554, 3141, 2986, 
1637, 1616, 1524, 1384, 1230, 968, 844 cm-1. MS (ESI): m/z 580 [M + H]+. 
3-(1-(4-(4-((Pyridin-4-ylmethoxy)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-
yl)phenyl)-1H-1,2,3-triazol-4-yl)benzoic acid, (34).  
The title compound was synthesized following the general procedure, starting from 
compound 28 (81 mg, 0.21 mmol) and 3-ethynylbenzoic acid (30.5 mg, 0.21 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 6:4 and petroleum ether/ethyl acetate 4:6 as eluents to afford 
compound 34 (63 mg, 0.12 mmol, 56%) as a white solid.  mp 169-170 °C. 1H NMR 
(300 MHz, CD3OD): δ = 9.60 (br s, 1H), 8.73-8.49 (m, 5H), 8.30-8.16 (m, 3H), 8.08-
7.68 (m, 5H), 7.47 (s, 1H), 5.43 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 172.1, 
162.4, 147.9, 147.6, 140.8, 139.3, 137.8, 134.8, 133.3 (q, J = 39.2 Hz), 133.0, 130.9, 
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130.8, 129.7, 129.5, 128.7, 128.3, 126.7, 125.4, 121.3, 120.9, 119.6 (q, J = 265.3 
Hz), 70.5. IR (KBr): ṽ = 3086, 2924, 2131, 1718, 1522, 1294, 1239, 1142, 808, 758 
cm-1. MS (ESI): m/z 535 [M + H]+. 
3-(1-(4-(4-((Benzyloxy)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-
1H-1,2,3-triazol-4-yl)benzoic acid, (35).  
The title compound was synthesized following the general procedure, starting from 
compound 29 (45.2 mg, 0.12 mmol) and 3-ethynylbenzoic acid (17 mg, 0.12 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 5:5 and petroleum ether/ethyl acetate 2:8 as eluents to afford 
compound 35 (42 mg, 0.08 mmol, 65%) as a white solid. mp 196-197 °C dec. 1H 
NMR (300 MHz, CD3OD): δ = 9.61 (br s, 1H), 8.55 (s, 1H), 8.44 (s, 1H), 8.21 (d, J 
= 8.6 Hz, 2H), 7.97 (d, J = 7.8 Hz, 1H), 7.88 (d, J = 8.6 Hz, 2H), 7.67 (t, J = 7.8 Hz, 
1H), 7.50-7.38 (m, 7H), 5.38 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 167.6, 
160.7, 147.3, 143.1, 134.3 (q, J = 39.3 Hz), 139.2, 138.1, 136.2, 132.3, 131.0, 130.0, 
129.7, 129.1 (2C), 128.8 (2C), 128.7, 128.6, 126.7, 121.2, 119.7 (q, J = 269 Hz), 
116.6, 67.1. IR (KBr): ṽ = 3092, 2933, 2131, 1721, 1522, 1298, 971, 850, 561 cm-1. 
MS (ESI): m/z 534 [M + H]+. 
3-(1-(4-(4-((2-Morpholinoethoxy)carbonyl)-5-(trifluoromethyl)-1H-pyrazol-1-
yl)phenyl)-1H-1,2,3-triazol-4-yl)benzoic acid, (36).  
The title compound was synthesized following the general procedure, starting from 
compound 30 (40.3 mg, 0.10 mmol) and 3-ethynylbenzoic acid (14.4 mg, 0.10 
mmol). The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 2:8 and ethyl acetate/methanol 9:1 as eluents to afford compound 
36 (29 mg, 0.05 mmol, 53%) as a yellow solid. mp 196-197 °C dec. 1H NMR (300 
MHz, DMSO-d6): δ = 8.40 (d, J = 7.6 Hz, 2H), 8.26 (s, 1H), 8.18 (s, 1H), 8.04 (s, 
1H), 7.52 (t, J = 7.6 Hz, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3Hz, 2H), 4.54 
(t, J = 5.8 Hz, 2H), 3.85-3.82 (m, 4H), 2.98 (t, J = 5.8 Hz, 2H), 2.84-2.80 (m, 4H). 
13C NMR (75 MHz, DMSO-d6): δ = 161.3, 158.7, 148.1, 145.6, 144.3, 144.2, 142.1, 
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132.1 (q, J = 39.2 Hz), 131.3, 129.7, 128.1, 127.0, 125.4, 124.3, 121.6, 119.3 (q, J = 
269.1 Hz), 116.2, 114.6, 68.1, 60.4, 55.8, 55.3. IR (KBr): ṽ = 2923, 2360, 2124, 
2092, 1725, 1512, 1299, 1226, 1143, 1037, 974 cm-1. MS (ESI): m/z 557 [M + H]+. 
3-(1-(4-(4-(Hydroxymethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-1H-
1,2,3-triazol-4-yl)benzoic acid, (38).  
The title compound was synthesized following the general procedure, starting from 
compound 37 (104.4 mg, 0.37 mmol) and 3-ethynylbenzoic acid (53.8 mg, 0.37 
mmol). The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 4:6 and petroleum ether/ethyl acetate 2:8 as eluents to afford 
compound 38 (132 mg, 0.31 mmol, 83%) as a white solid. mp 225-226°C. 1H NMR 
(300 MHz, acetone-d6): δ = 9.27 (s, 1H), 8.65 (s, 1H), 8.29-8.21 (m, 3H), 8.05 (d, J 
= 7.7 Hz, 1H), 7.87 (s, 1H), 7.77 (d, J = 8.5 Hz, 2H), 7.65 (t, J = 7.7 Hz, 1H), 4.75 
(s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 167.6, 147.3, 141.3, 139.3, 137.5, 132.2, 
131.0, 130.0, 129.7, 128.2, 127.2 (q, J = 37.7 Hz), 126.8, 126.7, 121.3 (2C), 121.2 
(q, J = 207.5 Hz), 121.0, 53.9. IR (KBr): ṽ = 3223, 3123, 2893, 2669, 1689, 1524, 
1306, 1140, 845, 759 cm-1. MS (ESI): m/z 430 [M + H]+.  
3-(1-(4-(4-(Isopropylcarbamoyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-
1H-1,2,3-triazol-4-yl)benzoic acid, (40).  
The title compound was synthesized following the general procedure, starting from 
compound 39 (150 mg, 0.44 mmol) and 3-ethynylbenzoic acid (65 mg, 0.44 mmol). 
The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 3:7 and ethyl acetate as eluents to afford compound 40 (185 mg, 
0.38 mmol, 87%) as a white solid. mp 237-238 °C. 1H NMR (300 MHz, DMSO-d6): 
δ = 9.52 (s, 1H), 8.56 (s, 1H), 8.36 (d, J = 7.4 Hz, 1H), 8.22 (d, J = 8.6 Hz, 2H), 8.15 
(s, 1H), 7.98 (d, J = 7.4 Hz, 1H), 7.78 (d, J = 8.6 Hz, 2H), 7.60 (t, J = 7.4 Hz, 1H), 
4.04 (ept, J = 6.3 Hz, 1H), 1.18 (s, 3H), 1.16 (s, 3H). 13C NMR (75 MHz, DMSO-
d6): δ =.168.8 (2C), 159.8, 147.7, 140.3, 139.1, 137.8, 134.7, 130.6, 129.8 (q, J = 
42.6 Hz), 129.7, 129.6, 129.1, 126.7, 122.7, 121.3, 120.7, 118.1 (q, J = 263.8 Hz), 
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41.6, 22.7. IR (KBr): ṽ = 2972, 2876, 1689, 1647, 1522, 1456, 1398, 1297, 1148, 
847, 815 cm-1. MS (ESI): m/z 485 [M + H]+.  
Ethyl 1-(4-(4-(3-(methoxycarbonyl)phenyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate, (55). 
The title compound was synthesized following the general procedure, starting from 
compound 13 (94 mg, 0.29 mmol) and alkyne 44 (46 mg, 0.29 mmol). The crude 
material was purified by column chromatography using petroleum ether/ethyl acetate 
7:3 and petroleum ether/ethyl acetate 5:5 as eluents to afford compound 55 as a 
yellow solid (83 mg, 0.17 mmol, 59%). mp 160-161 °C. 1H NMR (300 MHz, DMSO-
d6): δ = 9.61 (s, 1H), 8.55 (s, 1H), 8.37 (s, 1H), 8.31-8.10 (m, 3H), 7.99 (d, J = 7.7 
Hz, 1H), 7.84 (d, J =  6.1 Hz, 2H), 7.69 (t, J =  7.7 Hz, 1H), 4.34 (q, J =  7.1 Hz, 2H), 
3.92 (s, 3H), 1.32 (t, J =  7.0 Hz, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 166.5, 
160.9, 147.1, 143.0, 139.2, 138.0, 132.5 (q, J = 39.1 Hz), 131.2, 131.1, 130.5, 130.3, 
129.5, 128.6, 126.4, 121.2 (2C), 117.0, 115.3 (q, J = 269.1 Hz), 61.7, 52.9, 14.5. IR 
(KBr): ṽ = 3139, 2987, 1712, 1525, 1289, 1238, 971, 850 cm-1. MS (ESI): m/z 486 
[M + H]+. 
Ethyl 1-(4-(1-(3-acetylphenyl)-1H-1,2,3-triazol-4-yl)phenyl)-5-(trifluoromethyl)-
1H-pyrazole-4-carboxylate, (56).  
The title compound was synthesized following the general procedure, starting from 
compound 13 (150 mg, 0.46 mmol) and alkyne 46 (66 mg, 0.46 mmol). The crude 
material was purified by column chromatography using petroleum ether/ethyl acetate 
8:2 and petroleum ether/ethyl acetate 7:3 as eluents to afford compound 56 as a 
yellow solid (173 mg, 0.37 mmol, 80%). mp 213-214 °C. 1H NMR (300 MHz, 
DMSO-d6): δ = 9.61 (s, 1H), 8.51 (s, 1H), 8.37 (s, 1H), 8.27-8.17 (m, 3H), 8.00 (d, 
J = 7.7 Hz, 1H), 7.88 (d, J = 8.5 Hz, 2H), 7.69 (t, J = 7.7 Hz, 1H), 4.34 (q, J = 6.9 
Hz, 2H), 2.68 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 
198.4, 160.9, 147.4, 143.0, 139.2, 138.1, 138.0, 134.0 (q, J = 38.9 Hz), 131.1, 130.3, 
130.2, 128.8, 128.6, 126.2 (q, J = 252 Hz), 125.4, 121.3, 121.2, 118.5, 61.7, 27.4, 
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14.5. IR KBr): ṽ = 3137, 2914, 1718, 1677, 1524, 1238, 1158, 1076, 1036, 968, 852 
cm-1. MS (ESI): m/z 470 [M + H]+.  
Ethyl 1-(4-(4-(3-carbamoylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate, (57).  
The title compound was synthesized following the general procedure, starting from 
compound 13 (94.2 mg, 0.29 mmol) and alkyne 48 (42.1 mg, 0.29 mmol). The crude 
material was purified by column chromatography using petroleum ether/ethyl acetate 
5:5 and petroleum ether/ethyl acetate 2:8 as eluents to afford compound 57 as a 
yellow solid (89 mg, 0.19 mmol, 65%). mp 213.5-214.5 °C. 1H NMR (300 MHz, 
DMSO-d6): δ = 9.51 (s, 1H), 8.49 (s, 1H), 8.35 (s, 1H), 8.20 (d, J = 8.8 Hz, 2H), 8.10 
(d, J = 7.5 Hz, 1H), 7.98-7.80 (m, 3H), 7.59 (t, J = 7.5 Hz, 1H), 7.51 (br s, 2H), 4.32 
(q, J = 6.9 Hz, 2H), 1.30 (t, J = 6.9 Hz, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 
168.2, 160.8, 147.7, 143.0, 139.2, 138.1, 135.7, 132.3 (q, J = 38.9 Hz), 130.7, 129.6, 
128.5 (2C), 127.8, 125.3, 121.2, 120.9, 117.0, 116.8 (q, J = 269.2 Hz), 61.7, 14.5. IR 
(KBr): ṽ = 3436, 3130, 1690, 1557, 1523, 1257, 1039, 781, 682 cm-1. MS (ESI): m/z 
471 [M + H]+. 
Ethyl 1-(4-(1-(3-(hydroxymethyl)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate, (58). 
The title compound was synthesized following the general procedure, starting from 
compound 13 (315 mg, 0.97 mmol) and alkyne 50 (128 mg, 0.97 mmol). The crude 
material was purified by column chromatography using petroleum ether/ethyl acetate 
5:5 and petroleum ether/ethyl acetate 2:8 as eluents to afford compound 58 as a 
yellow solid (201 mg, 0.44 mmol, 45%). mp 200.5-201.5 °C. 1H NMR (300 MHz, 
DMSO.d6): δ = 9.45 (s, 1H), 8.37 (s, 1H), 8.19 (d, J = 7.2 Hz, 2H), 7.95 (s, 1H), 
7.91-7.80 (m, 3H), 7.45 (t, J = 6.9 Hz, 1H), 7.33 (d, J = 6.9 Hz, 1H), 4.59 (s, 2H), 
4.31 (t, J = 6.6 Hz, 2H), 1.32 (q, J = 6.9 Hz, 3H). 13C NMR (75 MHz, acetone-d6): 
δ = 171.1, 145.1, 144.3, 134.5, 134.1, 132.2 (q, J = 40.7 Hz), 132.0, 131.9, 129.1 
(2C), 125.5, 124.6 (q, J = 274 Hz), 123.7, 120.6, 116.5, 115.2, 110.7, 62.3, 61.4, 
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13.7. IR (KBr): ṽ = 3415, 2989, 2870, 1719, 1525, 1248, 1154, 1038, 977, 853 cm-
1. MS (ESI): m/z 458 [M + H]+.  
Ethyl 1-(4-(4-(3-sulfamoylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate, (59). 
The title compound was synthesized following the general procedure, starting from 
compound 13 (94.2 mg, 0.29 mmol) and alkyne 52 (52.6 mg, 0.29 mmol). The 
crude material was purified by column chromatography using petroleum ether/ethyl 
acetate 8:2 and petroleum ether/ethyl acetate 5:5 as eluents to afford compound 59 
as a yellow solid (76 mg, 0.15 mmol, 52%). mp 208.5-209.5 °C. 1H NMR (300 
MHz, DMSO-d6): δ = 9.61 (s, 1H), 8.46 (s, 1H), 8.38 (s, 1H), 8.22 (d, J = 8.8 Hz, 
2H), 8.15 (d, J = 7.7 Hz, 1H), 7.89-7.81 (m, 3H), 7.74 (t, J = 7.7 Hz, 1H), 7.51 (br 
s, 2H), 4.34 (q, J = 6.9 Hz, 2H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
DMSO-d6): δ = 160.8, 147.0, 145.6, 143.0, 139.3, 138.0, 132.0 (q, J = 38.9 Hz), 
131.3, 130.5, 129.1, 128.5, 126.0, 122.9, 121.3 (2C), 119.5 (q, J = 269 Hz), 117.0, 
61.7, 14.5. IR (KBr): ṽ = 3263, 2985, 1722, 1694, 1526, 1257, 1037, 849, 596 cm-1. 
MS (ESI): m/z 507 [M + H]+. 
Ethyl 1-(4-(4-(3-(hydroxycarbamoyl)phenyl)-1H-1,2,3-triazol-1-yl)phenyl)-5-
(trifluoromethyl)-1H-pyrazole-4-carboxylate, (60). 
To a solution of Cu(OAc)2 (2.63 mg, 0.0145 mmol, 0.05 eq) in THF (26 µL) TBTA 
(4.09 mg, 0.0077 mmol, 0.05 eq) was added and the resulting mixture was stirred at 
room temperature for 30 min. A solution of compound 13 (94.27 mg, 0.29 mmol, 1 
eq) in THF (0.05 mL), a solution of compound 54 (46.69 mg, 0.29 mmol, 1 eq) in 
THF (0.05 mL) and a solution of sodium ascorbate (5.94 mg, 0.03 mmol, 0.1 eq) 
solubilized in the minimum amount of water were added. The reaction was stirred at 
room temperature overnight. The precipitate was filtered and rinsed with water (x2) 
and diethyl ether (x2) to give a solid. The crude material was purified by column 
chromatography using petroleum ether/ethyl acetate 5:5 as eluent to afford 
compound 60 as an amorphous white solid (90 mg, 0.18 mmol, 42%). 1H NMR (300 
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MHz, CD3OD): δ = 9.17 (s, 1H), 8.61 (s, 1H), 8.22 (s, 1H), 8.18 (d, J = 8.2 Hz, 2H), 
7.75 (d, J = 8.2 Hz, 2H), 7.61 (t, J = 8.8 Hz, 1H), 7.49 (d, J = 8.8 Hz, 1H), 7.25 (d, J 
= 8.8 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
DMSO-d6): δ = 169.8, 163.2, 148.2, 143.5, 139.6, 134.9, 133.7 (q, J = 40.0 Hz), 
133.0, 131.8, 130.9, 130.4, 129.5, 128.9, 127.5, 126.2, 119.8, 118.2 (q, J = 278 Hz), 
116.8, 60.9, 15.7. IR (KBr): ṽ = 3554, 3473, 3413, 2924, 1778, 1737, 1617, 1523, 
969, 845 cm-1. MS (ESI): m/z 487 [M + H]+. 
3.5.2. Appendix 
1H NMR (DMSO-d6) of compound 23 
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1H NMR (CDCl3) of compound 31 
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4.1. Introduction 
As stated in Chapter 1.2.3, the key catabolic enzyme for tryptophan to 
kynurenines, indoleamine 2,3-dioxygenase 1 (IDO1), has been center-stage as a 
druggable target for cancer immunotherapy in the last 10 years with great hopes. 
However, among the thousands of compounds reported in the scientific and patent 
literature as IDO inhibitors, to date only five molecules have reached human clinical 
trials, confirming that the translation of in vitro to in vivo IDO inhibition is a big 
challenge.1 Moreover, epacadostat has recently failed to show a clinical benefit in 
combination to pembrolizumab in unresectable or metastatic melanoma.2 Thus, 
additional and continued efforts to identify new inhibitors with improved properties 
are needed. 
In 2014 the imidazothiazole compounds 1 and 2 were reported by Tojo et al. 
(Figure 1A)3 displaying IC50 values of 1.9 μM and 77 nM, respectively, in an 
enzyme-based assay. The crystal structure of the complex IDO1/1 was described 
(Figure 1B), demonstrating that the nitrogen of the imidazole ring is bound to the 
heme iron and the tolyl group is located in pocket A of the active site. Interestingly, 
a shift of Phe226 occurs and the resulting induced fit in pocket B allows for the 
allocation of the p-chlorophenyl ring adjacent to Phe226. In contrast, 2 showed an 
improved inhibitory activity: indeed, the rigid urea moiety allows the p-cyanophenyl 
group to interact with both Phe226 (π-π interaction) and Arg231 (electrostatic 
interaction). Surprisingly, despite the promising inhibitory activity on the purified 
enzyme, no inhibition was detectable when Dr. Fallarini’s research group tested 
compound 2 in a cell-based assay at concentration of 10 µM. 
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Figure 1. (A) Structure of imidazothiazole compounds 1 and 2. (B) Compound 1 bound to 
IDO1 (PDB code: 4PK6). Heme is depicted as cyan sticks and compound 1 as pale green 
sticks. Red surface: pocket A; green surface: pocket B. 
 
4.2. Aim of the work 
The peculiar profile of this class of molecules described above prompted us to 
investigate the synthesis and the biological evaluation of a range of imidazothiazoles 
compounds displaying a modified side chain, with the aim of both finding new 
analogues with an improved cellular activity against IDO1 and probing interactions 
with the active site aminoacids. Therefore, during my PhD I carried out the synthesis 
and the characterization of this class of molecules (See Chemistry section 4.5.1.). 
4.3. Results and discussion 
4.3.1. Chemistry 
For the synthesis of a first series of compounds we exploited the Ugi 
multicomponent reaction,4 which allows for the rapid and versatile generation of 
imidazothiazoles displaying different α-acylaminoamides in the side chain. 
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Starting from the required amine 3 described in literature,3 the isocyanide 5 was 
prepared by formylation with ethyl formate followed by dehydration in the presence 
of phosphorous oxychloride and triethylamine (Scheme 1). 
 
Scheme 1. Isocyanide synthetic pathway. 
(a) DMF-DMA, DMF, 80 °C, 99%; (b) ethyl bromoacetate, 80 °C, 76%; (c) DBU, DMF, 60 
°C, 99%; (d) LiAlH4, dry THF, 0 °C, 81%; (e) DPPA, DBU, DMF, 60 °C, 67%; (f) PPh3, 
H2O, THF, 45 °C, 96%; (g) HCOOEt, reflux, 99%; (h) POCl3, TEA, dry CH2Cl2, -30 °C, 
77%. 
With the isocyanide 5 in our hand, we performed the Ugi reaction with aqueous 
methylamine as the amine component and formalin as the carbonyl partner, in order 
to minimize the steric hindrance in the side chain and allow for the penetration in the 
deep and tight pocket B of IDO active site. As a proof of principle, acetic acid, 
different substituted benzoic acids and phenylacetic acid were used (Scheme 2). 
Products 6a-g precipitated from the reaction mixture as white solids and were 
obtained simply by filtration. 
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Scheme 2. Synthesis of U-4CR analogues. 
(a) 37% aqueous formaldehyde solution, 40% aqueous methylamine solution, R1-COOH, 
CH3OH, rt, 24-61%. 
As phenylacetic acid gave the best enzymatic inhibitory activity (see Biological 
evaluation section 4.3.2.), we decided to evaluate whether the substitution of the 
methyl on the nitrogen of 6g with a hydrogen would have improved the inhibitory 
activity. It is well known how difficult is to use ammonia in the Ugi reaction, 
especially when coupled with the highly reactive formaldehyde as the carbonyl 
compound, due to a number of possible side reactions.5 Indeed, when 33% aqueous 
ammonium hydroxide was used, no product was afforded, even when the less 
nucleophilic 2,2,2-trifluoroethanol6 was employed as solvent instead of methanol. 
Even the use of 2,4-dimethoxybenzylamine as ammonia equivalent and the 
subsequent removal of 2,4-dimethoxybenzyl group under acidic conditions proved 
to be unsuccessful.7 Thus, the reaction was carried out with ammonium chloride as 
a nitrogen source8 in the presence or absence of triethylamine as a base to access 6h, 
but the yield was very low under all the experimental conditions used (10-12%). 
Therefore, tritylamine was used as an ammonia surrogate,9 followed by deprotection 
with trifluoroacetic acid, leading to 6h in high yield (Scheme 3). 
 
Scheme 3. Synthesis of compound 6h.(a) Tritylamine, phenylacetic acid, paraformaldehyde, 
methanol, 40 °C, 93%; (b) TFA, CH2Cl2, 0 °C, 84%. 
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A drop in inhibitory activity occurred (see Biological evaluation section 4.3.2.), 
hence the methylamine was kept fixed and different substituents at different 
positions of the benzylic ring were explored. As the active site of IDO1, despite its 
marked hydrophobic nature, features a number of sites capable of hydrogen-bonding 
to inhibitors, moieties such as cyano and hydroxy were introduced, together with 
nitro and chlorine, able to affect the electronic properties. Compounds 6i, 6k and 6n-
p precipitated from the reaction mixture and were isolated in high purity (Scheme 
2), while 6j, 6l, 6m and 6q-s were purified by column chromatography. 
Next, we investigated whether the substitution of the N-methyl group with oxygen 
at the linker site might lead to an improvement in inhibitory activity. To this aim, 
Passerini reaction was performed10 and the isocyanide 5 was reacted with aqueous 
formaldehyde and functionalized phenyl acetic acids to afford compounds with 
different α-acyloxyamides in the side chain, 7a-l (Scheme 4). 
 
 
Scheme 4. Synthesis of P-3CR analogues. 
(a) 37% aqueous formaldehyde solution, R1-COOH, CH2Cl2, reflux, 35-87%. 
 
Finally, Passerini product 7a was hydrolyzed to access α-hydroxyamide 7m and 
test whether the presence of a shorter side-chain with a free hydroxyl group might 
affect the inhibitory activity (Scheme 5). 
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Scheme 5. Synthesis of compound 7m. 
(a) NaOH, H2O/acetone, rt, 70%. 
As the synthesized products displayed low cellular activity in the cell-based assay 
(see Biological evaluation section 4.3.2.), in an attempt to increase cell permeability, 
we investigated whether the introduction of a dipeptide structure in the side chain 
would retain the inhibitory activity on the enzyme, allowing for cell penetration. 
Indeed, a dipeptide structure might be recognized by peptide transporters such as 
PEPT1 and PEPT2.11 To this aim, two Boc-protected aminoacids, namely Boc-
phenylglycine and Boc-4-hydroxyphenylglycine, were reacted in the Ugi reaction 
with isocyanide 5, tritylamine and paraformaldehyde. Subsequent deprotection with 
TFA removed both Boc and trityl protecting groups (Scheme 6), affording 
compounds 8a and 8b. 
 
Scheme 6. Synthesis of compounds 8a and 8b. 
(a) Boc-protected aminoacid, tritylamine, paraformaldehyde, CH3OH, 40 °C, 43-88%; (b) 
TFA, CH2Cl2, 0 °C, 34-39%. 
4.3.2. Biological evaluation 
The synthesized molecules have been tested in the laboratory of Dr. Fallarini.  
The measurement of cell viability is mandatory when reporting cellular IDO1 
inhibitory activity, because the observed reduction of tryptophan degradation could 
simply be an effect of cytotoxicity. Thus, we decided to first investigate the 
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cytotoxicity of all the synthesized compounds on A375 cell line. Cells were treated 
(48 h) with each compound (10 µM) and cell viability was measured by MTT assay. 
As reported in Table 1, compounds 6c, 6e, 6m and 6-s affected cell viability. In 
particular, 6q and 6s were the most cytotoxic, inducing a reduction of cell viability 
of -29% and -36%, respectively.  
The ability of the synthesized compounds to inhibit human IDO1 was first 
analyzed by a cell-free assay using a purified recombinant human IDO1 (rhIDO1) 
enzyme. Each compound (1 µM) was added to the reaction buffer and the rhIDO1 
conversion of L-Trp to L-Kyn determined spectrophotometrically using p-
dimethylaminobenzaldehyde. Under these conditions, the IC50 value of 2 was 
consistent with previous data in literature.3. For all the synthesized compounds 
displaying an inhibition above 60% the IC50 value was determined.  
 
 
Cpd X R1 R2 
Cell 
viability 
(%) at 
10 µM 
±SEM 
Enzymatic 
assay 
inhibition 
(%) @ 1 
µM 
Enzymatic 
IC50 (µM) 
IDO 
cellular 
assay 
inhibition 
(%) @ 10 
µM 
1-methyl-L-tryptophan (L-1MT) 100±8 - - 38 
2    99±3 97 0.08 0 
6a N methyl methyl 98±5 21   
6b N phenyl methyl 96±4 50  6.9 
6c N 4-cyanophenyl methyl 87±2 47   
6d N 4-nitrophenyl methyl 100±6 45   
6e N 
4-
methoxyphenyl 
methyl 82±8 49   
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Cpd X R1 R2 
Cell 
viability 
(%) at 
10 µM 
±SEM 
Enzymatic 
assay 
inhibition 
(%) @ 1 
µM 
Enzymatic 
IC50 (µM) 
IDO 
cellular 
assay 
inhibition 
(%) @ 10 
µM 
6f N 
3-
methoxyphenyl 
methyl 98±5 48   
6g N benzyl methyl 100±4 62 0.69 2.5 
6h N benzyl H 100±8 46   
6i N 4-cyanobenzyl methyl 92±7 18   
6j N 3-cyanobenzyl methyl 90±9 0   
6k N 
4-
hydroxybenzyl 
methyl 91±11 55  0 
6l N 
3-
hydroxybenzyl 
methyl 100±2 63 0.45 0 
6m N 
2-
hydroxybenzyl 
methyl 88±14 0   
6n N 4-nitrobenzyl methyl 100±3 66 0.81 24 
6o N 3-nitrobenzyl methyl 93±5 65 0.63 8 
6p N 2-nitrobenzyl methyl 92±12 67 0.73 11 
6q N 4-chlorobenzyl methyl 64±4 51   
6r N 3-chlorobenzyl methyl 83±7 39   
6s N 2-chlorobenzyl methyl 71±12 41   
7a O benzyl - 98±6 72 0.58 0 
7b O 4-cyanobenzyl - 100±3 69 0.34 0 
7c O 3-cyanobenzyl - 97±5 29   
7d O 
4-
hydroxybenzyl 
- 100±4 89 0.20 4 
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Cpd X R1 R2 
Cell 
viability 
(%) at 
10 µM 
±SEM 
Enzymatic 
assay 
inhibition 
(%) @ 1 
µM 
Enzymatic 
IC50 (µM) 
IDO 
cellular 
assay 
inhibition 
(%) @ 10 
µM 
7e O 
3-
hydroxybenzyl 
- 100±3 59  14 
7f O 
2-
hydroxybenzyl 
- 100±3 73 0.87 0 
7g O 4-nitrobenzyl - 100±7 39   
7h O 3-nitrobenzyl - 100±5 50  0 
7i O 2-nitrobenzyl - 100±10 41   
7j O 4-chlorobenzyl - 100±3 32   
7k O 3-chlorobenzyl - 100±6 39   
7l O 2-chlorobenzyl - 100±3 46   
7m OH - - 97±8 48   
8a N 
(S)-2-amino-2-
phenyl 
H 96±7 10   
8b N 
(S)-2-amino-2-
(4-
hydroxyphenyl) 
H 100±5 0   
 
Table 2. Structure and biological profile of imidazothiazole compounds. 
 
4.3.3. Enzymatic IDO1 inhibition and SAR study 
Structure-activity studies of the α-acylaminoamides have fully explored the 
chemical space around this structure (Table 1). First, acetic acid, benzoic acid and 
phenylacetic acid were used in the Ugi reaction to access 6a, 6b and 6g. While the 
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inhibitory activity was low when a methyl group was present (6a, 21% of inhibition 
at 1 µM), the introduction of a phenyl in 6b or a benzyl in 6g improved the inhibition 
effect (50% and 62%, respectively), with an IC50 value for compound 6g equal to 
0.69 µM. The introduction of different substituents on the phenyl ring (6c-f) did not 
produce any improvement of the activity. 
As the benzylic substructure displayed the highest inhibitory activity, the 
substitution of the N-Me in 6g with a NH in 6h was investigated. The decrease in 
lipophilicity produced a decrease in inhibitory activity (46%). 
Keeping the N-Me group fixed, the effect of different substituents on the benzyl 
ring was investigated (6i-s). The cyano group produced a complete loss of activity 
when present at position 3’ (6j, 0%) and 4’ (6i, 18%). The same occurred when the 
hydroxyl moiety was introduced at position 2’ (6m, 0%). On the contrary, the 
hydroxyl group at position 3’ gave rise to the most active compound of this series, 
6l, with an IC50 value of 0.45 µM, while its presence at position 4’ gave the 
compound 6k displaying an inhibitory activity of 55%. The presence of a nitro group 
produced a progressive increase in activity by moving the substituent from position 
4’ (6n, IC50 = 0.81 µM) to either position 2’ (6p, IC50 = 0.73 µM) or 3’ (6o, IC50 = 
0.63 µM). The presence of a chlorine at different positions on the benzylic ring did 
not produce any improvement of activity (6q-s), which was settled between 39 and 
and 51%. 
In parallel with Passerini reactions, α-acyloxyamides 7a-l were synthesized and, 
in general, they showed a better inhibitory activity compared to the corresponding α-
acylaminoamides 7i-s, revealing that the different bond angles between -O- and -N- 
at the linker site, together with the different flexibility of the side chain, largely 
altered the location of the benzylic ring and its substituent and positively affected the 
interaction with the enzyme aminoacids. This is confirmed by comparison of the 
non-substituted compound 7a (IC50 = 0.58 µM) with the corresponding analogue 6g 
(IC50 = 0.69 µM). 
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Analogously, the influence of different substituents on the benzyl ring was 
studied. Electron-withdrawing groups such as nitro and chlorine gave rise, at any 
position, to a loss of activity (7g-l) with a percentage of inhibition lower than 50%. 
Cyano group, when present at position 3’, did not produce a remarkable effect on 
IDO1 inhibition (7c, 29%), while when displayed at position 4’ produced a 
significant increase in activity (7b, 69%, IC50 = 0.34 µM). Even the polar hydroxyl 
group when present at position 4’ increased inhibitory potency, giving rise to the 
most potent compound of this class of imidazothiazoles (7d, 89%, IC50 = 0.20 µM) 
(Figure 2), with a slight loss of activity when moved to either position 3’ (7e, 59%) 
or 2’ (7f, 73%, IC50 = 0.87 µM). 
 
Figure 2. Concentration-response curve for compound 7d in IDO1 inhibition enzymatic 
assay. 
The presence of a α-hydroxyamide moiety in the side-chain was shown to 
maintain a moderate inhibitory activity (7m, 48%). 
A final round of SAR revealed that the introduction of an additional primary 
amino group at the α-position of the amide is detrimental for inhibitory activity both 
in 8a (10%) and 8b (0%) and this experimental evidence is consistent with the 
pronounced hydrophobic nature of the IDO1 active site. Therefore, these two 
products did not proceed further in the cell-based assay, despite the presence of the 
dipeptide substructure. 
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Figure 3. Graphical representation of SARs relative to the side chain. 
Compounds that showed an inhibition value greater than 50% in the enzymatic 
assay were then evaluated in a cell-based assay, except for 6q which resulted 
cytotoxic at 10 µM.  
4.3.4. Cellular IDO1 inhibitory activity 
The ability of selected compounds to inhibit human IDO1 activity was determined 
in an in vitro cell-based assay, to evaluate their inhibitory effect together with their 
ability to permeate the cell membrane. The human melanoma A375 cell line was 
selected for the cellular assay because does not express either IDO1 gene or protein 
under normal culture condition, but efficiently up regulates IDO1 expression and 
enhances L-Kyn level in response to IFN-γ treatment. A375 cells were stimulated 
with IFN-γ (500U/mL), incubated in the presence of each selected compound (10 
µM) for 48 h and enzymatic activity of IDO determined by measuring the formation 
of the L-Kyn product by high-performance liquid chromatography (HPLC) method. 
IDO1 inhibitor L-1MT was used as positive control in this system and showed a 
percentage of inhibition of 38%. Results are shown in Table 1. The synthesized 
compounds proved to be inactive when tested in the cell-based assay, except for 
compounds 6n, 6p and 7e, which displayed a percentage of inhibition higher than 
10% at 10 µM. 6n was the most potent inhibitor, leading to a 24% of activity, 
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comparable to L-1MT. In all cases, a significant discrepancy between the enzymatic 
and the cellular inhibition was observed. cLogP values (calculated by ACDlab 
software) of the synthesized compounds are between 3.80 and 5.50, ruling out that a 
low hydrophobicity is the reason for the poor cellular activity. Similarly, pKa values 
referred to the basic imidazole nitrogen (calculated by ACDlab software) are around 
4.5, leading to such a low degree of protonation at physiological pH that cannot 
explain the low cell penetration. Alternative reasons for poor performance of the 
inhibitors in the cell-based assay could be that compounds are poorly soluble in the 
cell–based assay conditions and have the tendency to precipitate. It is also possible 
that they get transported out of the cell or bind to serum proteins in the cell growth 
medium, although this is currently speculative.  
4.3.5. Molecular modeling 
In collaboration with the computational chemist Dr. Massarotti, molecular 
modeling was used to understand the potential pose of the most promising 
imidazothiazoles 7d and 6n in the IDO1 binding site. Docking studies were carried 
out using the software OMEGA212 and FRED13, showing that the two structures lay 
with a partially different orientation than compound 1 (Figure 1). The p-
bromophenyl ring of both 7d and 6n is accommodated in the hydrophobic pocket A 
(Tyr126, Cys129, Val130, Phe163 and Phe164), while the imidazothiazole core is 
able to form a strong nitrogen–iron bond with the heme group (Figure 4A, 4B). The 
side chain of 7d and 6n extends in proximity to pocket B (Phe226 and Arg231) and 
one carbonyl group is found to be forming a hydrogen bond with Arg231. The benzyl 
group protrudes into a different pocket (Leu234, Ser235, Gly236, Lys238, Ala260, 
Gly261 and Gly262), named C, which is located in the most external part of the IDO 
binding site (Figure 4C). In particular, the aromatic ring interacts with Gly261 in 
both the compounds, the hydroxyl group of 7d donates a H-bond interaction to the 
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carbonyl moiety of Lys238, while the nitro group of 6n accepts a H-bond interaction 
with the nitrogen of the same backbone residue. 
 
Figure 4. Docking poses of compounds 7d (A) and 6n (B). Structures are depicted as pink 
and orange sticks, respectively, while heme is depicted as cyan sticks. Red surface: pocket 
A; green surface: pocket B; blue surface: pocket C. Visualization of A-B-C pockets on 
protein surface (C). 
4.4. Conclusions 
In summary, starting from a common isocyanide intermediate, we have prepared 
a range of imidazothiazoles by a straightforward multicomponent approach. Iterative 
cycles of synthesis and testing resulted in the rapid identification of 7d with an IC50 
value in the enzyme-based assay of 200 nM. The computational study suggests that 
7d is characterized by a unique binding mode. The coordination formed between the 
imidazole nitrogen and the heme iron, the hydrophobic interaction of the p-
bromophenyl ring in pocket A and the hydrogen bonds with Arg231 in pocket B and 
Lys238 in pocket C are the major interactions between 7d and IDO1. The hydrogen 
bond with Lys238 appears to confer increased potency to this class of inhibitors and 
explains the higher activity associated with both 7d and 6n. While compound 7d 
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doesn’t display significant inhibitory activity in A375 cells, 6n shows a full 
biocompatibility and a 24% of IDO1 inhibition at 10 µM, together with an enzymatic 
IC50 of 810 nM. Overall, the information acquired in this study provides a new 
direction for future design of IDO1 inhibitors. Indeed, we have demonstrated that an 
isocyanide based-multicomponent approach represents a straightforward and 
versatile access to IDO1 inhibitors displaying a densely-functionalized side-chain. 
This allows for the construction of a network of interactions with both the heme 
group and the residues located in three different pockets of the active site. Building 
on these findings, further studies aimed at developing compounds with an improved 
cellular inhibitory activity led us to the identification of a novel promising class of 
compounds that targets IDO1. This discovery will be illustrated in detail in the 
following Chapter. 
4.5. Experimental section 
General Methods. Commercially available reagents and solvents were purchased 
from Sigma-Aldrich and Alfa Aesar and used without further purification. When 
needed, solvents were distilled and stored on molecular sieves. Melting points were 
determined in an open glass capillary with a Stuart scientific SMP3 apparatus. All 
the target compounds were checked by using IR (FT-IR Thermo-Nicolet Avatar), 1H 
and 13C APT (Jeol ECP 300 MHz), and mass spectrometry (Thermo Finningan LCQ-
deca XP-plus) devices equipped with an ESI source and an ion trap detector. 
Chemical shifts (δ) are reported in parts per million (ppm) and coupling costants (J) 
are expressed in Hz. Column chromatography was performed on silica gel Merck 
Kieselgel 70-230 mesh ASTM. Thin layer chromatography (TLC) was carried out 
on 5 cm x 20 cm plates with a layer thickness of 0.25 mm (Merck silica gel 60). The 
spots were visualized by ultraviolet light (wavelengths 254 and 366 nm) and, when 
necessary, with Dragendorff reagent and KMnO4. The purity of the targets 
Chapter 4 
110 
compounds (>95%) was determined via elemental analysis and was within ±0.4% of 
the calculated value. 
4.5.1. Chemistry 
N-((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)formamide, (4). 
The amine 3 (1 eq, 13.6 mmol) was dissolved in ethyl formate (84 mL) and the 
resulting mixture was heated at reflux for 3 hours. When the reaction was finished, 
the volatile was removed under reduced pressure to give N-((3-(4-
bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)formamide 4. The crude material 
was used in the next step without further purification. White solid. Yield: 99%.  
3-(4-Bromophenyl)-5-(isocyanomethyl)imidazo[2,1-b]thiazole, (5). 
To a solution of N-((3-(4-bromophenyl)imidazo[2,1-b]thiazol-5-
yl)methyl)formamide 4 (1 eq, 10.5 mmol) in dry CH2Cl2 (33.3 mL), TEA (5 eq, 6.90 
mL) was added. The reaction was cooled to - 30 °C and a solution of POCl3 (1.5 eq, 
1.36 mL) in dry CH2Cl2 (11 mL) was added dropwise. After stirring for 2 hours, a 
saturated aqueous solution of NaHCO3 was added and the mixture was allowed to 
reach room temperature. CH2Cl2 was added and the organic phase was washed with 
a saturated aqueous solution of NaHCO3 (x 2), dried over sodium sulfate and 
evaporated. The crude material was purified by chromatography column using 
PE/CHCl3 1:9 as eluent yielding 3-(4-bromophenyl)-5-
(isocyanomethyl)imidazo[2,1-b]thiazole 5. Yellow-white solid. Yield: 77%. mp 
128.3-129.3 °C. νmax cm-1 3093, 2972, 2906, 2142, 1574, 1455, 1430, 1146, 841, 
757, 539. 1H NMR (300 MHz, DMSO-d6): δ = 7.75 (d, J = 7.8 Hz, 2H), 7.64 (d, J = 
7.8 Hz, 2H), 7.34 (s, 2H), 4.73 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 157.9, 
151.7, 136.1, 131.7, 131.2, 129.7, 128.0, 118.8, 111.6, 110.9, 36.2.  
General procedure for the synthesis of compounds 6a-g and 6i-s. 
37% aqueous formaldehyde solution (3 eq) was dissolved in CH3OH, then 40% 
aqueous methylamine solution (2 eq) was added under vigorous stirring. After 30 
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minutes carbossilic acid (1 eq) and isocyanide 5 (1 eq) were added in order. The 
reaction mixture was left to react. In some cases (6a, 6b, 6c, 6d, 6e, 6f, 6g, 6i, 6k, 
6n, 6o, 6p) product precipitates and the precipitated white solid was collected by 
filtration using a Buchner funnel and rinsed with ethyl acetate. In case that no 
precipitation was observed (6j, 6l, 6m, 6q, 6r, 6s), CH3OH was evaporated and the 
reaction was worked up by diluition with ethyl acetate and washing with a saturated 
aqueous solution of Na2CO3 (except for the compounds 6l and 6m which were 
washed with a saturated aqueous solution of NaHCO3). The organic layer was dried 
over sodium sulfate and evaporated. The crude material was purified by 
chromatography column. 
N-((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)-2-(N-
methylacetamido)acetamide, (6a). 
White solid. Yield: 55%. mp 250-250.5 °C dec. Found: C, 48.52; H, 4.15; N, 13.27. 
C17H17BrN4O2S requires C, 48.46; H, 4.07; N, 13.30. νmax cm-1 3310, 3082, 2931, 
1920, 1645, 1450, 1072, 1013, 609. 1H NMR (300 MHz, DMSO-d6): δ = 8.05 (s, 
1H), 7.91 (s, 1H), 7.69 (d, J = 7.7 Hz, 2H), 7.55 (d, J = 7.7 Hz, 2H), 7.21 (br s, 1H), 
3.99 (s, 2H), 3.67 (s, 2H), 2.90 (s, 3H), 1.98 (s, 3H). 13C NMR (75 MHz, DMSO-d6, 
referred to the main rotamer): δ = 170.9, 168.3, 155.1, 132.3, 132.1, 132.0, 131.8, 
129.2, 123.8, 115.5, 111.7, 50.2, 37.6, 34.4, 21.7. MS (ESI) m/z 445 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
N-methylbenzamide, (6b). 
White solid. Yield: 52%. mp 249-250 °C. Found: C, 54.84; H, 4.02; N, 11.57. 
C22H19BrN4O2S requires C, 54.66; H, 3.96; N, 11.59. νmax cm-1 3277, 3056, 2933, 
1645, 1629, 1547, 1456, 821, 696. 1H NMR (300 MHz, DMSO-d6): δ = 8.05 (s, 1H), 
7.68 (d, J = 10.7 Hz, 2H), 7.55 (m, 2H), 7.42 (m, 4H), 7.25 (m, 2H), 4.04 (s, 2H), 
3.61 (s, 2H), 2.48 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 170.2, 167.7, 149.9, 
136.8, 135.0, 133.0, 132.2, 132.0 (2C), 131.2, 129.0, 127.3, 124.7, 123.6, 111.6, 
52.8, 38.4, 35.2. MS (ESI) m/z 485 [M+H]+. 
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N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
4-cyano-N-methylbenzamide, (6c). 
White solid. Yield: 55%. mp 243-244 °C dec. Found: C, 54.25; H, 3.56; N, 13.85. 
C23H18BrN5O2S requires C, 54.34; H, 3.57; N, 13.78. νmax cm-1 3282, 2940, 2230, 
1643, 1548, 1455, 843, 817. 1H NMR (300 MHz, DMSO-d6): δ = 8.09 (s, 1H), 7.91 
(d, J = 8.8 Hz, 2H), 7.59 (m, 6H), 7.21 (s, 1H), 3.86 (s, 2H), 3.36 (s, 2H), 2.82 (s, 
3H). 13C NMR (75 MHz, DMSO-d6, referred to the main rotamer): δ = 170.1, 167.5, 
149.9, 141.3, 134.7, 133.1, 132.2, 132.1, 131.9, 129.2, 128.4, 128.1, 124.0, 123.8, 
118.9, 112.7, 53.4, 50.0, 34.3. MS (ESI) m/z 510 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
N-methyl-4-nitrobenzamide, (6d). 
White solid. Yield: 24%. mp 245-246 °C dec. Found: C, 50.15; H, 3.47; N, 13.22. 
C22H18BrN5O4S requires C, 50.01; H, 3.43; N, 13.25. νmax cm-1 3281, 3084, 2930, 
2353, 1644, 1544, 1072, 1013. 1H NMR (300 MHz, DMSO-d6): δ = 8.28 (d, J = 8.5 
Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 
7.26 (s, 1H), 6.73 (s, 1H), 3.98 (s, 2H), 3.47 (s, 2H), 3.00 (s, 3H). 13C NMR (75 MHz, 
DMSO- d6): δ = 169.9, 169.3, 167.4, 149.9, 148.4, 143.1, 142.8, 134.7, 132.0 (2C), 
129.2, 128.8, 128.6, 124.3, 123.8, 53.3, 49.9, 34.3. MS (ESI) m/z 530 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
4-methoxy-N-methylbenzamide, (6e). 
White solid. Yield: 25%. mp 248-249 °C dec. Found: C, 54.01; H, 4.17; N, 10.88. 
C23H21BrN4O3S requires C, 53.81; H, 4.12; N, 10.91. νmax cm-1 3272, 3066, 2836, 
2365, 1640, 1541, 1455, 1257, 839, 763. 1H NMR (300 MHz, DMSO-d6): δ = 8.13 
(s, 1H), 8.03 (br s, 1H), 7.92 (d, J = 8.3 Hz, 2H), 7.78 (d, J = 8.9 Hz, 2H), 7.66 (d, J 
= 8.9 Hz, 2H), 7.33 (s, 1H), 7.17 (d, J = 8.3 Hz, 2H), 4.58 (s, 2H), 4.08 (s, 2H), 3.83 
(s, 3H), 3.47 (s, 3H). 13C NMR (75 MHz, DMSO- d6): δ = 168.0, 160.8, 149.9, 134.5, 
Synthesis, biological evaluation and molecular docking studies of Ugi and Passerini 
adducts as novel indoleamine 2,3-dioxygenase 1 inhibitors 
 
113 
132.3, 132.0, 131.8 (2C), 129.3, 129.1, 128.9, 124.4, 123.8, 114.0, 111.6, 77.2, 55.6, 
35.3, 34.4. MS (ESI) m/z 515 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
3-methoxy-N-methylbenzamide, (6f). 
White solid. Yield: 56%. mp 247-248 °C dec. Found: C, 53.97; H, 4.21; N, 10.85. 
C23H21BrN4O3S requires C, 53.81; H, 4.12; N, 10.91. νmax cm-1 3274, 3064, 2937, 
2835, 1646, 1625, 1456, 1241, 785, 697. 1H NMR (300 MHz, DMSO-d6): δ = 8.05 
(s, 1H), 7.68 (m, 2H), 7.57 (d, J = 9.3 Hz, 2H), 7.32 (m, 2H), 7.21 (m, 3H), 4.04 (s, 
2H), 3.78 (s, 3H), 3.61 (s, 2H), 2.84 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 
169.7, 167.8, 159.5, 149.8, 138.1, 134.6, 132.1 (2C), 130.1, 129.1, 123.8, 119.2, 
115.7, 112.8, 112.4, 111.8, 105.4, 55.7, 53.6, 49.9, 34.4. MS (ESI) m/z 537 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
N-methyl-2-phenylacetamide, (6g). 
White solid. Yield: 39%. mp 194-195 °C. Found: C, 55.40; H, 4.18; N, 11.34. 
C23H21BrN4O2S requires C, 55.54; H, 4.26; N, 11.26. νmax cm-1 3289, 3027, 2922, 
2358, 1733, 1539, 1398, 1242, 929, 817. 1H NMR (300 MHz, DMSO-d6): δ = 8.08 
(s, 1H), 7.93 (br s, 1H), 7.70 (d, J = 7.7 Hz, 2H), 7.56 (t, J = 8.2 Hz, 2H), 7.21 (m, 
6H), 3.99 (s, 2H), 3.71 (s, 2H), 3.28 (s, 3H), 2.96 (s, 2H). 13C NMR (75 MHz, 
DMSO-d6, referred to the main rotamer): δ = 171.4, 168.2, 136.1, 134.5, 132.2, 
132.0, 131.8, 129.7, 129.6, 128.7, 128.6, 126.7, 124.4, 123.8, 111.6, 50.4, 37.3, 34.9, 
34.4. MS (ESI) m/z 499 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(4-cyanophenyl)-N-methylacetamide, 6i. 
White solid. Yield: 42%. mp 240-241 °C. Found: C, 55.30; H, 3.92; N, 13.35. 
C24H20BrN5O2S requires C, 55.18; H, 3.86; N, 13.41. νmax cm-1 3297, 2939, 2362, 
2229, 1644, 1541, 1458, 1014, 816. 1H NMR (300 MHz, DMSO-d6, referred to the 
main rotamer): δ = 8.12 (s, 1H), 7.96 (br s, 1H), 7.76 (d, J = 7.7 Hz, 2H), 7.69 (d, J 
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= 7.9 Hz, 2H), 7.56 (d, J = 7.7 Hz, 2H), 7.41 (d, J = 7.9 Hz, 2H), 7.22 (s, 1H), 3.99 
(s, 2H), 3.84 (s, 2H), 3.71 (s, 2H), 2.97 (s, 3H). 13C NMR (75 MHz, DMSO-d6, 
referred to the main rotamer): δ = 170.5, 167.8, 149.7, 142.4, 134.6, 132.5, 132.4, 
132.1, 132.0, 131.9, 131.1, 124.5, 123.8, 119.4, 111.7, 109.8, 52.4, 50.6, 37.4, 34.5. 
MS (ESI) m/z 523 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(3-cyanophenyl)-N-methylacetamide, (6j). 
White solid. Yield: 61%. Chromatography: PE/EtOAc 1/9. mp 67-69 °C. Found: C, 
55.32; H, 3.91; N, 13.32. C24H20BrN5O2S requires C, 55.18; H, 3.86; N, 13.41. νmax 
cm-1 3248, 3077, 2878, 2231, 1673, 1451, 1214, 1152, 1011. 1H NMR (300 MHz, 
DMSO-d6): δ = 7.61 (d, J = 6.6 Hz, 2H), 7.43 (m, 6H), 7.26 (s, 1H), 6.48 (s, 1H), 
4.41 (s, 2H), 3.80 (s, 2H), 3.71 (s, 2H), 3.08 (s, 3H). 13C NMR (75 MHz, DMSO-d6): 
δ = 170.9, 167.9, 150.6, 136.0, 134.7, 133.9, 132.9, 132.5 (2C), 132.3, 132.0, 130.8, 
129.5, 128.4, 124.6, 123.3, 118.7, 112.7, 52.1, 39.7, 37.5, 34.3. MS (ESI) m/z 523 
[M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(4-hydroxyphenyl)-N-methylacetamide, (6k). 
White solid. Yield: 41%. mp 214-216 °C. Found: C, 54.02; H, 4.15; N, 10.77. 
C23H21BrN4O3S requires C, 53.81; H, 4.12; N, 10.91. νmax cm-1 3320, 3085, 3007, 
2927, 1645, 1520, 1455, 1409, 1281, 804. 1H NMR (300 MHz, DMSO-d6, referred 
to the main rotamer): δ = 9.17 (br s, 1H), 8.87 (br s, 1H), 7.75-7.63 (m, 2H), 7.62-
7.42 (m, 2H), 7.16-7.23 (m, 2H), 7.00-6.96 (m, 2H), 6.71-6.59 (m, 2H), 3.99 (s, 2H), 
3.70 (s, 2H), 3.56 (d, J = 4.4 Hz, 2H), 2.92 (s, 3H). 13C NMR (75 MHz, DMSO-d6, 
referred to the main rotamer): δ = 171.7, 168.2, 156.4, 149.7, 134.6, 132.1, 131.9, 
130.5, 129.9, 129.2, 126.2, 124.4, 123.8, 115.6, 111.7, 52.3, 50.4, 37.4, 35.0. MS 
(ESI) m/z 514 [M+H]+. 
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N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(3-hydroxyphenyl)-N-methylacetamide, (6l). 
White solid. Yield: 48%. Chromatography: PE/EtOAc 1/9. mp 204-206 °C. Found: 
C, 54.03; H, 4.18; N, 10.87. C23H21BrN4O3S requires C, 53.81; H, 4.12; N, 10.91. 
νmax cm-1 3284, 3109, 2935, 1641, 1534, 1458, 1406, 1262, 820, 774. 1H NMR (300 
MHz, DMSO-d6, referred to the main rotamer): δ = 9.32 (br s, 1H), 7.96 (br s, 1H), 
7.69 (d, J = 8.3 Hz, 2H), 7.64-7.46 (m, 3H), 7.21 (d, J = 8.3 Hz, 2H), 7.06 (s, 1H), 
6.62 (s, 1H), 6.58 (s, 1H), 3.99 (s, 2H), 3.70 (d, J = 5.0 Hz, 2H), 3.60 (s, 2H), 2.93 
(s, 3H). 13C NMR (75 MHz, DMSO-d6, referred to the main rotamer): δ = 171.3, 
168.2, 157.8, 149.7, 137.4, 134.6, 132.1, 131.9, 129.9, 129.7, 129.1, 124.4, 123.8, 
120.2, 116.5, 113.9, 111.7, 52.3, 50.4, 37.5, 35.0. MS (ESI) m/z 514 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(2-hydroxyphenyl)-N-methylacetamide, (6m). 
White solid. Yield: 40%. Chromatography: PE/EtOAc 1/9. mp 82-84 °C. Found: C, 
53.67; H, 4.10; N, 10.93. C23H21BrN4O3S requires C, 53.81; H, 4.12; N, 10.91. νmax 
cm-1 3272, 3060, 2925, 1800, 1666, 1595, 1455, 1398, 1246, 754. 1H NMR (300 
MHz, DMSO-d6, referred to the main rotamer): δ = 7.59 (d, J 7.7 Hz, 2H), 7.48 (s, 
1H), 7.27 (d, J = 7.7 Hz, 2H), 7.18-7.00 (m, 2H), 6.83 (d, J = 8.2 Hz, 2H), 6.60 (s, 
1H), 6.40 (br s, 1H), 4.09 (s, 2H), 3.84 (s, 2H), 3.70 (s, 2H), 3.21 (s, 3H). 13C NMR 
(75 MHz, DMSO-d6, referred to the main rotamer): δ = 173.8, 155.9, 134.2, 133.2, 
132.3, 132.1, 130.9, 129.4, 129.0, 128.1, 124.7, 123.4, 121.3, 120.4, 120.1, 117.3, 
110.7, 60.5, 52.2, 36.3, 14.3. MS (ESI) m/z 514 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
N-methyl-2-(4-nitrophenyl)acetamide, (6n). 
White solid. Yield: 43%. mp 205-207 °C. Found: C, 50.77; H, 3.70; N, 12.97. 
C23H20BrN5O4S requires C, 50.93; H, 3.72; N, 12.91. νmax cm-1 3295, 3105, 3047, 
2945, 1647, 1523, 1452, 1348, 1112, 819. 1H NMR (300 MHz, DMSO-d6): δ = 8.16 
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(d, J = 8.5 Hz, 2H), 7.98 (br s, 1H), 7.69 (d, J = 6.7 Hz, 2H), 7.57 (d, J = 8.5 Hz, 
2H), 7.51 (d, J = 6.7 Hz, 2H), 7.20 (s, 1H), 7.17 (s, 1H), 3.91 (s, 2H), 3.83 (s, 2H), 
3.76 (d, J = 4.4 Hz, 2H), 3.00 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 170.4, 
168.2, 146.8, 144.7, 133.3, 132.2, 131.9, 131.4, 130.3, 129.9, 129.2, 129.1, 124.4, 
123.8, 123.7, 52.3, 50.6, 37.4, 34.7. MS (ESI) m/z 543 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
N-methyl-2-(3-nitrophenyl)acetamide, (6o). 
White solid. Yield: 46%. mp 191-193 °C. Found: C, 51.04; H, 3.80; N, 12.88. 
C23H20BrN5O4S requires C, 50.93; H, 3.72; N, 12.91. νmax cm-1 3291, 3089, 3047, 
2924, 1642, 1522, 1455, 1343, 807, 739. 1H NMR (300 MHz, DMSO-d6, referred to 
the main rotamer): δ = 8.11 (s, 1H), 8.05 (br s, 1H), 7.69 (d, J = 6.6 Hz, 2H), 7.64-
7.55 (m, 5H), 7.22 (s, 1H), 7.17 (s, 1H), 3.93 (s, 2H), 3.84 (s, 2H), 3.75 (d, J 5.5 Hz, 
2H), 3.02 (s, 3H). 13C NMR (75 MHz, DMSO-d6, referred to the main rotamer): δ = 
170.7, 168.1, 149.7, 148.1, 138.9, 137.1, 134.6, 132.1, 132.0, 131.9, 130.0, 129.9, 
129.1, 124.9, 123.8, 121.9, 111.8, 52.3, 50.6, 37.3, 35.1. MS (ESI) m/z 543 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
N-methyl-2-(2-nitrophenyl)acetamide, (6p). 
White solid. Yield: 40%. mp 200-202 °C dec. Found: C, 50.77; H, 3.68; N, 12.95. 
C23H20BrN5O4S requires C, 50.93; H, 3.72; N, 12.91. νmax cm-1 3296, 3086, 3051, 
2933, 1643, 1542, 1519, 1456, 1341, 738. 1H NMR (300 MHz, DMSO-d6, referred 
to the main rotamer): δ = 8.01 (s, 1H), 7.87 (br s,1H), 7.79-7.43 (m, 6H), 7.36 (s, 
1H), 7.27-7.08 (m, 2H), 4.13 (s, 2H), 3.98 (s, 2H), 3.70 (s, 2H), 3.04 (s, 3H). 13C 
NMR (75 MHz, DMSO-d6, referred to the main rotamer): δ = 169.7, 168.0, 149.8, 
134.6, 133.8, 132.2, 132.1, 131.9, 131.8, 129.9, 129.1, 128.7, 125.0, 124.4, 123.8, 
111.7, 111.0, 52.2, 50.5, 38.5, 37.1. MS (ESI) m/z 543 [M+H]+. 
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N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(4-chlorophenyl)-N-methylacetamide, (6q). 
Yellow-white solid. Yield: 60%. Chromatography: PE/EtOAc 1/9. mp 78-80 °C. 
Found: C, 52.10; H, 3.85; N, 10.51. C23H20BrClN4O2S requires C, 51.94; H, 3.79; N, 
10.53. νmax cm-1 3290, 3050, 2925, 1650, 1537, 1455, 1291, 1014, 810, 744. 1H NMR 
(300 MHz, CDCl3, referred to the main rotamer): δ = 7.61 (d, J = 8.0 Hz, 2H), 7.56-
7.44 (m, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 7.11 (s, 1H), 6.63 
(s, 1H), 6.38 (br s,1H), 4.13 (s, 2H), 3.79 (s, 2H), 3.65 (s, 2H), 3.05 (s, 3H). 13C NMR 
(75 MHz, CDCl3, referred to the main rotamer): δ = 171.7, 168.1, 150.4, 134.6, 
132.9, 132.2, 130.8, 130.4, 129.4, 129.0, 128.9, 124.6, 123.5, 110.8, 110.2, 52.0, 
39.8, 37.5, 34.2. MS (ESI) m/z 532 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(3-chlorophenyl)-N-methylacetamide, (6r). 
Yellow-white solid. Yield: 56%. Chromatography: PE/EtOAc 1/9. mp 183-185 °C. 
Found: C, 51.86; H, 3.73; N, 10.59. C23H20BrClN4O2S requires C, 51.94; H, 3.79; N, 
10.53. νmax cm-1 3276, 3211, 3058, 2926, 1683, 1654, 1534, 1458, 1399, 774. 1H 
NMR (300 MHz, CDCl3, referred to the main rotamer): δ = 7.59 (d, J = 8.3 Hz, 2H), 
7.46 (s, 1H), 7.32 (d, J 8.3 Hz, 2H), 7.16 (d, J = 4.4 Hz, 1H), 7.12 (m, 2H), 7.01 (s, 
1H), 6.73 (br s, 1H), 6.59 (s, 1H), 4.10 (d, J = 3.8 Hz, 2H), 3.77 (s, 2H), 3.61 (s, 2H), 
3.02 (s, 3H). 13C NMR (75 MHz, CDCl3, referred to the main rotamer): δ = 170.8, 
168.2, 138.9, 133.3, 132.1, 132.0, 130.4, 129.9, 129.1, 128.7, 128.6, 126.8, 124.5, 
123.8, 111.8, 111.1, 52.4, 50.6, 37.4, 35.1. MS (ESI) m/z 532 [M+H]+. 
N-(2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-
2-(2-chlorophenyl)-N-methylacetamide, (6s). 
Yellow solid. Yield: 61%. Chromatography: PE/EtOAc 1/9. mp 192-194 °C. Found: 
C, 52.03; H, 4.01; N, 10.46. C23H20BrClN4O2S requires C, 51.94; H, 3.79; N, 10.53.  
νmax cm-1 3285, 3055, 2925, 1648, 1541, 1458, 1400, 1243, 820, 750. 1H NMR (300 
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MHz, DMSO-d6, referred to the main rotamer): δ = 7.61 (d, J 8.3 Hz, 2H), 7.52-7.43 
(m, 2H), 7.31 (d, J = 8.3 Hz, 2H), 7.26 (s, 1H), 7.24-7.14 (m, 2H), 6.63 (s, 1H), 6.35 
(br s, 1H), 4.13 (d, J = 5.0 Hz, 2H), 3.85 (s, 2H), 3.78 (s, 2H), 3.11 (s, 3H). 13C NMR 
(75 MHz, DMSO-d6, referred to the main rotamer): δ = 170.3, 169.2, 134.7, 134.2, 
132.5, 132.2, 132.1, 131.9, 129.9, 129.4, 129.1, 128.9, 127.5, 124.5, 123.8, 111.7, 
111.0, 52.3, 50.6, 38.0, 35.1. MS (ESI) m/z 532 [M+H]+. 
Synthesis of N-((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)-2-(2-
phenylacetamido)acetamide, (6h). 
To a solution of paraformaldehyde (1 eq, 0.63 mmol) in CH3OH (1.25 mL), 
tritylamine (1 eq) was added and the reaction was heated at 40 °C and left to react 
for 40 minutes under vigorous stirring. After, phenylacetic acid (1 eq) and isocyanide 
5 (1 eq) were added and the mixture was allowed to reach room temperature and 
stirred for 15 hours. The volatile was removed under reduced pressure, ethyl acetate 
was added and the organic phase was washed with a saturated aqueous solution of 
Na2CO3, dried over sodium sulfate and evaporated to give N-(2-(((3-(4-
bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl)-2-phenyl-N-
tritylacetamide as a yellow solid which was used in the next step without further 
purification. The residue was dissolved in CH2Cl2 (2 mL), the reaction was cooled to 
0°C and CF3COOH (2 mL) was added. After 30 minutes at 0°C and 4 hours at room 
temperature NaOH 2M was added upon pH 7-8 and the mixture was extracted with 
ethyl acetate (x 1), dried over sodium sulfate and evaporated. The crude material was 
purified by chromatography column using PE/EtOAc 1/9 as eluent. Yellow-white 
solid. Yield: 78%. mp 178-180 °C. Found: C, 54.78; H, 3.97; N, 11.52. 
C22H19BrN4O2S requires C, 54.66; H, 3.96; N, 11.59. νmax cm-1 3288, 3190, 2921, 
1748, 1662, 1544, 1450, 1139, 1008, 702. 1H NMR (300 MHz, CDCl3, referred to 
the main rotamer): δ = 7.57 (d, J = 8.5 Hz, 2H), 7.40-7.18 (m, 7H), 7.08 (s, 1H), 6.61 
(s, 1H), 6.59 (br s, 1H), 6.48 (br s, 1H), 4.11 (d, J = 4.4 Hz, 2H), 3.61 (d, J = 4.7 Hz, 
2H), 3.51 (s, 2H). 13C NMR (75 MHz, CDCl3, referred to the main rotamer): δ = 
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169.5, 166.3, 150.4, 138.8, 134.5, 132.3, 132.1, 130.7, 130.3 (2C), 128.2, 124.6, 
118.6, 111.2, 110.8, 49.4, 30.6, 17.6. MS (ESI) m/z 485 [M+H]+. 
General procedure for the synthesis of compounds 7a-l. 
To a solution of 3-(4-bromophenyl)-5-(isocyanomethyl)imidazo[2,1-b]thiazole 5 (1 
eq) in dry CH2Cl2, 37% aqueous formaldehyde solution (5 eq) and carbossilic acid 
(1 eq) were added and the resulting mixture was stirred at reflux. When the reaction 
was finished, the organic phase was washed with a saturated aqueous solution of 
Na2CO3 (except for the compounds 7d, 7e and 7f which were washed with a saturated 
aqueous solution of NaHCO3), dried over sodium sulfate and evaporated. Ethyl 
acetate was added to the crude material and the precipitated white solid was collected 
by filtration using a Buchner funnel and rinsed with ethyl acetate. In case that no 
precipitation occurs (7a, 7c, 7d, 7g, 7i), the crude material was purified by 
chromatography column. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
phenylacetate, (7a). 
White solid. Yield: 41%. Chromatography: PE/EtOAc 5/5. mp 102-104 °C. Found: 
C, 54.69; H, 3.81; N, 8.63. C22H18BrN3O3S requires C, 54.55; H, 3.75; N, 8.68. νmax 
cm-1 3288, 3190, 2921, 1748, 1662, 1544, 1450, 1139, 1008, 702. 1H NMR (300 
MHz, CDCl3): δ = 7.50 (d, J 8.0 Hz, 2H), 7.14 (d, J = 4.7 Hz, 2H), 7.11-7.03 (m, 
6H), 6.60 (s, 1H), 5.75 (br s, 1H), 4.30 (s, 2H), 4.07 (d, J = 4.4 Hz, 2H), 3.61 (s, 2H). 
13C NMR (75 MHz, CDCl3): δ = 169.5, 166.1, 153.0, 135.2, 133.4, 132.2, 132.0, 
130.6, 129.0, 128.8, 128.1, 127.6, 124.7, 122.3, 110.8, 62.3, 41.4, 34.1. MS (ESI) 
m/z 486 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(4-cyanophenyl)acetate, (7b). 
White solid. Yield: 74%. mp 196-198 °C. Found: C, 54.37; H, 3.40; N, 10.95. 
C23H17BrN4O3S requires C, 54.23; H, 3.36; N, 11.00. νmax cm-1 3260, 3125, 3086, 
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2937, 2218, 1756, 1660, 1540, 1463, 1156. 1H NMR (300 MHz, DMSO-d6): δ = 8.12 
(br s, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.66 (d, J = 8.2 Hz, 2H), 7.60-7.48 (m, 4H), 7.22 
(s, 1H), 7.16 (s, 1H), 4.32 (s, 2H), 4.02 (d, J = 4.4 Hz, 2H), 3.90 (s, 2H). 13C NMR 
(75 MHz, DMSO-d6): δ = 170.6, 166.4, 149.8, 140.5, 134.6, 132.8, 132.2, 132.1, 
131.9, 131.2, 129.1, 124.2, 123.9, 119.4, 111.8, 110.4, 62.9, 39.8, 34.5. MS (ESI) 
m/z 511 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(3-cyanophenyl)acetate, (7c). 
White solid. Yield: 87%. Chromatography: PE/EtOAc 5/5. mp 161-163 °C. Found: 
C, 54.14; H 3.39; N, 11.12. C23H17BrN4O3S requires C, 54.23; H, 3.36; N, 11.00. 
νmax cm-1 3274, 3062, 2922, 2229, 1735, 1650, 1541, 1452, 1176, 740. 1H NMR (300 
MHz, CDCl3): δ = 7.59 (d, J = 7.7 Hz, 2H), 7.54-7.44 (m, 2H), 7.34 (d, J = 7.7 Hz, 
2H), 7.29 (d, J = 7.3 Hz, 2H), 7.00 (s, 1H), 6.65 (s, 1H), 6.37 (br s, 1H), 4.39 (s, 2H), 
4.18 (d, J = 4.0 Hz, 2H), 3.72 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 170.7, 
166.5, 149.8, 136.4, 135.2, 134.6, 133.7, 132.2, 132.1, 131.9, 131.3, 130.0, 129.1, 
124.2, 123.9 119.3, 111.9, 111.8, 62.9, 39.8, 34.5. MS (ESI) m/z 511 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(4-hydroxyphenyl)acetate, (7d). 
White solid. Yield: 76%. Chromatography: PE/EtOAc 5/5. mp 164-166 °C. Found: 
C, 52.99; H, 3.64; N, 8.33. C22H18BrN3O4S requires C, 52.81; H, 3.63; N, 8.40. νmax 
cm-1 3256, 3111, 3035, 2937, 1750, 1645, 1516, 1455, 1145, 783. 1H NMR (300 
MHz, DMSO-d6): δ = 9.35 (br s, 1H), 8.11 (br s, 1H), 7.67 (d, J 6.6 Hz, 2H), 7.54 
(d, J = 6.6 Hz, 2H), 7.20 (s, 1H), 7.18 (s, 1H), 7.08 (d, J = 7.2 Hz, 2H), 6.72 (d, J = 
7.2 Hz, 2H), 4.31 (s, 2H), 4.05 (s, 2H), 3.62 (s, 2H). 13C NMR (75 MHz, DMSO-d6): 
δ = 171.7, 166.6, 156.8, 156.7, 134.5, 132.2, 132.1, 131.9, 130.9, 129.1, 124.8, 124.2, 
123.9, 115.7, 111.8, 62.7, 39.8, 34.5. MS (ESI) m/z 502 [M+H]+. 
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2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(3-hydroxyphenyl)acetate, (7e). 
White solid. Yield: 84%. mp 211-213 °C. Found: C, 52.66; H, 3.57; N, 8.53. 
C22H18BrN3O4S requires C, 52.81; H, 3.63; N, 8.40. νmax cm-1 3264, 3129, 3064, 
2941, 1750, 1648, 1550, 1459, 1144, 770. 1H NMR (300 MHz, DMSO-d6): δ = 9.36 
(br s, 1H), 8.06 (br s,1H), 7.67 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H), 7.25-
7.05 (m, 3H), 6.75-6.62 (m, 3H), 4.28 (s, 2H), 4.03 (s, 2H), 3.64 (s, 2H). 13C NMR 
(75 MHz, DMSO-d6): δ = 171.3, 166.7, 155.9, 149.7, 134.5, 132.2, 132.1, 131.9, 
131.6, 129.1, 128.7, 124.2, 123.9, 121.5, 119.4, 115.4, 111.7, 62.6, 35.3, 34.5. MS 
(ESI) m/z 502 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(2-hydroxyphenyl)acetate, (7f). 
White solid. Yield: 48%. mp 187-188 °C. Found: C, 52.63; H, 3.59; N, 8.46. 
C22H18BrN3O4S requires C, 52.81; H, 3.63; N, 8.40. νmax cm-1 3341, 3125, 3043, 
2929, 1735, 1665, 1535, 1457, 1251. 1H NMR (300 MHz, CDCl3): δ = 9.51 (br s,1H), 
7.97 (br s, 1H), 7.66 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.27-7.01 (m, 4H), 
6.82-6.68 (m, 2H), 4.27 (s, 2H), 4.03 (s, 2H), 3.63 (s, 2H). 13C NMR (75 MHz, 
CDCl3): δ = 171.3, 166.7, 155.9. 149.7, 134.5, 132.2, 132.1, 131.9, 131.6, 129.1, 
128.7, 124.2, 123.9, 121.5, 119.4, 115.4, 111.7, 62.6, 35.3, 34.5. MS (ESI) m/z 502 
[M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(4-nitrophenyl)acetate, (7g). 
White solid. Yield: 42%. Chromatography: PE/EtOAc 4/6. mp 200-202 °C. Found: 
C, 50.03; H, 3.31; N, 10.53. C22H17BrN4O5S requires C, 49.92; H, 3.24; N, 10.58. 
νmax cm-1 3243, 3117, 3072, 2929, 1754, 1660, 1415, 1341, 1157, 724. 1H NMR (300 
MHz, DMSO-d6): δ = 8.20 (d, J 7.7 Hz, 2H), 8.12 (br s, 1H), 7.76-7.51 (m, 6H), 7.22 
(s, 1H), 7.16 (s, 1H), 4.33 (s, 2H), 4.06 (s, 2H), 3.96 (s, 2H). 13C NMR (75 MHz, 
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DMSO-d6): δ = 170.5, 166.4, 149.7, 147.1, 142.7, 134.5, 132.2, 132.1, 131.9, 131.5, 
129.1, 124.2, 123.9, 123.8, 111.8, 62.9, 39.8, 34.5. MS (ESI) m/z 531 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(3-nitrophenyl)acetate, (7h). 
White solid. Yield: 35%. mp 98-100 °C. Found: C, 50.14; H, 3.27; N, 10.51. 
C22H17BrN4O5S requires C, 49.92; H, 3.24; N, 10.58. νmax cm-1 3060, 2922, 2855, 
1749, 1627, 1522, 1457, 1349, 1146, 727. 1H NMR (300 MHz, DMSO-d6): δ = 8.21 
(br s, 1H), 8.14 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 7.4 Hz, 1H), 7.75-7.65 (m, 3H), 7.55 
(d, J = 8.3 Hz, 2H), 7.22 (s, 1H), 7.16 (s, 1H), 4.33 (s, 2H), 4.03 (d, J = 4.7 Hz, 2H), 
3.98 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 170.8, 166.4, 149.7, 148.2, 137.1, 
137.0, 134.5, 132.2, 132.1, 131.9, 130.3, 129.1, 124.9, 124.2, 123.9, 122.5, 111.8, 
62.9, 39.8, 34.5. MS (ESI) m/z 531 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(2-nitrophenyl)acetate, (7i). 
White solid. Yield: 75%. Chromatography: CHCl3. mp 162-164 °C dec. Found: C, 
49.77; H, 3.19; N, 10.67. C22H17BrN4O5S requires C, 49.92; H, 3.24; N, 10.58. νmax 
cm-1 3272, 3063, 2950, 1739, 1646, 1531, 1448, 1350, 1171, 721. 1H NMR (300 
MHz, DMSO-d6): δ = 8.10 (d, J = 8.8 Hz, 2H), 8.08 (br s, 1H), 7.79-7.51 (m, 6H), 
7.21 (s, 1H), 7.17 (s, 1H), 4.32 (s, 2H), 4.16 (s, 2H), 4.05 (d, J = 3.0 Hz, 2H). 13C 
NMR (75 MHz, DMSO-d6): δ = 170.2, 166.3, 150.0, 149.0, 134.6, 134.3, 132.2, 
132.1 (2C), 131.9, 130.0, 129.5, 129.1, 125.4, 124.1, 123.9, 111.8, 62.9, 38.9, 34.5. 
MS (ESI) m/z 531 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(4-chlorophenyl)acetate, (7j). 
White solid. Yield: 66%. mp 182-183 °C. Found: C, 51.15; H, 3.34; N, 8.03. 
C22H17BrClN3O3S requires C, 50.93; H, 3.30; N, 8.10. νmax cm-1 3268, 3125, 3080, 
2912, 1754, 1661, 1540, 1463, 1157, 734. 1H NMR (300 MHz, DMSO-d6): δ = 8.10 
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(br s, 1H), 7.67 (d, J = 8.3 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H), 7.38 (d, J = 8.4 Hz, 
2H), 7.31 (d, J = 8.4 Hz, 2H) 7.22 (s, 1H), 7.16 (s, 1H), 4.31 (s, 2H), 4.02 (d, J = 4.4 
Hz, 2H), 3.77 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 171.0, 166.5, 149.8, 134.6, 
133.7, 132.2, 132.1 (2C), 131.9 (2C), 129.1, 128.8, 124.2, 123.9, 111.8, 62.8, 39.8, 
34.5. MS (ESI) m/z 520 [M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(3-chlorophenyl)acetate, (7k). 
White solid. Yield: 60%. mp 131-133 °C. Found: C, 51.08; H, 3.36; N, 8.06. 
C22H17BrClN3O3S requires C, 50.93; H, 3.30; N, 8.10. νmax cm-1 3272, 3100, 3060, 
2933, 1742, 1649, 1544, 1450, 1167, 726. 1H NMR (300 MHz, DMSO-d6): δ = 8.10 
(br s, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.41-7.32 (m, 4H), 7.22 
(s, 1H), 7.16 (s, 1H), 4.32 (s, 2H), 4.03 (s, 2H), 3.80 (s, 2H). 13C NMR (75 MHz, 
DMSO-d6): δ = 170.9, 166.5, 149.8, 137.1, 134.5, 133.4, 132.2, 132.1, 131.9, 130.7, 
130.0, 129.1, 128.8, 127.4, 124.2, 123.9, 111.8, 62.8, 39.8, 34.5. MS (ESI) m/z 520 
[M+H]+. 
2-(((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-2-oxoethyl 2-
(2-chlorophenyl)acetate, (7l). 
White solid. Yield: 69%. mp 179-180 °C. Found: C, 50.77; H, 3.23; N, 8.18. 
C22H17BrClN3O3S requires C, 50.93; H, 3.30; N, 8.10. νmax cm-1 3428, 3100, 2949, 
2917, 1732, 1680, 1520, 1452, 1245, 750. 1H NMR (300 MHz, DMSO-d6): δ = 8.03 
(br s, 1H), 7.67 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7-50-7.40 (m, 2H), 
7.37-7.28 (m, 2H), 7.22 (s, 1H), 7.16 (s, 1H), 4.32 (s, 2H), 4.03 (s, 2H), 3.89 (s, 2H). 
13C NMR (75 MHz, DMSO-d6): δ = 170.2, 166.4, 149.8, 134.6, 134.3, 132.9, 132.7, 
132.2, 132.1, 131.9 (2C), 129.7, 129.1, 127.8, 124.2, 123.9, 111.8, 62.9, 38.6, 34.5. 
MS (ESI) m/z 520 [M+H]+. 
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Synthesis of N-((3-(4-Bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)-2-
hydroxyacetamide, (7m). 
To a solution of 2-(((3-(4-bromophenyl)imidazo[2,1-b]thiazol-5-yl)methyl)amino)-
2-oxoethyl 2-phenylacetate 7a (1eq, 3.14 mmol) in water (1mL) and acetone (1mL) 
NaOH (2eq) was added. The resulting mixture was stirred overnight. The organic 
phase was washed with a saturated aqueous solution of NaHCO3 (x 2), dried over 
sodium sulfate and evaporated. The crude product was purified by chromatography 
column using CHCl3 as eluent. White solid. Yield: 70%.  mp 198-200 °C. Found: C, 
45.83; H, 3.25; N, 11.57. C14H12BrN3O2S requires C, 45.91; H, 3.30; N, 11.47. νmax 
cm-1 3274, 2826, 1647, 1533, 1464, 1342, 1146, 1079, 820, 762. 1H NMR (300 MHz, 
DMSO-d6): δ = 7.69 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 7.19 (s, 1H), 7.09 
(s, 1H), 5.22 (br s, 1H), 4.03 (d, J = 5.2Hz, 2H), 3.67 (s, 2H), 3.27 (br s, 1H). 13C 
NMR (75 MHz, DMSO-d6): δ = 172.0, 149.4, 134.1, 133.2, 132.1, 130.0, 129.2, 
125.2, 125.1, 123.9, 61.8, 34.0. MS (ESI) m/z 368 [M+H]+. 
General procedure for the synthesis of compounds 8a-b. 
To a solution of tritylamine (1 eq) in CH3OH parafolmadehyde was added (1 eq). 
The mixture was stirred at 40 °C for 40 minutes. Then, BOC-protected amino acid 
(1eq) and isocyanide (1eq) were added and the mixture was stirred overnight at room 
temperature. When the reaction was finished, the solvent was evaporated. After 
dilution with EtOAc and washing with saturated aqueous solution of Na2CO3 (x 2), 
the organic phase was dried over sodium sulfate and evaporated to obtain a yellow 
solid which was used in the next step without further purification. The residue was 
dissolved in CH2Cl2 and CF3COOH was added at 0 °C. After stirring for 30 minutes 
at 0 °C, a solution of NaOH 2M was added to adjust the pH to 10. The mixture was 
extracted with EtOAc (x 2) and the collected organic phases were dried over sodium 
sulfate and evaporated. The crude material was purified by chromatography column. 
 
Synthesis, biological evaluation and molecular docking studies of Ugi and Passerini 
adducts as novel indoleamine 2,3-dioxygenase 1 inhibitors 
 
125 
 (S)-2-Amino-N-(2-(((3-(4-bromophenyl)imidazo[2,1-b]thiazol-5-
yl)methyl)amino)-2-oxoethyl)-2-phenylacetamide, (8a). 
Yellow solid. Yield: 17%. Chromatography: EtOAc. mp 56-58 °C. Found: C, 53.17; 
H, 4.11; N, 13.98. C22H20BrN5O2S requires C, 53.02; H, 4.04; N, 14.05. νmax cm-1 
3056, 2921, 2851, 1670, 1521, 1457, 1244, 1201, 1013, 813. 1H NMR (300 MHz, 
CDCl3, referred to the main rotamer): δ = 7.82 (br s, 1H), 7.60 (d, J = 8.5 Hz, 2H), 
7.38-7.20 (m, 7H), 7.10 (s, 1H), 6.60 (s, 1H), 6.30 (br s, 1H), 4.56 (s, 1H), 4.15 (dd, 
Js = 5.0, 15.7 Hz, 1H), 4.03 (dd, Js = 5.0, 15.7 Hz, 1H), 3.76 (dd, Js = 5.5, 16.3 Hz, 
1H), 3.64 (dd, Js = 5.5, 16.3 Hz, 1H).
 13C NMR (75 MHz, CDCl3): δ = 173.6, 168.3, 
150.5, 140.0, 134.6, 132.2, 132.0, 130.8, 128.9, 128.4, 128.3, 126.8, 124.6, 123.3, 
110.7, 59.5, 42.8, 34.4. MS (ESI) m/z 500 [M+H]+. 
 (S)-2-Amino-N-(2-(((3-(4-bromophenyl)imidazo[2,1-b]thiazol-5-
yl)methyl)amino)-2-oxoethyl)-2-(4-hydroxyphenyl)acetamide, (8b). 
Yellow solid. Yield: 30%. Chromatography: EtOAc. mp 160-162 °C. Found: C, 
51.50; H, 3.96; N, 13.54. C22H20BrN5O3S requires C, 51.37; H, 3.92; N, 13.61. νmax 
cm-1 3064, 2927, 2419, 1665, 1513, 1458, 1248, 1144, 1013, 838. 1H NMR (300 
MHz, CD3OD): δ = 7.66 (d, J = 7.6 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 
7.6 Hz, 2H), 7.03 (s, 1H), 6.97 (s, 1H), 6.71 (d, J = 8.2 Hz, 2H), 4.41 (s, 1H), 4.11 
(d, J = 6.3 Hz, 2H), 3.70 (dd, Js = 5.2, 16.7 Hz, 1H), 3.56 (dd, Js = 5.2, 16.7 Hz, 1H).
 
13C NMR (75 MHz, CD3OD): δ = 169.4, 157.2, 133.6, 132.2, 131.8, 131.3, 131.1, 
129.9, 129.3, 128.6, 128.1, 124.1, 123.6, 115.3, 111.3, 110.6, 58.4, 41.9. MS (ESI) 
m/z 516 [M+H]+. 
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4.5.2. Appendix 
1H NMR (DMSO-d6) of compound 7d 
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5.1. Introduction 
In our ongoing effort to develop small molecules for targeting the tryptophan 
catabolism we have already discovered two different classes of IDO1 inhibitors, 
displaying the imidazole1 and imidazothiazole2 scaffold, respectively. In this context, 
I have personally worked on the latter project that has led to the identification of two 
compounds, 6n and 7d described in Chapter 4, endowed with a unique binding mode 
in the IDO1 active site: the long side-chain protrudes into an additional pocket that 
we named C, where a crucial hydrogen bond is formed with Lys238. Unfortunately, 
while the compounds displayed a good potency in the enzymatic assay and a full 
biocompatibility, they were not able to significantly permeate the cell membrane and 
inhibited IDO1 in a cell-based assay just to a small extent. This is the first time in 
which it was proven that pocket C can be exploited in the design of IDO1 inhibitors. 
This information was therefore integrated in a structure-based virtual screening 
performed by Dr. Massarotti. First of all, the virtual screening protocol was 
validated. To this aim, all the bioactivity data of known tested molecules extracted 
mainly from scientific literature were downloaded. The data were manually 
inspected and integrated with in-house information. The database chosen for our 
screening purpose was ZINC15,3 a collection of commercially available molecules. 
We used the “in stock” “drug-like” subset (8.2 million molecules), containing readily 
purchasable compounds with drug like properties. The screening database was 
docked within IDO1 active site. After visual inspection of the top 500 molecules, 50 
compounds were purchased for biological assays. Screening in cell-based assays 
(human melanoma A375 cell lines) for IDO1 inhibitory activity led to the discovery 
of three hit compounds. Among them, compound 1, depicted in Figure 1A, is the 
most active against IDO1 with an IC50 of 16 nM (Figure 1C). Moreover, it does not 
display cytotoxicity up to 48 hours at 10 μM. Promisingly, this molecule is endowed 
with promising features: i) it is a novel chemotype; ii) it shows a peculiar binding 
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mode in the IDO1 active site (Figure 1B); iii) it displays synthetic feasibility and 
tractability.  
 
Figure 1. (A) Structure of the identified hit compound 1; (B) Docking pose of 1. Structure 
is depicted as pink sticks and heme is depicted as cyan sticks. Red shape: pocket A; green: 
pocket B; blue: pocket C; (C) Dose-response curve for 1. 
5.2. Aim of the work 
The goal of the project was to re-synthesize the hit 1 in order to confirm its activity 
and in silico-design and synthesize a series of structural analogues. Moreover, the 
inhibitory activity against IDO1 of the related structural congeners is being evaluated 
in a cell-based assay carried out in Dr. Fallarini’s laboratory and a preliminary 
structure-activity relationship study (SAR) is being performed. I have been involved 
in the synthesis and characterization of this class of benzimidazoles (See Chemistry 
section 5.5.1.). 
5.3. Results and discussion 
5.3.1. Chemistry 
First of all, the hit was re-synthesized. To this aim, aniline 5 was prepared according 
to Scheme 1. The synthetic protocol afforded the desired compound in two steps: 
substitution and subsequent reduction of the aromatic nitrile 4. Subsequent coupling 
between intermediate 5 and 4-bromo-1H-pyrrole-2-carboxylic acid easily provided 
6 in good yield. 
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Scheme 1. Re-synthesis of the hit compound. 
(a) KOH, acetone, 60 °C, 4 h, 99%; (b) LiAlH4, dry THF, 65 °C - rt, 18 h, 70%; (c) TEA, 
HOBt, EDCI, 4-bromo-1H-pyrrole-2-carboxylic acid, dry CH2Cl2, rt, 18 h, 50%. 
Next, in order to examine the role of the 4-bromopirrole moiety, a series of 
analogues was in silico-designed and synthesized (29-50, 54). In particular, 
synthetically feasible and purchasable carboxylic acids have been virtually combined 
and the resulted library of candidates has been screened in the IDO1 active site. 
Compounds have been ranked according to their binding energies in the two proteins, 
as well as their drug-like profiles, including predicted solubility and membrane 
permeability. The virtual candidates that displayed the highest score have been 
selected for the synthesis.  
Picked compounds 29-50 were efficiently obtained by coupling aniline 5 with 
different carboxylic acids (7-28) (Scheme 2). The reaction provided the desired 
benzimidazoles in good (29, 30, 32-41, 43, 44, 46-48, 50) to excellent (31, 42) yields, 
while in some cases, the yields were poor (45, 49).  
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Scheme 2. Synthesis of compounds 29-50. 
(a) TEA, HOBt, EDCI, dry CH2Cl2, rt, 18 h, 13-86 %. 
For the synthesis of compound 54 protection and deprotection of the additional 
amine group were necessary, according to Scheme 3. 
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Scheme 3. Synthesis of compound 54. 
(a) 2 M aq. NaOH, Boc2O, THF, 16 h, 86%; (b) compound 4, TEA, HOBt, EDCI, dry 
CH2Cl2, rt, 18 h, 57%; (c) CF3COOH, dry CH2Cl2, 0 °C, 30 min, 71%. 
Then, docking studies revealed that the introduction of a bromine atom in the 6’ 
position of the benzimidazole core might improve the affinity with pocket A in IDO1 
active site. Taking advantage of this information, compound 60 has been synthesized 
by coupling reaction as described above (Scheme 4). Hence, the desired aniline 59 
was prepared via a three-step procedure: substitution, cyclization and reduction of 
the nitrile group (Scheme 4).  
 
Scheme 4. (a) K2CO3, DMSO, 72 °C, 16 h, 13%; (b) formic acid, Fe, 85 °C, 16 h, 69%; (c) 
LiAlH4, dry THF, rt, 16 h, 40%; (d) TEA, HOBt, EDCI, dry CH2Cl2, rt, 18 h, 39 %. 
 
 
 
Chapter 5 
136 
5.3.2. Biological evaluation 
As already explained in Chapter 4.3.2., the measurement of cell viability is 
mandatory when reporting cellular IDO1 inhibitory activity, because the observed 
reduction of tryptophan degradation could simply be an effect of cytotoxicity. Thus, 
we decided to first investigate the cytotoxicity of all the synthesized compounds on 
A375 cell line. Cells were treated (48 h) with each compound (1 µM) and cell 
viability was measured by MTT assay. As shown in Table 1, compounds 44 and 50 
displayed a cytotoxic effect, inducing a reduction of cell viability of -18% and -45%, 
respectively, while the other compounds resulted in being non-cytotoxic and 
biocompatible. The ability of the synthesized compounds to inhibit human IDO1 was 
analyzed in an in vitro cell-based assay, to evaluate their inhibitory effect together 
with their ability to permeate the cell membrane. IDO1 expression was induced in 
A375 cell line by IFN-γ and enzymatic activity was determined after 48 h by 
measuring the formation of the L-kynurenine (L-Kyn) product by high-performance 
liquid chromatography (HPLC). IC50 values were calculated for compounds that 
displayed an inhibition value greater than 80%. Biological evaluation is still ongoing 
and the results obtained so far are reported in the Table below. 
 
 
Cpd R1 R2 
Cell viability 
(%) @ 1 µM 
± SD  
IDO cellular 
assay inhibition 
(%) @ 1 µM 
IC50 
6 H 
 
96 ± 2 98 16 nM 
29  H 
 
98 ± 2 32 - 
30  H 
 
94 ± 3 88 BE 
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Cpd R1 R2 
Cell viability 
(%) @ 1 µM 
± SD  
IDO cellular 
assay inhibition 
(%) @ 1 µM 
IC50 
31  H 
 
97 ± 3 81 BE 
32 H 
 
96 ± 4 98 BE 
33  H 
 
96 ± 4 99 BE 
34 H 
 
89 ± 7 88 BE 
35 H 
 
100 ± 1 88 90 nM 
36 H 
 
94 ± 1 44 - 
37 H 
 
99 ± 1 37 - 
38 H 
 
100 ± 0 32 - 
39 H 
 
100 ± 0 37 - 
40  H 
 
98 ± 1 62 - 
41 H 
 
94 ± 6 72 - 
42  H 
 
96 ± 3 5 - 
Chapter 5 
138 
 
Cpd R1 R2 
Cell viability 
(%) @ 1 µM 
± SD  
IDO cellular 
assay inhibition 
(%) @ 1 µM 
IC50 
43 H 
 
100 ± 1 0 - 
44 H 
 
88 ± 1 77 - 
45  H 
 
100 ± 0 87 413 nM 
46  H 
 
100 ± 0 81 407 nM 
47  H 
 
99 ± 4 94 72 nM 
48  H 
 
99 ± 1 90 636 nM 
49 H 
 
99 ± 1 82 781 nM 
50 H 
 
55 ± 11 - - 
54  H 
 
100 ± 0 0 - 
60  Br 
 
99 ± 1 99 19 nM 
Table 1. Structure and biological profile of benzimidazole compounds. BE = being 
evaluated. 
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5.3.3. Preliminary SAR study 
First, the presence of a phenyl ring at R2 position and the effect of various 
substituents at different positions of the phenyl ring was investigated. While the 
inhibitory activity was low when a non-substituted phenyl ring was present (29, 
32%), the addiction of a cyano group at position 4’ produced a significative increase 
in activity (35, IC50 = 90 nM). However, the simultaneous presence of a cyano group 
at position 4’ with a methyl group at 3’ position (36, 44%) or, alternatively, a fluorine 
at 2’ position (37, 37%) or at 3’ position (38, 32%) produced a loss of activity. 
Electron-withdrawing groups such as chlorine, fluorine, bromine and trifluoromethyl 
at position 4’ gave the compounds 31 – 34 displaying inhibitory activities between 
88 and 99%. The same occurred when the methyl moiety was introduced at position 
4’ (30, 88%).  Moreover, the introduction of a polar structure at R2 position induced 
a loss of activity (43, 0%; 54, 0%). The presence of a bromine group at 3’ position 
on the pirrole ring of compound 6 seems to be crucial: indeed, when it was removed, 
a decrease in activity was observed (41, 72%). Similarly, different pentatomic 
heterocycles such as furan 39 and thiophene 40 produced a decrease in inhibitory 
activity (37 and 62%, respectively). Then, the influence of different fused 
heterocycles was studied. Nitrogenated heterocycles such as indole (47, 72 nM) and 
benzimidazole (46, 407 nM) showed a good activity, despite the IC50 values were 
higher compared to the hit compound. The presence of a polar hydroxyl group at 
position 5’ of the indole ring (49, 781 nM) or, alternatively, a methyl group at the 
same position was tolerated (48, 636 nM). Lastly, benzofuran 45 showed an IC50 
value of 413 nM comparable to benzimidazole compound (46, 407 nM), while the 
presence of a benzodioxolane ring was not tolerated (42, 5%). Subsequently, we 
investigated whether the addiction of a bromine atom at R1 position on the 
benzimidazole core might enhance the potency of the hit. Gratifyingly, compound 
60 gave rise to the most active compound of this class of analogues with an IC50 
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value of 19 nM. The preliminary results of this SAR study are summarized in Figure 
2.  
 
Figure 2. Preliminary SAR study of benzimidazoles. 
Preliminary docking studies on 60 revealed that it can bind in the IDO catalytic 
pocket as hit compound 1 (Figure 1B). Nitrogen moiety of benzimidazole can interact 
with the heme group, while the Br substituent bind in the pocket A, near Cys129. 
The central aromatic ring is near pocket B, while the pyrrole end group is located in 
the pocket C. Its NH moiety, with NH of the amide linker, can give hydrogen 
bonding interaction with acid moiety of heme (Figure 3). 
 
Figure 3. Docking pose of 60. Structure is depicted as green sticks and heme is depicted as 
cyan sticks. Red shape: pocket A; green: pocket B; blue: pocket C. Hydrogen bond 
interactions are indicated as dashed yellow lines. 
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5.4. Conclusions 
In conclusion, exploiting a structure-based virtual screening approach, we 
identified a promising hit, 1, with an IC50 value against IDO1 in the nanomolar range. 
While a plethora of structural different molecules have been described in the 
literature as IDO1 inhibitors, to the best of our knowledge the benzimidazole scaffold 
has never been reported. The hit was re-synthesized by us and its biological activity 
was confirmed. Moreover, a preliminary SAR study of this class of compounds has 
been performed proving that at R2 position: i) polar structures are not tolerated, ii) 
indole and 3-bromopirrole heterocycles show good inhibitory activities, iii) the 
removal of Br atom on the pirrole ring of the hit compound results in a decrease in 
inhibitory activity, iv) a cyano group in 4’ position on the phenyl ring produces a 
significant increase in activity. We also demonstrated that the addiction of a bromine 
atom at R1 significantly increased inhibitory potency.  
In summary, together with the hit (6, IC50 = 16 nM), a potent compound has been 
identified, 60,  with an IC50 value against IDO1 of 19 nM. 
Furthermore, docking studies suggest that this class of compounds might be 
accommodated also in the active site of IDO2 and TDO, as a similar pocket C is also 
present on the active site of these two dioxygenases. In this context, since recent 
reports have suggested that the combinatorial targeting of the three enzymes might 
deepen efficacy, limit acquired resistance to IDO1 blockade and reduce autoimmune 
side effects of immunotherapy, we realized that development of a dual/pan inhibitor 
of IDO1, IDO2 and TDO would be a more effective strategy in cancer therapy.4  
For these reasons, the selectivity profile over these two enzymes and the ADME 
properties will be investigated for compounds 6 and 30; indeed, since they showed 
comparable inhibitory activities the determination of metabolic and selectivity 
profile will be pivotal. Finally, as soon as a promising candidate will be identified, 
after appropriate maximal tolerated dose (MTD) and pharmacokinetics (PK) 
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experiments the efficacy of the compounds in triple-negative breast (4T1) cancer and 
in hepatocellular carcinoma (Hep-55.1c) will be evaluated. 
5.5. Experimental section 
General Methods. Commercially available reagents and solvents were used as 
purchased without further purification. When needed, solvents were distilled and 
stored on molecular sieves. Column chromatography was performed on silica gel 
Merck Kieselgel 70-230 mesh ASTM. Thin layer chromatography (TLC) was 
carried out on 5 cm x 20 cm plates with a layer thickness of 0.25 mm (Merck silica 
gel 60 F254). The spots were visualized by ultraviolet light (wavelengths 254 and 
366 nm) and, when necessary, with Dragendorff reagent, aqueous KMnO4 or 
aqueous Pancaldi solution. Melting points were determined in open glass capillary 
with a Stuart scientific SMP3 apparatus. All the target compounds were checked by 
IR (FT-IR Thermo-Nicolet Avatar), 1H and 13C NMR (Jeol ECP 300 MHz), and mass 
spectrometry (Thermo Finningan LCQ-deca XP-plus) equipped with an ESI source 
and an ion trap detector. Chemical shifts are reported in parts per million (ppm).  
5.5.1. Chemistry 
3-((1H-benzo[d]imidazol-1-yl)methyl)benzonitrile, (4). 
To a solution of benzimidazole (3.00 g, 25.39 mmol, 1 eq) in acetone (83 mL) KOH 
(2.90 g, 50.79 mmol, 2 eq) and 3-(bromomethyl)benzonitrile (4.98 g, 25.39 mmol, 1 
eq) were added in order. The reaction mixture was heated at 60 °C for 4 hours. Then, 
acetone was removed in vacuo, water was added and the aqueous layer was extracted 
with EtOAc (x1). The organic extract was dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by silica gel column chromatography using 
petroleum ether/ethyl acetate 3:7 provided the desired compound (5.86 g, 25.14 
mmol, 99%) as a yellow solid. mp 110-112 °C. 1H NMR (300 MHz, CDCl3): δ = 
7.98 (s, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.59 (d, J= 7.7 Hz, 1H), 7.76 (s, 1H), 7.43 (d, 
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J = 7.4 Hz, 1H), 7.33-7.25 (m, 3H), 7.22 (t, J = 7.4 Hz, 1H), 5.40 (s, 2H). 13C NMR 
(75 MHz, CD3OD): δ = 143.9, 143.3, 137.4, 133.6, 131.9, 131.4, 130.4, 130.0, 123.6, 
122.7, 120.5, 118.4, 113.0, 110.0, 47.9. IR (KBr): ṽ = 3099, 3077, 3051, 2865, 2757, 
2560, 1496, 1439, 743 cm-1. MS (ESI): m/z 234 [M + H]+. 
(3-((1H-benzo[d]imidazol-1-yl)methyl)phenyl)methanamine, (5). 
Compound 4 (1.50 g, 6.43 mmol, 1 eq) was solubilized in dry THF (49 mL). The 
solution was cooled to 0 °C and LiAlH4 (0.49 g, 16.09 mmol, 2.5 eq) was slowly 
added. The mixture was stirred at rt overnight and then heated at 65 °C for 2 hours. 
Then, EtOAc was added and the organic layer was washed with aqueous saturated 
Na2SO4 solution (x1), with water (x1), dried over Na2SO4 and concentrated in vacuo. 
Purification by silica gel column chromatography using ethyl acetate/MeOH 7:3 
provided the title compound (1.07 g, 4.50 mmol, 70%) as a yellow oil. 1H NMR (300 
MHz, CD3OD): δ = 8.28 (s, 1H), 7.66 (t, J = 7.2 Hz, 1H), 7.43 (t, J = 7.2 Hz, 1H), 
7.30-7.15 (m, 6H), 5.74 (s, 2H), 3.75 (s, 2H). 13C NMR (75 MHz, CD3OD): δ = 
143.9, 143.2, 137.4, 133.6, 131.9, 131.4, 130.4, 130.0, 123.6, 122.7, 120.5, 118.4, 
113.0, 110.0, 47.8. IR (KBr): ṽ = 3359, 3048, 2984, 1730, 1494, 1438, 1286, 1201, 
741 cm-1. MS (ESI): m/z 238 [M + H]+. 
General procedure for the synthesis of compounds 6, 29-50, 60. 
To a solution of compound 5 (167.11 mg, 0.7 mmol, 1 eq) in dry CH2Cl2 (5 mL) 
TEA (220 µL, 1.54 mmol, 2.2 eq), EDCI (161.28 mg, 0.84 mmol, 1.2 eq), HOBt 
(113.51 mg, 0.84 mmol, 1.2 eq) and carboxylic acid (0.84 mmol, 1.2 eq) were added 
in order. The resulting mixture was stirred at room temperature for 16 h. CH2Cl2 was 
added and the organic phase was washed with aqueous saturated NH4Cl solution 
(x1), dried over sodium sulfate and evaporated. Purification by silica gel column 
chromatography afforded compounds 6, 29-50. 
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N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-bromo-1H-pyrrole-2-
carboxamide, (6). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (90 mg, 0.38 mmol) and 4-bromo-1H-pyrrole-2-carboxylic acid (86 mg, 
0.46 mmol). The crude material was purified by column chromatography using 
petroleum ether/ethyl acetate 2:8 as eluent to afford compound 5 (77 mg, 0.19 mmol, 
50%) as a white solid. Mp 212-214 °C. 1H NMR (300 MHz, CD3OD): δ = 8.21 (s, 
1H), 7.65 (d, J = 7.4 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.31-7.12 (m, 6H), 6.90 (s, 
1H), 6.73 (s, 1H), 5.44 (s, 2H), 4.44 (s, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 
160.2, 144.8, 144.1, 140.9, 137.5, 134.3, 129.3, 127.3 (2C), 127.2, 127.0, 126.9, 
126.5, 123.0, 122.2, 121.9, 120.1, 95.6, 48.2, 40.6. IR (KBr): ṽ = 3285, 3118, 2913, 
2850, 2446, 2360, 3242, 1945, 1722, 748 cm-1. MS (ESI): m/z 409 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)benzamide, (29). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and benzoic acid (102 mg, 0.84 mmol). The crude 
material was purified by column chromatography using petroleum ether/ethyl acetate 
3:7 as eluent to afford compound 29 (128 mg, 0.39 mmol, 54%) as a white solid. 1H 
NMR (300 MHz, CD3OD): δ = 8.24 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 
8.2 Hz, 1H), 7.55-7.49 (m, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.38 (d, J = 7.7 Hz, 1H), 
7.31-7.15 (m, 7H), 5.45 (s, 2H), 4.51 8s, 2H. MS (ESI): m/z 342 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-methylbenzamide, (30). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (76 mg, 0.32 mmol) and 2-oxo-2-(p-tolyl)acetic acid (52 mg, 0.38 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 30 (79 mg, 0.21 mmol, 69%) as 
a white solid. Mp 137 – 139 °C.1H NMR (300 MHz, CD3OD): δ = 8.22 (s, 1H), 7.81-
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7.58 (m, 3H), 7.38 (d, J = 7.6 Hz, 1H), 7.36-7.06 (m, 8H), 5.43 (s, 2H), 4.90 (s, 2H), 
2.36 (s, 3H). MS (ESI): 356 m/z [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-(trifluoromethyl)benzamide, 
(31). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 4-(trifluoromethyl)benzoic acid (57 mg, 0.30 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 31 (84 mg, 0.21 mmol, 82%) as 
a white solid. Mp 154 – 158 °C.1H NMR (300 MHz, CD3OD): δ = 8.27 (s, 1H), 7.89 
(d, J = 8.2 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 7.4 Hz, 1H), 7.39 (d, J = 
8.2 Hz, 1H), 7.33-7.12 (m, 6H), 5.49 (s, 2H), 4.52 (s, 2H). MS (ESI): 410 m/z [M + 
H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-bromobenzamide, (32). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 4-bromobenzoic acid (61 mg, 0.30 mmol). The 
crude material was purified by column chromatography using ether/ethyl acetate 3:7 
as eluent to afford compound 32 (81 mg, 0.19 mmol, 77%) as a white solid. Mp 151 
– 153 °C. 1H NMR (300 MHz, CD3OD): δ = 8.27 (s, 1H), 7.73-7.56 (m, 5H), 7.41 
(d, J = 7.1 Hz, 1H), 7.35 (d, J = 7.4 Hz, 2H), 7.29-7.18 (m, 4H), 5.50 (s, 2H), 4.61 
(s, 2H). MS (ESI): 420 m/z [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-chlorobenzamide, (33). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 4-chlorobenzoic acid (47 mg, 0.30 mmol). The 
crude material was purified by column chromatography using ether/ethyl acetate 3:7 
as eluent to afford compound 33 (57 mg, 0.15 mmol, 60%) as a white solid. Mp 125 
– 127 °C. 1H NMR (300 MHz, CD3OD): δ = 8.25 (s, 1H), 7.73 (d, J = 8.5 Hz, 2H), 
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7.65 (d, J = 7.1 Hz, 1H), 7.49-7.37 (m, 3H), 7.33-7.09 (m, 6H), 5.48 (s, 2H), 4.50 (s, 
2H). MS (ESI): 376 m/z [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-fluorobenzamide, (34). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 4-fluorobenzoic acid (43 mg, 0.30 mmol). The 
crude material was purified by column chromatography using ether/ethyl acetate 3:7 
as eluent to afford compound 34 (70 mg, 0.19 mmol, 78%) as a grey solid. Mp 116 
– 118 °C. 1H NMR (300 MHz, CD3OD): δ = 8.26 (s, 1H), 7.87-7.78 (m, 2H),  7.65 
(d, J = 6.8 Hz, 1H), 7.41 (d, J = 6.8 Hz, 1H), 7.35 (d, J = 8.0 Hz, 2H), 7.27-7.09 (m, 
6H), 5.49 (s, 2H), 4.52 (s, 2H). MS (ESI): 360 m/z [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-cyanobenzamide, (35). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 4-cyanobenzoic acid (123 mg, 0.84 mmol). 
The crude material was purified by column chromatography using ether/ethyl acetate 
3:7 as eluent to afford compound 35 (197 mg, 0.54 mmol, 77%) as a white solid. Mp 
192-194 °C. 1H NMR (300 MHz, CD3OD): δ = 8.25 (s, 1H), 7.90-7.79 (m, 4H), 7.64 
(d, J = 6.8 Hz, 1H), 7.39 (d, J = 6.8 Hz, 1H), 7.35-7.16 (m, 6H), 5.49 (s, 2H), 4.52 
(s, 2H). IR (KBr): ṽ 3553, 3414, 3348, 3082, 2923, 2358, 2227, 1638, 1546, 1492, 
1443, 736, 742 cm-1. MS (ESI): m/z 367 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-cyano-3-methylbenzamide, 
(36). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 4-cyano-3-methylbenzoic acid (49 mg, 0.30 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 36 (48 mg, 0.13 mmol, 51%) as 
a yellow solid. Mp 178 – 180 °C. 1H NMR (300 MHz, DMSO-d6): δ = 9.21 (br s, 
1H), 8.40 (s, 1H), 7.90 (d, J = 6.9 Hz, 2H), 7.78 (d, J = 8.0 Hz, 1H), 7.65 (d , J = 5.0 
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Hz, 1H),  7.51 (d , J = 5.0 Hz, 1H), 7.34-7.27 (m, 2H), 7.21-7.17 (m, 4H), 5.48 (s, 
2H), 4.50 (s, 2H). MS (ESI): 381 m/z [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-cyano-2-fluorobenzamide, 
(37). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 2-oxo-2-(p-tolyl)acetic acid (49 mg, 0.30 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 37 (58 mg, 0.15 mmol, 60%) as 
a white solid. Mp 103 – 105 °C. 1H NMR (300 MHz, CD3OD): δ = 8.28 (s, 1H), 7-
79-7.57 (m, 4H), 7.42 (d, J = 5.2 Hz, 1H), 7.34 (d, J = 8.5 Hz, 2H), 7.27-7.19 (m, 
4H), 5.51 (s, 2H), 4.53 (s, 2H). MS (ESI): 385 m/z [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-cyano-3-fluorobenzamide, 
(38). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (60 mg, 0.25 mmol) and 4-cyano-3-fluorobenzoic acid (50 mg, 0.30 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 38 (46 mg, 0.11 mmol, 48%) as 
a yellow solid. Mp 192 – 194 °C. 1H NMR (300 MHz, DMSO-d6): δ = 9.37 (br s, 
1H), 8.58 (s, 1H), 8.08 (t, J = 8.08 Hz, 1H), 7.95-7.80 (m, 2H), 7.65 (d, J = 7.6 Hz, 
1H), 7.56 (d, J = 7.6 Hz, 1H), 7.43-7.16 (m, 6H), 5.53 (s, 2H), 4.45 (s, 2H). MS 
(ESI): 385 m/z  [M + H]+.  
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)furan-2-carboxamide, (39). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and furan-2-carboxylic acid (94 mg, 0.84 mmol). 
The crude material was purified by column chromatography using ether/ethyl acetate 
4:6 as eluent to afford compound 39 (150 mg, 0.46 mmol, 65%) as a white solid. Mp 
153-154 °C. 1H NMR (300 MHz, CD3OD): δ = 8.19 (s, 1H), 7.64-7.57 (m, 3H), 7.34 
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(d, J = 7.4 Hz, 1H), 7.35-7.04 (m, 7H), 5.36 (s, 2H), 4.44 (s, 2H). IR (KBr): ṽ = 3477, 
3231, 3070, 2977, 2926, 1742, 1638, 1495, 1442, 1365, 1015, 769, 745cm-1. MS 
(ESI): m/z 332 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)thiophene-2-carboxamide, (40). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (160 mg, 0.67 mmol) and thiophene-2-carboxylic acid (103 mg, 0.81 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 40 (182 mg, 0.52 mmol, 78%) 
as a yellow solid. Mp 171-173 °C. 1H NMR (300 MHz, CD3OD): δ = 8.19 (s, 1H), 
7.64-7.57 (m, 3H), 7.34 (d, J = 7.4 Hz, 1H), 7.35-7.04 (m, 7H), 5.36 (s, 2H), 4.44 (s, 
2H). IR (KBr): ṽ = 3555, 3414, 3263, 3070, 2892, 1636, 1618, 1498, 1365, 744 cm-
1. MS (ESI): m/z 348 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-1H-pyrrole-2-carboxamide, 
(41). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 1H-pyrrole-2-carboxylic acid (93 mg, 0.84 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 2:8 as eluent to afford compound 41 (143 mg, 0.43 mmol, 62%) 
as a yellow solid. Mp 206-208 °C. 1H NMR (300 MHz, CD3OD): δ = 8.23 (s, 1H), 
7.64 (dd, Js = 1.0, 8.3 Hz), 7.39 (d, J = 6.9 Hz, 1H), 7.26-7.13 (m, 7H), 7.76 (s, 1H), 
6.16 (d, J = 2.5 Hz, 1H), 5.43 (s 2H), 5.36 (s, 2H). IR (KBr): ṽ = 3220, 3087, 2935, 
2701, 2563, 1628, 1560, 1491, 1437, 1438, 776, 745 cm-1. MS (ESI): m/z 331 [M + 
H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-2-(benzo[d][1,3]dioxol-5-
yl)acetamide, (42). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 2-(benzo[d][1,3]dioxol-5-yl)acetic acid ( 151 
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mg, 0.84 mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 42 (235 mg, 0.59 mmol, 84%) 
as an amorphous yellow solid. 1H NMR (300 MHz, CD3OD): δ = 8.13 (s, 1H), 7.66 
(d, J = 8.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.30-7.00 (m, 7H), 6.74 (s, 1H), 6.66 
(s, 1H), 5.76 (s, 2H), 5.27 (s, 2H), 4.23 (s, 2H), 3.30 (s, 2H). IR (KBr): ṽ = 3735, 
3629, 3255, 2887, 2790, 1845, 1654, 1500, 1442, 1260, 1190, 1040, 668 cm-1. MS 
(ESI): m/z 400 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-3-morpholinopropanamide, 
(43). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 3-morpholinopropanoic acid (133 mg, 0.84 
mmol). The crude material was purified by column chromatography using ethyl 
acetate/MeOH 9:1 as eluent to afford compound 43 (146 mg, 0.39 mmol, 55%) as an 
amorphous yellow solid. 1H NMR (300 MHz, CD3OD): δ = 8.25 (s, 1H), 7.68 (t, J = 
3.0 Hz, 1H), 7.43 (t, J = 3.0 Hz, 1H), 7.34-7.24 (m, 5H), 7.18 (d, J = 6.9 Hz, 1H), 
5.48 (s, 2H), 4.34 (s, 2H), 3.58-3.50 (m, 4H), 2.60 (t, J = 7.0 Hz, 2H), 2.42- 2.39 (m, 
4H), 2.36 (t, J = 7.0 Hz, 2H). IR (neat): ṽ = 3268, 2062, 1649, 1550, 1495, 1457, 
1287, 1114, 743 cm-1. MS (ESI): m/z 379 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)benzo[b]thiophene-2-
carboxamide, (44). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and benzo[b]thiophene-2-carboxylic acid (149 
mg, 0.84 mmol). The crude material was purified by column chromatography using 
petroleum ether/ethyl acetate 5:5 as eluent to afford compound 44 (144 mg, 0.36 
mmol, 52%) as a white solid. Mp 185-187 °C.  1H NMR (300 MHz, acetone-d6): δ = 
8.48 (s, 1H), 8.23 (s, 1H), 8.00-7.98 (m, 2H), 7.89 (dd, JS = 1.9, 7.1 Hz, 1H), 7.77-
7.63 (m, 1H), 7.48-7.47 (m, 2H), 7.44-7.41 (m, 2H), 7.33-7.28 (d, J = 5.8 Hz, 2H), 
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7.21-7.11 (m, 2H), 5.50 (s, 2H), 4.59 (s, 2H). IR (KBr): ṽ = 3183, 3055, 1642, 1560, 
1495, 1458, 1290, 742 cm-1. MS (ESI): m/z 398 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)benzofuran-2-carboxamide, (45). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and benzofuran-2-carboxylic acid (136 mg, 0.84 
mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 45 (98 mg, 0.26 mmol, 37%) as 
a yellow solid. Mp 161-163 °C. 1H NMR (300 MHz, CD3OD): δ = 8.26 (s, 1H), 7.65 
(d, J = 7.9 Hz, 1H), 7.60-7.57 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.41 (m, 2H), 7.36-
7.31 (m, 2H), 7.25 (m, 3H), 7.13-7.10 (m, 3H), 5.43 (s, 2H), 4.52 (s, 2H). IR (KBr): 
ṽ = 3892, 3801, 3735, 2927, 2850, 1734, 1590, 1560, 1496, 1474, 747 cm-1. MS 
(ESI): 382 m/z [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-1H-benzo[d]imidazole-2-
carboxamide, (46). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 1H-benzo[d]imidazole-2-carboxylic acid 
(136 mg, 0.84 mmol). The crude material was purified by column chromatography 
using ether/ethyl acetate 4:6 as eluent to afford compound 46 (229 mg, 0.60 mmol, 
86%) as a white solid. Mp 226-227 °C. 1H NMR (300 MHz, DMSO-d6): δ = 9.40 (br 
s, 1H), 8.34 (s, 1H), 7.77-7.58 (m, 3H), 7.47 (d, J = 7.2 Hz,1H), 7.36 (s, 1H), 7.27-
7.21 (m, 4H), 7.16-7.06 (m, 3H), 5.46 (s, 2H), 4.46 (s, 2H). IR (KBr): ṽ = 3418, 3047, 
1666, 1507, 1494, 1436, 1330, 744 cm-1. MS (ESI): m/z 382 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-1H-indole-2-carboxamide, (47). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 1H-indole-2-carboxylic acid (135 mg, 0.84 
mmol). The crude material was purified by column chromatography using petroleum 
ether/ethyl acetate 4:6 as eluent to afford compound 47 (144 mg, 0.38 mmol, 54%) 
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as a yellow solid. Mp 231-233 °C. 1H NMR (300 MHz, DMSO-d6): δ = 11.53 (br s, 
1H), 8.94 (br s, 1H), 8.37 (s, 1H), 7.68-7.55 (m, 2H),  7.53-7.40 (m, 2H), 7.37 (s, 
1H), 7.31-7.26 (m, 2H), 7.21-7.15, (m, 5H), 7.04 (t, J = 7.9 Hz, 1H), 5.49 (s, 2H), 
4.48 (s, 2H). IR (KBr): ṽ = 3218, 3053, 2926, 2853, 2721, 2648, 1638, 1564, 1495, 
1310, 746 cm-1. MS (ESI): m/z 381 [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-5-methyl-1H-indole-2-
carboxamide, (48). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 5-methyl-1H-indole-2-carboxylic acid (147 
mg, 0.84 mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 48 (134 mg, 0.34 mmol, 49%) 
as a white solid. Mp 222-224 °C. 1H NMR (300 MHz, CD3OD): δ = 8.25 (s, 1H), 
7.62 (dd, Js = 1.9, 7.7 Hz, 1H), 7.41-7.28 (m, 6H), 7.18-7.16 (m, 3H), 7.61 (d, J = 
7.7 Hz, 1H), 6.93 (s, 1H), 5.48 (s, 2H),4.53 (s, 2H), 2.40 (s, 3H). IR (KBr): ṽ = 3232, 
3090, 3061, 2922, 1637, 1560, 1496, 1419, 802, 736 cm-1. MS (ESI): m/z 395 [M + 
H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-5-hydroxy-1H-indole-2-
carboxamide, (49). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 5-hydroxy-1H-indole-2-carboxylic acid (148 
mg, 0.84 mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 3:7 as eluent to afford compound 49 (35 mg, 0.09 mmol, 13%) as 
a yellow solid. Mp 210-212 °C. 1H NMR (300 MHz, acetone-d6): δ = 10.42 (br s, 
1H), 8.32 (s, 1H), 7.52(dd, JS = 1.7, 7.1 Hz, 1H), 7.32-7.20 (m, 6H), 7.18-7.15 (m, 
3H), 7.59 (d, J = 7.7 Hz, 1H), 7.01 (s, 1H), 5.67 (br s, 1H), 5.50 (s, 2H), 4.58 (s, 2H), 
3.31 (br s, 1H). IR (KBr): ṽ = 3745, 2359, 2342, 1742, 1557, 1496, 1362, 1257 cm-1. 
MS (ESI): m/z 397 [M + H]+. 
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N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-5-methoxy-1H-indole-2-
carboxamide, (50). 
The title compound was synthesized following the general procedure, starting from 
compound 5 (166 mg, 0.70 mmol) and 5-methoxy-1H-indole-2-carboxylic acid (160 
mg, 0.84 mmol). The crude material was purified by column chromatography using 
ether/ethyl acetate 2:8 as eluent to afford compound 50 (160 mg, 0.39 mmol, 56%) 
as a yellow solid. Mp 225-227 °C. 1H NMR (300 MHz, DMSO-d6): δ = 11.43 (br s, 
1H), 8.97 (s, 1H), 8.39 (s, 1H), 7.65 (d, J = 7.1 Hz, 1H), 7.50 (d, J = 7.1 Hz, 1H), 
7.33 (t, J = 6.3 Hz, 1H), 7.27 (d, J = 6.3 Hz, 2H), 7.22-7.18 (m, 3H), 7.06 (d, J = 6.3 
Hz, 2H), 6.83 (d, J = 8.5 Hz, 1H), 5.48 (s, 2H), 4.47 (s, 2H), 3.75 (s, 3H). IR (KBr): 
ṽ = 3246, 3087, 3004, 2926, 2803, 1637, 1559, 1497, 1359, 1269, 163, 742 cm-1. MS 
(ESI): 411 m/z [M + H]+. 
4-((tert-butoxycarbonyl)amino)butanoic acid, (52). 
To a solution of 4-aminobutanoic acid (200 mg, 1.94 mmol, 1 eq) in 2 M aq. NaOH 
(3 mL), a solution of BOC2O (507.50 mg, 2.33 mmol, 1.2 eq) in THF (5 mL) was 
added dropwise and the reaction was stirred at rt overnight. The solvent was removed 
in vacuo. The aqueous layer was acidified with 2M aq. HCl until pH 4 and extracted 
with EtOAc (6x). Additionally, the aqueous layer was saturated with NaCl and 
extracted with THF (3x). The combined organic layers were dried over Na2SO4, 
filtrated and concentrate in vacuo yielding the desired compound (339 mg, 1.67 
mmol, 86%) as a yellow oil, which was used directly in the next step without further 
purification. 1H NMR (300 MHz, DMSO-d6): δ = 6.77 (br s, 1H), 2.92 (t, J = 6.3 Hz, 
2H), 2.16 (t, J = 6.3 Hz, 2H), 1.58 (quint, J = 6.9 Hz, 2H), 1.41 (s, 9H). MS (ESI): 
204 m/z [M + H]+. 
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-aminobutanamide, (54). 
Step 1: To a solution of compound 5 (166.11 mg, 0.70 mmol, 1 eq) in dry CH2Cl2 
(5 mL) TEA (220 µL, 1.54 mmol, 2.2 eq), EDCI (161.28 mg, 0.84 mmol, 1.2 eq), 
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HOBt (113.51 mg, 0.84 mmol, 1.2 eq) and compound 52 (170.71 mg, 0.84 mmol, 
1.2 eq) were added in order. The resulting mixture was stirred at room temperature 
for 16 h. CH2Cl2 was added and the organic phase was washed with H2O (x3), dried 
over sodium sulfate and evaporated. Purification by silica gel column 
chromatography using EtOAc as eluent afforded compound 53 (168 mg, 0.40 mmol, 
57%) as a yellow solid. 
Step 2: To a solution of compound 53 (148 mg, 0.35 mmol, 1 eq) in CH2Cl2 (2.5 
mL) at 0 °C CF3COOH (1.23 mL) was added. The reaction mixture was stirred at 
the same temperature for 30 min and then for 3 hours at rt. 2 M aq. NaOH was added 
until pH 7 and the aqueous layer was extracted with EtOAc (x3). The collected 
organic layers were dried over Na2SO4, filtrated and concentrated in vacuo. 
Purification by silica gel column chromatography using CH3CN/NH3 9:1as eluent 
afforded compound 54 (80 mg, 0.25 mmol, 71%) as a yellow oil. 1H NMR (300 
MHz,CD3OD): δ = 8.24 (s, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 
7.23-7.13 (m, 6H), 5.41 (s, 2H), 4.30 (s, 2H), 2.61 (t, J = 7.4 Hz, 2H), 2.19 (t, J = 7.4 
Hz, 2H), 1.70 (quint, J = 6.8 Hz, 2H). IR (KBr): ṽ = 3478, 2621, 1617, 1521, 1540, 
1456, 615 cm-1. MS (ESI): 323 m/z [M + H]+. 
3-(((5-bromo-2-nitrophenyl)amino)methyl)benzonitrile, (57). 
To a solution of 2,4-dibromo-1-nitrobenzene (100 mg, 0.36 mmol, 1 eq) in DMSO 
(1 mL), K2CO3 (73 mg, 0.53 mmol, 1.5 eq) and 3-(aminomethyl)benzonitrile (51 mg, 
0.39 mg, 1.01 eq) were added in order. The reaction mixture was stirred at 72 °C 
overnight. EtOAc was added and the organic later was washed with NaHCO3 (3x), 
dried over Na2SO4, filtrated and concentrated in vacuo. Purification by silica gel 
column chromatography using petroleum ether/ehyl acetate 95:5 as eluent afforded 
compound 57 (15 mg, 0.05 mmol, 13%) as a yellow solid. Mp 196-198 °C. 1H NMR 
(300 MHz, CDCl3): δ = 8.42 (s,1H), 8.08 (d, J = 7.8 Hz, 1H), 7.62-7.49 (m, 2H), 
7.51 (d, J = 7.8 Hz, 1H), 6.88-6.83 (m, 2H), 4.57 (d, J = 4.7 Hz, 2H). IR (KBr): ṽ = 
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3390, 2921, 2229, 1962, 1890, 1520, 1408, 1257, 1049, 750, 618 cm-1. MS (ESI): 
332 m/z [M + H]+. 
3-((6-bromo-1H-benzo[d]imidazol-1-yl)methyl)benzonitrile, (58). 
To a solution of compound 57 (0.93 g, 56.24 mmol, 1 eq) in formic acid (29 mL), Fe 
(3.14 g, 56.24 mmol, 20 eq) was added. The reaction mixture was heated to 85 °C 
for 16 hours. MeOH (29 mL) was added, the reaction was filtered and the filtrate 
concentrate in vacuo. The crude material was purified by silica gel column 
chromatography using petroleum ether/ehyl acetate 4:6 as eluent yielding a yellow 
solid (1.21 g, 38.81 mmol, 69%). Mp 123-125 °C. 1H NMR (300 MHz, CDCl3): δ = 
8.00 (s, 1H), 7.62 (m, 2H), 7.42-7.26 (m, 5H), 5.35 (s, 2H). IR (KBr): ṽ = 3063, 2921, 
2722, 2356, 2228, 1699, 1493, 1462, 1361, 1283, 767, 690 cm-1. MS (ESI): 313 m/z 
[M + H]+. 
(3-((6-bromo-1H-benzo[d]imidazol-1-yl)methyl)phenyl)methanamine, (59). 
Compound 59 was synthesized as previously reported for the preparation of 
compound 5, starting from compound 58 (350 mg, 1.17 mmol) and compound 9 (290 
mg, 0.97 mmol).  The crude material was purified by column chromatography using 
ethyl acetate/MeOH 7:3 to obtain the desired compound 59 (147 mg, 0.47 mmol, 
40%) as a yellow oil. 1H NMR (300 MHz, CD3OD): δ = 8.21 (s, 1H), 7.55 (t, J = 7.1 
Hz, 1H), 7.36 (dd, Js = 1.4, 7.4 Hz, 1H), 7.23-7.17 (m, 4H), 7.05 (s, 1H), 5.32 (s, 
2H), 3.7 (s, 2H). IR (KBr): ṽ = 3521, 3444, 2922, 2855, 1496, 1562, 1458, 1367, 745 
cm-1. MS (ESI): 316 m/z [M + H]+. 
4-bromo-N-(3-((6-bromo-1H-benzo[d]imidazol-1-yl)methyl)benzyl)-1H-pyrrole-
2-carboxamide, (60). 
The title compound was synthesized following the general procedure, starting from 
compound 59 (100 mg, 0.32 mmol) and 4-bromo-1H-pyrrole-2-carboxylic acid (71 
mg, 0.38 mmol). The crude material was purified by column chromatography using 
petroleum ether/ethyl acetate 3:7 as eluent to afford compound 60 (61 mg, 0.12 
Benzimidazole derivatives as indoleamine 2,3-dioxygenase 1 inhibitors: in silico-driven 
synthesis, biological evaluation and structure-activity relationship study 
 
155 
mmol, 39%) as a white solid. Mp 200-202 °C.1H NMR (300 MHz, CD3OD): δ = 
8.26 (s, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 7.7 Hz, 1H) 7.31-7.13 (m, 5H), 
6.91 (s, 1H), 6.73 (s, 1H), 7.15 (s, 2H), 4.45 (s,2H). IR (KBr): ṽ = 3484, 3407, 3224, 
3119, 3291, 2769, 1564, 1525, 1459, 749 cm-1. MS (ESI): 489 m/z [M + H]+.  
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5.5.2. Appendix 
1H NMR (CD3OD) of compound 6 
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6.1. Introduction 
As described above, heterozygous mutations in Ext1 or Ext2 genes cause HME, 
which results in decrease in HS levels. The current available therapy consists of 
surgical removal of exostoses and palliative drugs for pain control. Unfortunately, 
no pharmacological treatment is available for treating HME. 
Consequently, the discovery of small molecules able to increase the HS 
expression could be of considerable clinical benefit.  
In this context, Esko and co-workers developed a phenotypic screening assay 
based on binding of fluorescent derivative of fibroblast growth factor 2 (FGF2) to 
HS. They screened for molecules that increase HS levels on the plasma membrane 
of Chinese hamster ovary (CHO) cells. In detail 57,471 compounds were purchased 
and, after removal of the cytotoxic agents, the remaining 57,342 compounds were 
tested at 10 μM in a primary screen. Hits were then reconfirmed at a screening 
concentration in triplicate. After dose-response analysis and further studies N-aryl-
2-aminothiazoles were identified as a promising class of molecules. Secondary 
assays confirmed that the effect of these molecules is due to specific interaction with 
a biological target and does not result from common non-specific mechanism or 
assay interference. Among this class of compounds was a promising hit, named 415, 
that displayed an EC50 value of ~ 5 µM in the cell-based assays and had no 
cytotoxicity (Figure 1).  
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Figure 1. (A) Chemical structure of hit compound 415. (B) Dose response profile using the 
optical high throughput assay for compound 415 in CHO cells using FGF-streptavidin as 
probe. (C) Compound 415 enhances heparan sulfate expression on A375 cells in a dose 
and time dependent manner. 
 
6.2. Aim of the work 
The goals of this project were to re-synthesize the representative hit compound 
415 in order to confirm its activity and to design and synthesize a series of related 
structural analogues to enable a first assessment of structure activity relationship 
(SAR). Moreover, physicochemical properties of the most promising compounds 
including acidity (pKa), lipophilicity (logD7.4) and aqueous solubility was 
determined. As a visiting PhD student of Prof. C. Ballatore’s research group I 
participated in the synthesis and characterization of this class of compounds (See 
sections 6.5.1.and 6.5.3.). 
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6.3. Results and discussion 
6.3.1. Chemistry 
First of all the hit compound 415 was re-synthesized using two different synthetic 
strategies (Scheme 1A, 1B). The first one explored consists of condensation of 
bromoketone 4, easily obtained by bromination of ketone 3, with thiourea 2. The 
latter was synthesized by conversion of aniline 1 first to isothiocyanate1 and then to 
the desired thiourea. In the second procedure, 415 synthesis was accomplished in 
three steps: bromination, condensation and subsequent coupling of 2-aminothiazole 
5.2 The exploited procedures gave an 60% and 46% overall yields, respectively, 
suggesting that the convergent synthesis resulted more efficient to obtain the hit (6).  
 
Scheme 1. Convergent (A) vs sequential (B) synthesis of hit compound, 415. 
(a) i) H2O, CS2, rt, 16 h ii) 2,4,6-trichloro-1,3,5-triazine, DCM, 50 min, rt, 91%; (b) 7 N 
NH3 in MeOH, rt, 1 h, 63%; (c) HOAc/HBr, Br2, 15 °C to 75 °C, 1 h, 100%; (d) thiourea, 
EtOH, microwaves, 110 °C, 30 min, 60-80%; (e) 4-bromo-N,N-diethylaniline, Pd(OAc)2, 
tBuBrettPhos, K2CO3, degassed H2O, t-BuOH, 110 °C, 58%. 
Of notice, recrystallization from CH2Cl2/DMSO of compound 6 resulted in 
crystals that were suitable for single crystal X-ray diffraction analysis (Figure 2). 
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Figure 2. X-ray structure determination of compound 6. 
Then, in order to conduct SAR investigation a first series of analogues was 
synthesized by varying the diethyl amino group of the p-phenyl ring. To this aim, N-
aryl-2-aminothiazoles 26-29 and 33-39 were synthesized according to the Hantzsch 
thiazole synthesis, by condensing α-bromoketones with thioureas in refluxing EtOH 
under microwave irradiation. Thioureas 23-25 were commercially available, while 
thioureas 15-22 were rapidly obtained in moderate to good yields by treating the 
appropriate aniline and NH4SCN in acidic condition. Hydrolysis of the methyl ester 
of compound 26 gives the corresponding carboxylic acid 30, while reduction of the 
nitroaniline 27 provided aminoaniline 31. Azide 32 was prepared from the 
corresponding aryl bromide 28 under extremely mild conditions (Scheme 2).3  
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Scheme 2. Synthesis of the first series of analogues. 
(a) NH4SCN, aqueous HCl, 100 °C, 16 h, 37-66%; (b) HOAc/HBr, Br2, 15 °C to 75 °C, 1 
h, 100%; (c) EtOH, microwaves, 110 °C, 30 min, 30-93%; (d) 2 M aqueous NaOH, 
MeOH, reflux, 1h, 98%; (e) hydrazine monohydrate, Pd/C, dry MeOH, 60 °C, 16 h, 65%; 
(f) sodium ascorbate, CuI, N1,N2-dimethylethane-1,2-diamine, EtOH/H2O, reflux, 40 min, 
55%. 
Next, to investigate the role of the pyridine ring a second series of derivatives (47-
53) was designed and synthesized (Scheme 3). In this case, the thiourea 2 was reacted 
with the appropriate bromoketone (40-46) as described above. Bromoketones were 
commercially available except for compound 40 which was synthesized from the 
corresponding ketone.  
 
Scheme 3. Synthesis of the second series of analogues. 
(a) EtOH, microwaves, 110 °C, 30 min, 26-98%. 
Finally, in order to evaluate the SAR of the central 5-membered ring heterocycle, 
two 415 analogs bearing a central thiadiazole and oxadiazole were synthesized (56-
57) as highlighted in Scheme 4. In both cases, the common thiosemicarbazide (55) 
intermediate was prepared by treating isothiocyanate 54 with hydrazine in EtOH. 
Then, condensation of 55 with isonicotinic acid in the presence of the dehydrating 
agent, POCl3, led to thiadiazole 56, while the corresponding oxadiazole derivative, 
57, could be accessed by reacting 55 and isonicotinic acid in the presence of coupling 
agent, EDCI.4  
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Scheme 4. Synthesis of thiadiazole and oxadiazole compounds. 
(a) hydrazine hydrate, EtOH, 30 min, rt, 87%; (b) isonicotinic acid, POCl3, dry dioxane, 
90 °C, 3 h; (c) isonicotinic acid, EDCI, TEA, CH2Cl2, rt, 12 h. 
 
6.3.2. Biological evaluation 
The biological evaluation was carried out thanks to the collaboration with Prof. 
Esko’s laboratory. The ability of the synthesized compounds to enhance HS levels 
was quantified in vitro on wild-type CHO cells using flow cytometry technique. 
Briefly, the ability of compounds to modulate HS levels was monitored by measuring 
the increase in fibroblast growth factor 2 (FGF2) binding to HS on the cell surface. 
FGF2 has been shown to bind HS with strong affinity and therefore represent a 
surrogate marker for HS expression. Thus, after incubation of CHO cells with test 
compounds, biotinylated FGF2 was added and bound biotinylated protein was 
quantified by using fluorescent-tagged streptavidin and flow cytometry. The results 
are shown in the table below. Compound 53 was not evaluated since it appeared 
cytotoxic while compound 33 displays a negligible cytotoxicity. 
 Design, synthesis and evaluation of N-aryl-2-aminothiazole derivatives as potential leads 
for the treatment of hereditary multiple exostoses 
167 
 
Cpd R1 R2 A 
Activity 
@10 µM 
VS 
untreated¥ 
Activity 
@10 µM 
VS 415 
Untreated - - 
- 
1 - 
415 
   
1.635 1 
26 
 
COOMe 
 
1.364 0.836 
27 
 
NO2 
 
0.948 0.576 
28 
 
Br 
 
1.104 0.677 
29 
 
OH 
 
1.257 0.738 
30 
 
COOH 
 
1.195 0.732 
31 
 
NH2 
 
1.345 0.824 
32 
 
N3 
 
1.120 0.686 
33 
 
t-Bu 
 
1.859  1.131  
34 
 
Me 
 
1.077 0.660 
35 
   
1.728 0.991 
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Cpd R1 R2 A 
Activity 
@10 µM 
VS 
untreated¥ 
Activity 
@10 µM 
VS 415 
36 
   
0.990 0.607 
37 
 
F 
 
1.130 0.693 
38 
 
CF3 
 
1.114 0.683 
39 
 
OMe 
 
1.276 0.782 
47 
   
0.976 0.564 
48 
   
0.992 0.835 
49 
   
1.248 0.721 
50 
   
0.953 0.801 
51 
   
1.103 0.558 
52 
   
1.539 0.778 
53 
   
ND* ND* 
56 
  
 
0.986 0.570 
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Cpd R1 R2 A 
Activity 
@10 µM 
VS 
untreated¥ 
Activity 
@10 µM 
VS 415 
57 
  
 
1.061 0.645 
 
Table 1. Values of 415 and its analogues activity. 
¥ The ability of test compounds to enhance HS levels on the surface of CHO cells was determined at 
10 µM compound concentration, relative to untreated cells; # The ability of test compounds to enhance 
HS levels on the surface of CHO cells was determined at 10 µM compound concentration, relative to 
treated with 10µM of 415; * not determined 
 
The primary outcomes of this preliminary SAR studies can be summarized as follows: (1) 
compounds bearing substituents at the R2 position that are relatively large, lipophilic and 
electron donating appear to be preferred (cf., 35 and 36, 33 and 34); (2) replacement of the 
central thiazole ring with other 5-membered ring heterocycles reduces biological activity in 
the in vitro assay (e.g., see 56 and 57); (3) with respect to the R1 fragment, a pyridine ring 
substitutent in the 3- or 4-position appears to be generally preferred (cf., 415, 52, 53, and 49) 
(Figure 2). Finally, although these studies did not result in the identification of compounds 
with significantly improved potency in the in vitro assay relative to 415, the data presented 
in Table 1 suggest the existence of a rather discontinuous SAR, small changes in structure 
often produce significant changes in biological activity. This observation indicates that the 
interaction of 415 with its target is specific.  
 
Figure 2. Summary of preliminary SAR. 
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6.3.3. Physicochemical evaluation 
The most active compounds 33 and 35 were selected together with 415 for 
physicochemical properties evaluation (pKa, logD7.4, aqueous solubility). The 
results, reported in Table 2, showed a good agreement between experimentally 
obtained pKa, and logD 7.4 and calculated values. 
Cpd 
Calculated 
pKa a 
Measured 
pKa n=6 b 
Calculated 
logD7.4 a 
Measured 
logD7.4 c 
Thermodynamic 
solubility d  
Kinetic  
solubility d 
415 
(6) 
3.94 
6.75 
5.16 ± 0.06 
6.97 ± 0.09 
4.39 4.54 ± 0.01 2.60 µM § 23.86 µM 
33 3.94 5.09 ± 0.08 5.12 ND* ND* ND* 
35 
3.94 
6.48 
4.90 ± 0.07 
5.77 ± 0.04 
4.53 3.76 ± 0.01  3.003 µM 55.03 µM 
Table 2. aCalculated properties using MarvinSketch. bpKa values determined by 
potentiometric titration using Sirius T3 system. c Distribution coefficient between n-octanol 
and aqueous buffer (pH 7.4) determined by potentiometric titration using a Sirius T3 titrator 
according to manufacturer instructions. d Solubility value measured using a Sirius T3 titrator 
according to manufacturer instructions. § intrinsic solubility value calculated from General 
Solubility Equation (GSE) * not determinable. 
As shown in Table 2, the test compounds appear to be rather lipophilic as revealed 
by the logD values between 3-5, as well as sparingly soluble with equilibrium 
solubility values in the low µM range. Although these characteristics suggest that 
further optimization is likely necessary, compounds of this type appear to be 
potentially viable starting points for probe/drug development plans.  
6.4. Conclusions 
In summary, the representative hit has been synthesized using both sequential and 
convergent synthetic procedures. Moreover, a small library of analogues was 
synthesized and a preliminary SAR study was performed proving that: i) the pyridine 
ring at the 5-position of the thiazole ring seems to be required; ii) bulky, lipophilic 
and electron-donating groups at position 4 of the phenyl ring appeared to be 
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preferred; iii) the substitution of thiazole ring with different heterocycle appeared to 
be detrimental. Further characterization of selected physicochemical properties, such 
as pKa, logD7.4 and water solubility, of the most promising compounds identified in 
these studies suggests that compounds of this type may be suitable for in vivo testing. 
6.5. Experimental section 
General Methods. All solvents were reagent grade. All reagents were purchased 
from Aldrich or Acros and used as received. Thin layer chromatography (TLC) was 
performed with 0.25 mm E. Merck precoated silica gel plates. Silica gel column 
chromatography was performed with silica gel 60 (particle size 0.040-0.062 mm) 
supplied by Silicyte and Sorbent Technologies. TLC spots were detected by viewing 
under a UV light, or using KMnO4. Chemical shifts were reported relative to the 
residual solvent’s peak. Infrared spectra were recorded on a Nicolet 380 FTIR 
instrument using the neat thin film technique. High Resolution Mass Spectra 
(HRMS) were acquired on an Agilent 6230 High Resolution time-of-flight mass 
spectrometer and reported as m/z for the molecular ion [M+Na]+, [M+H]+, [M-H]+. 
Proton (1H) and carbon (13C) NMR spectra were recorded on a Bruker AMX-500 
spectrometer. The single crystal X-ray diffraction studies were carried out on a 
Bruker Kappa APEX-II CCD diffractometer equipped with Mo Kα radiation (λ = 
0.71073) at University of California San Diego. 
6.5.1. Chemistry 
N,N-diethyl-4-isothiocyanatoaniline, (54).  
To a stirred solution of commercially available N1 ,N1 -diethylbenzene-1,4-diamine 
(4.00 g, 24.40 mmol, 1.00 equiv) in H2O (24.32 mL), CS2 (5.84 mL, 97.40 mmol, 
4.00 equiv) was added dropwise. The solution was stirred at r.t. for 16 h (formation 
of a yellow precipitate). Then, the reaction was cooled to 0 °C and a solution of 2.25 
g of 2,4,6-trichloro-1,3,5-triazine in 18.42 mL of dichloromethane was added 
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dropwise. After stirring for 50 min, 6 N NaOH was added until pH > 11 and the 
aqueous layer was extracted with dichloromethane (x1). The organic layer was 
washed with H2O (x8), dried over Na2SO4, filtered and concentrated. Purification by 
silica gel column column chromatography (100% hexanes) provided the desired 
compound (4.57 g, 22.20 mmol, 91%) as a yellow oil. 1H NMR (600 MHz, CDCl3) 
δ = 7.08 (d, J = 9.1 Hz, 2H), 6.55 (d, J = 9.1 Hz, 2H), 3.35 (q, J = 7.1 Hz, 4H), 1.16 
(t, J = 7.1 Hz, 6H).13C NMR (151 MHz, CDCl3) δ 146.71, 131.55, 126.89, 117.20, 
111.54, 44.45, 12.46. HRMS (ES+) calculated for C11H15N2S [M + H]
+ 207.0950, 
found 207.0950. 
1-(4-(diethylamino)phenyl)thiourea, (2). 
N,N-diethyl-4-isothiocyanatoaniline (4.00 g, 19.40 mmol, 1.00 equiv) was 
solubilized in a 7 N solution of NH3 in MeOH (4.12 mL) and the mixture was stirred 
for 1 h at r.t. The mixture was concentrated to give a solid, which was filtered and 
washed with Et2O to give the desired compound (2.72 g, 12.19 mmol, 63%) as a 
white solid without further purification. 1H NMR (600 MHz, CDCl3) δ = 6.80 (br s, 
1H), 6.59 (d, J = 8.5 Hz, 2H), 6.17 (d, J = 8.5 Hz, 2H), 2.89 (q, J = 7.1 Hz, 4H), 0.70 
(t, J = 7.1 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 181.97, 147.42, 127.37, 123.34, 
112.06, 44.44, 12.42. HRMS (ES+) calculated for C11H17N3SNa [M+ Na]
+ 246.1035, 
found 246.1035. 
4-(2-bromoacetyl)pyridin-1-ium bromide, (4). 
To a stirred solution of 1-(pyridin-4-yl)ethan-1-one (2.00 g, 16.50 mmol, 1.00 equiv) 
in HBr (48 wt %, 8.12 mL) at 15 °C under N2, Br2 (0.851 mL, 16.50 mmol, 1.00 
equiv) was added dropwise. The solution was stirred at 40 °C for 1 h, then at 75 °C 
for 1 h. After cooling to r.t, Et2O (80.00 mL) was added, and the reaction was stirred 
at 20 °C for 30 min, during which a white precipitate was formed. Filtration afforded 
the title compound (4.62 g, 16.5 mmol, 100%) a pale rose solid, which was used in 
the next step without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 8.95 
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(d, J = 6.7 Hz, 2H), 8.14 (d, J = 6.7 Hz, 2H), 5.04 (s, 2H). 13C NMR (151 MHz, 
DMSO-d6) δ = 187.30 162.57, 141.71, 125.08, 93.50 
4-(pyridin-4-yl)thiazol-2-amine, (5).  
Thiourea (0.56 g, 7.87 mmol, 1.00 equiv), 4-(2-bromoacetyl)pyridin-1-ium bromide 
(2.21 g, 7.87 mmol, 1.00 equiv) and EtOH (10.80 mL) were added to a microwave 
vial. The vial was sealed, warmed to 100 °C and stirred under microwave irradiation 
(Biotage Initiator) for 30 min. After cooling to r.t., the solid was filtered, washed 
with EtOH and with saturated satd. aq. NaHCO3 and concentrated in vacuo to give 
the desired compound (1.12 g, 6.32 mmol, 80%) as a pale rose solid without further 
purification. 1H NMR (600 MHz, DMSO-d6) δ = 8.54 (d, J = 5.9 Hz, 2H), 7.72 (d, J 
= 5.9 Hz, 2H), 7.40 (s, 1H), 7.22 (s, 2H). 
N1,N1-diethyl-N4-(4-(pyridin-4-yl)thiazol-2-yl)benzene-1,4-diamine, (6). 
Method A: 1-(4-(diethylamino)phenyl)thiourea (0.50 g, 2.24 mmol, 1.00 equiv), 4-
(2-bromoacetyl)pyridin-1-ium bromide (0.63 g, 2.24 mmol, 1.00 equiv) and EtOH 
(2.50 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., EtOAc was added and the organic extract was washed with satd. aq. NaHCO3 
(x1), with brine (x1), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by silica gel column chromatography (30% EtOAc in dichloromethane) 
provided the desired compound as a pale grey solid (0.43 g, 1.33 mmol, 59%). 
Method B: An oven-dried test tube was charged with Pd(OAc)2 (0.8 mg, 1.5 mol%) 
and tBuBrettPhos (3.6 mg, 3.3 mol %). The vessel was evacuated and backfilled with 
argon (this sequence was carried out a total of three times). To this vessel was added 
tBuOH (904 µL) and degassed H2O (0.3 µL, 6 mol %) via syringe, and the solution 
was placed in an oil bath at 110 °C for 1.5 min. A second oven-dried test tube 
equipped with a magnetic stir bar was charged with compound 5 (40 mg, 0.23 mmol, 
1 eq), K2CO3 (4.4 mg, 0.32 mmol, 1.4 mmol), and 4-bromo-N,N-diethylaniline (51 
mg, 0.23 mmol, 1 eq). The tube was then sealed, evacuated, and backfilled with 
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argon (this sequence was carried out a total of three times). The hot catalyst solution 
was then cannulated into the second tube containing the substrates and the second 
tube was then placed into an oil bath at 110 °C for 3 h. The reaction mixture was 
then cooled to r.t., diluted with ethyl acetate, and washed once each with water and 
brine, dried over Mg2SO4, filtered, and concentrated in vacuo. Purification by silica 
gel column chromatography (30% EtOAc in dichloromethane) provided the desired 
compound as a pale grey solid (43 mg, 0.13 mmol, 58%). X-ray quality crystals were 
obtained by slow evaporation from a CH2Cl2/DMSO solution. M.p. 179-180 °C. 
1H 
NMR (600 MHz, DMSO-d6) δ = 9.92 (br s, 1H), 8.59 (d, J = 6.1 Hz, 2H), 7.82 (d, J 
= 6.1 Hz, 2H), 7.57 (s, 1H), 7.46 (d, J = 9.0 Hz, 2H), 6.70 (d, J = 9.0 Hz, 2H), 3.30 
(q, J = 7.0 Hz, 4H), 1.07 (t, J = 7.0 Hz, 6H). 13C NMR (151 MHz, DMSO-d6) δ = 
165.03, 150.15, 147.77, 143.49, 141.28, 130.32, 119.95, 119.93, 112.68, 106.13, 
43.91, 12.46. HRMS (ES+) calculated for C18H21N4S [M + H]
+ 325.1481, found 
325.1482. IR ṽ = 3178.1, 3094.2, 2967.0, 1598.7, 1574.6, 1514.8 cm-1. 
Methyl 4-thioureidobenzoate, (15). 
To a stirred solution of methyl 4-aminobenzoate (4.00 g, 26.46 mol, 1.00 equiv) in 1 
M HCl (28.00 mL) at 100 °C, ammonium thiocyanate (2.01 g, 26.46 mmol, 1.00 
equiv) was added, and the solution was stirred at 100 °C for 16 h. After cooling to 
r.t, the reaction was diluited with H2O (32.00 mL), and the resulting solution was 
stirred at 5 °C for 2 h, during which a yellow precipitate was formed. The yellow 
solid was filtered and dried. Purification by silica gel column chromatography (40-
90% EtOAc in hexanes) afforded the title compound (2.03 g, 9.68 mmol, 45%) as a 
white solid. 1H NMR (600 MHz, DMSO-d6) δ = 10.01 (br s, 1H), 7.89 (d, J = 8.7 
Hz, 2H), 7.67 (d, J = 8.7 Hz, 2H), 3.82 (s, 3H). 13C NMR (151 MHz, DMSO-d6) δ = 
181.15, 165.85, 143.98, 129.89, 124.28, 121.13, 51.94. HRMS (ES+) calculated for 
C9H11N2O2S [M + H]
+ 211.0536, found 211.0537. 
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1-(4-nitrophenyl)thiourea, (16).  
To a stirred solution of 4-nitroaniline (1.00 g, 7.20 mmol, 1.00 equiv) in 1 M HCl at 
100 °C, ammonium thiocyanate (0.55 g, 7.20 mmol, 1.00 equiv) was added, and the 
solution was stirred at 100 °C for 16 h. After cooling to r.t, the reaction was diluited 
with H2O (8.60 mL), and the resulting solution was stirred at 5 °C for 2 h, during 
which a yellow precipitate was formed. The yellow solid was filtered and dried. 
Purification by silica gel column chromatography (50-90% EtOAc in hexanes) 
afforded the title compound (0.63 g, 3.20 mmol, 55%) as a yellow solid. 1H NMR 
(600 MHz, DMSO-d6) δ = 10.27 (br s, 1H), 8.18 (d, J = 9.2 Hz, 2H), 7.85 (d, J = 9.2 
Hz, 2H); 13C NMR (151 MHz, DMSO-d6) δ = 181.41, 146.18, 142.29, 124.59, 
120.97. HRMS (ES-) calculated for C7H6N3O2S [M - H]
- 196.0186, found 196.0186. 
1-(4-bromophenyl)thiourea, (17).  
To a stirred solution of 4-bromoaniline (2.00 g, 11.60 mmol, 1.00 equiv) in 1 M HCl 
(14.40 mL) at 100 °C, ammonium thiocyanate (0.89 g, 11.60 mmol, 1.00 equiv) was 
added, and the resulting solution was stirred at 100 °C for 16 h. After cooling to r.t, 
the reaction was diluited with H2O (13.90 mL), and the resulting solution was stirred 
at 5 °C for 2h, during which a white precipitate was formed. The white solid was 
filtered and dried. Purification by gel column chromatography (50-90% EtOAc in 
hexanes) afforded the title compound (0.77 g, 3.33 mmol, 37%) as a white solid. 1H 
NMR (600 MHz, DMSO-d6) δ = 9.75 (br s, 1H), 7.49 (d, J = 8.6 Hz, 2H), 7.40 (d, J 
= 8.6 Hz, 2H); 13C NMR (151 MHz, DMSO-d6) δ = 181.22, 138.79, 131.54, 125.01, 
116.36; HRMS (ES+) calculated for C7H8BrN2S [M + H]
+ 230.9586, found 
230.9588. 
1-(4-hydroxyphenyl)thiourea, (18).   
To a stirred solution of 4-aminophenol (1.50 g, 13.70 mmol, 1.00 equiv) in 1 M HCl 
(10.8 mL) at 100 °C, ammonium thiocyanate (1.05 g, 13.70 mmol, 1.00 equiv) was 
added, and the resulting solution was stirred at 100 °C for 16 h. After cooling to r.t, 
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the reaction was diluited with H2O (12.90 mL), and the resulting solution was stirred 
at 5 °C for 2h, during which dark brown precipitate was formed. Filtration afforded 
the title compound (0.79 g, 4.70 mmol, 43%) as a dark brown solid, which was used 
in the next step without further purification.1H NMR (600 MHz, DMSO-d6) δ = 9.40 
(br s, 1H), 9.37 (br s, 1H), 7.05 (d, J = 8.5 Hz, 2H), 6.71 (d, J = 8.5 Hz, 2H). 13C 
NMR (151 MHz, DMSO-d6) δ =180.27, 155.16, 130.79, 126.11, 115.51. HRMS 
(ES+) calculated for C7H9N2OS [M + H]
+ 169.0430, found 169.0429. 
1-(4-(tert-butyl)phenyl)thiourea, (19). 
To a stirred solution of 4-(tert-butyl)aniline (1.50 g, 10.10 mmol, 1.00 equiv), in 1 
M HCl (10.80 mL) at 100 °C, ammonium thiocyanate (0.77 g, 10.10 mmol, 1.00 
equiv) was added, and the resulting solution was stirred at 100 °C for 16 h. After 
cooling to r.t, the reaction was diluited with H2O (12.90 mL), and the resulting 
solution was stirred at 5 °C for 2h, during which a white precipitate was formed. The 
white solid was filtered and dried. Purification by silica gel column chromatography 
(50% EtOAc in hexanes) afforded the title compound 19 (0.80 g, 3.82 mmol, 51%) 
as white solid.1H NMR (600 MHz, DMSO-d6) δ = 9.61 (br s, 1H), 7.34 (d, J = 8.6 
Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 1.27 (s, 9H); 13C NMR (151 MHz, DMSO-d6) δ = 
180.85, 146.80, 136.44, 125.46, 122.88, 34.15, 31.21. HRMS (ES+) calculated for 
C11H17N2S [M + H]
+ 209.1107, found 209.1105. 
1-(4-(piperidin-1-yl)phenyl)thiourea, (20). 
To a stirred solution of 4-(piperidin-1-yl)aniline (0.26 g, 1.49 mmol, 1.00 equiv), in 
1 M HCl (1.88 mL) at 100 °C, ammonium thiocyanate (0.11 g, 1.49 mmol, 1.00 
equiv) was added, and the resulting solution was stirred at 100 °C for 16 h. After 
cooling to r.t, the reaction was diluited with H2O (12.90 mL), and the resulting 
solution was stirred at 5 °C for 2h. Basification of the reaction mixture with satd. aq. 
NaHCO3 (until pH 6) caused precipitation of the title compound, which was filtered 
and dried. Purification by silica gel column chromatography (66% EtOAc in 
hexanes) afforded the title compound 20 as a white solid. 1H NMR (600 MHz, 
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DMSO-d6) δ = 9.40 (br s, 1H), 7.10 (d, J = 7.7 Hz, 2H), 6.88 (d, J = 7.7 Hz, 2H), 
3.09 (t, J = 6 Hz, 4H), 1.63 – 1.57 (m, 4H), 1.54 – 1.48 (m, 2H). 13C NMR (151 MHz, 
DMSO-d6) δ = 180.76, 149.19 (2C), 124.96, 116.03, 49.77, 25.29, 23.90. HRMS 
(ES+) calculated for C12H18N3S [M + H]
+ 236.1216, found 236.1215. 
1-(4-morpholinophenyl)thiourea, (21).  
To a stirred solution of 4-morpholinoaniline (0.50 g, 2.81 mmol, 1.00 equiv) in 1 M 
HCl (3.60 mL) at 100 °C, ammonium thiocyanate (0.21 g, 2.81 mmol, 1.00 equiv) 
was added, and the resulting solution was stirred at 100 °C for 16 h. After cooling to 
r.t, the reaction was diluited with H2O (3.40 mL), and the resulting solution was 
stirred at 5 °C for 2h. The mixture was basified with satd. aq. NaHCO3 (until pH 6), 
extracted with EtOAc (x1), dried over sodium sulfate and evaporated to give a violet 
solid (0.26 g, 1.08 mmol, 45%), which was in the next step without further 
purification. 1H NMR (600 MHz, DMSO-d6) δ =9.44 (br s, 1H), 7.21 – 7.10 (m, 2H), 
6.90 (d, J = 7.5 Hz, 2H), 3.78 – 3.67 (m, 4H), 3.14 – 3.02 (m, 4H). 13C NMR (151 
MHz, DMSO-d6) δ = 180.83, 163.53, 148.49, 124.93, 115.32, 66.13, 48.64. HRMS 
(ES-) calculated for C11H14N3OS [M - H]
- 236.0863, found 236.0862. 
1-(4-methoxyphenyl)thiourea, (22).  
To a stirred solution of 4-methoxyaniline (1.00 g, 8.12 mmol, 1.00 equiv) in 1 M 
HCl (7.20 mL) at 100 °C, ammonium thiocyanate (0.62 g, 8.12 mmol, 1.00 equiv) 
was added, and the resulting solution was stirred at 100 °C for 16 h. After cooling to 
r.t, the reaction was diluited with H2O (8.60 mL), and the resulting solution was 
stirred at 5 °C for 2h, during which a purple precipitate was formed. Filtration 
afforded the title compound (0.53 g, 2.92 mmol, 47%) as a purple solid, which was 
used in the next step without further purification. 1H NMR (600 MHz, DMSO-d6) δ 
= 9.48 (br s, 1H), 7.21 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 3.73 (s, 3H); 13C 
NMR (151 MHz, DMSO-d6) δ = 181.47, 156.99, 132.09, 125.99, 114.40, 55.67. 
HRMS (ES+) calculated for C8H11N2OS [M + H]
+ 183.0587, found 183.0587. 
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Methyl 4-((4-(pyridin-4-yl)thiazol-2-yl)amino)benzoate, (26). 
4-thioureidobenzoate (0.074 g, 0.36 mmol, 1.00 equiv), 4-(2-bromoacetyl)pyridin-
1-ium bromide (0.100 g, 0.36 mmol, 1.00 equiv) and EtOH (0.49 mL) were added to 
a microwave vial. The vial was sealed, warmed to 100 °C and stirred under 
microwave irradiation (Biotage Initiator) for 30 min. After cooling to r.t., the solid 
was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 and 
concentrated in vacuo to give the desired compound 26 (0.074 g, 0.24 mmol, 67%) 
as a yellow solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 
10.97 (br s, 1H), 8.78 (d, J = 5.6 Hz, 2H), 8.22 (d, J = 5.6 Hz, 2H), 8.15 (s, 1H), 7.97 
(d, J = 8.5 Hz, 2H), 7.88 (d, J = 8.5 Hz, 2H), 3.82 (s, 3H). 13C NMR (151 MHz, 
DMSO-d6) δ = 166.20, 163.23, 146.88, 146.43, 145.13, 131.05, 122.35, 121.58, 
116.70, 113.30, 52.15. HRMS (ES+) calculated for C16H14N3O2S [M + H]
+ 312.0807, 
found 312.0802. IR ṽ = 2957.3, 2917.8, 2848.4, 1712.5, 1284.4 cm−1. 
N-(4-nitrophenyl)-4-(pyridin-4-yl)thiazol-2-amine, (27).  
1-(4-nitrophenyl)thiourea (0.100 g, 0.36 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (0.070 g, 0.36 mmol, 1.00 equiv), and EtOH 
(0.49 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.088 g , 0.29 mmol, 83%) 
as a yellow solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 
8.63 (d, J = 5.3 Hz, 2H), 8.23 (d, J = 8.7 Hz, 2H), 7.91 (d, J = 5.3 Hz, 2H), 7.90 – 
7.87 (m, 3H). 13C NMR (151 MHz, DMSO-d6) δ = 162.11, 149.07, 147.42, 146.52, 
141.60, 140.27, 125.46, 120.27, 116.32, 110.81. HRMS (ES+) calculated for 
C14H11N4O2S [M + H]
+ 299.0597, found 299.0600. IR ṽ = 1539.9, 1327.8 cm−1. 
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N-(4-bromophenyl)-4-(pyridin-4-yl)thiazol-2-amine, (28). 
1-(4-bromophenyl)thiourea (0.49 g, 2.14 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (0.60 g, 2.14 mmol, 1.00 equiv), and EtOH 
(2.93 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.66 g , 1.99 mmol, 93%) 
as an orange solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ= 
10.73 (br s, 1H), 8.85 (d, J = 5.7 Hz, 2H), 8.34 (d, J = 5.7 Hz, 2H), 8.24 (s, 1H), 7.74 
(d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ = 
163.76, 147.20, 146.19, 144.34, 140.26, 132.10, 122.08, 119.39, 114.62, 113.25. 
HRMS (ES+) calculated for C14H11BrN3S [M + H]
+ 331.9852, found 331.9851. IR ṽ 
= 2597.3, 2171.8, 1549.5 cm−1 
4-((4-(pyridin-4-yl)thiazol-2-yl)amino)phenol, (29).  
Methyl 1-(4-hydroxyphenyl)thiourea (0.10 g, 0.59 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (0.17 g, 0.59 mmol, 1.00 equiv) and EtOH (0.81 
mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C and 
stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling to 
r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.14 g, 0.52 mmol, 88%) 
as a brown solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 
10.03 (br s, 1H), 9.21 (br s, 1H), 8.59 (d, J = 5.2 Hz, 2H), 7.82 (d, J = 5.2 Hz, 2H), 
7.60 (s, 1H), 7.48 (d, J = 8.6 Hz, 2H), 6.76 (d, J = 8.6 Hz, 2H). 13C NMR (151 MHz, 
DMSO-d6) δ = 164.92, 152.87, 150.45, 148.00, 141.51, 133.34, 120.24, 119.71, 
115.86, 106.80. HRMS (ES+) calculated for C14H12N3OS [M + H]
+ 270.0696, found 
270.0697. IR ṽ = 3444.2, 1579.4, 1514.8, 1411.6, 1235.2 cm−1. 
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4-((4-(pyridin-4-yl)thiazol-2-yl)amino)benzoic acid, (30). 
To a suspension of compound 26 (0.050 g, 0.16 mmol, 1.00 equiv) in MeOH (0.80 
mL), 2 M aq. NaOH (0.40 mL) was added. The reaction was stirred at reflux for 1 h. 
After cooling to r.t., the reaction mixture was concentrated in vacuo. 1 M aq. HCl 
was added until pH = 4 and resulting the precipitate was filtered and washed with 
H2O and concentrated in vacuo to give the desired compound (0.048 g, 0.16 mmol, 
98%) as a yellow solid without further purification. 1H NMR (600 MHz, DMSO-d6) 
δ = 11.32 (br s, 1H), 8.90 (d, J = 6.3 Hz, 2H), 8.50 (d, J = 6.3 Hz, 2H), 8.43 (s, 1H), 
7.95 (d, J = 8.7 Hz, 2H), 7.90 (d, J = 8.7 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) 
δ = 167.43, 163.72, 148.89, 145.86, 144.86, 142.54, 131.24, 123.82, 122.84, 116.94, 
116.85. HRMS (ES+) calculated for C15H12N3O2S [M + H]
+ 298.0645, found 
298.0645. IR ṽ =3370.0, 3074.9, 2927.4, 1603.5, 1544.7 cm−1. 
N1-(4-(pyridin-4-yl)thiazol-2-yl)benzene-1,4-diamine, (31). 
To a stirred solution of compound 27 (0.23 g, 0.75 mmol, 1.00 equiv) in degassed 
MeOH (0.80 mL) under N2, Pd/C (10 wt % (wet), 0.040 g, 0.05 equiv) and hydrazine 
monohydrate (0.37 mL, 7.54 mmol, 10.00 equiv) were added. The resulting mixture 
was stirred at 60 °C for 16 hours. After cooling to r.t., the reaction mixture was 
filtered through a pad of Celite, washed with MeOH. Evaporation of the solvent in 
vacuo provided the title compound 31 (0.13 g, 0.48 mmol, 65%) as a beige solid 
without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 9.80 (br s, 1H), 8.58 
(d, J = 5.3 Hz, 2H), 7.80 (d, J = 5.3 Hz, 2H), 7.54 (s, 1H), 7.28 (d, J = 8.2 Hz, 2H), 
6.58 (d, J = 8.2 Hz, 2H), 4.89 (br s, 2H). 13C NMR (151 MHz, DMSO-d6) δ = 165.62, 
150.13, 147.76, 144.44, 141.30, 130.54, 120.31, 119.91, 114.39, 105.97. HRMS 
(ES+) calculated for C14H13N4S [M + H]
+ 269.0855, found 269.0855. IR ṽ = 2927.4, 
1736.6, 1598.7, 1514.8 cm−1. 
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N-(4-azidophenyl)-4-(pyridin-4-yl)thiazol-2-amine, (32). 
Compound 28 (0.100 g, 0.30 mmol, 1.00 equiv), sodium ascorbate (2.98 mg, 0.015 
mmol, 0.05 equiv), copper iodide (5.73 mg, 0.030 mmol, 0.10 equiv), N1,N2-
dimethylethane-1,2-diamine (5.00 µL, 0.045 mmol, 0.15 equiv) and EtOH/H2O (7:3, 
0.60 mL) were added in order in a round-bottom flask. The mixture was degassed 
and then introduced under a N2 atmosphere. The reaction was stirred at reflux for 40 
min. Then, EtOAc was added and the organic layer was washed with H2O (x2), brine 
(x1), dried over MgSO4, filtered and evaporated in vacuo to give the desired 
compound (49.00 mg, 0.17 mmol, 55%) as a beige solid without further purification. 
1H NMR (600 MHz, DMSO-d6) δ = 10.54 (br s, 1H), 8.67 – 8.60 (m, 2H), 7.87 (d, J 
= 5.3 Hz, 2H), 7.78 (s, 1H), 7.73 (d, J = 8.9 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H). 13C 
NMR (151 MHz, DMSO-d6) δ = 163.5, 150.7, 148.2, 141.3, 140.7, 132.2 (2C), 
119.3, 113.0, 108.5. HRMS (ES+) calculated for C14H11N6S [M + H]
+ 295.2760, 
found 295.0766. IR ṽ =2922.6, 2853.2, 1706.7, 1603.5 cm−1. 
N-(4-(tert-butyl)phenyl)-4-(pyridin-4-yl)thiazol-2-amine, (33).  
1-(4-(tert-butyl)phenyl)thiourea (0.11 g, 0.53 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (0.15 g, 0.53 mmol, 1.00 equiv) and EtOH (0.80 
mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C and 
stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling to 
r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.85 g, 0.27 mmol, 51%) 
as a beige solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 
10.31 (br s, 1H), 8.61 (d, J = 5.6 Hz, 2H), 7.86 (d, J = 5.6 Hz, 2H), 7.69 (s, 1H), 7.64 
(d, J = 8.5 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 1.28 (s, 9H). 13C NMR (151 MHz, 
DMSO-d6) δ = 163.64, 150.20, 147.70, 143.82, 141.11, 138.53, 125.71, 119.96, 
116.83, 107.24, 33.99, 31.32. HRMS (ES+) calculated for C18H20N3S [M + H]
+ 
310.1372, found 310.1373. IR ṽ = 3035.4, 2962.1, 1063.5, 1514.8 cm−1. 
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4-(pyridin-4-yl)-N-(p-tolyl)thiazol-2-amine, (34). 
Commercially available 1-(p-tolyl)thiourea (0.059 g, 0.36 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (0.100 g, 0.36 mmol, 1.00 equiv) and EtOH 
(0.50 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.077 g, 0.29 mmol, 81%) 
as an orange solid without further purification. 1H NMR (600 MHz, DMSO- d6) δ = 
10.30 (br s, 1H), 8.64 (d, J = 5.7 Hz, 2H), 7.91 (d, J = 5.7 Hz, 2H), 7.75 (s, 1H), 7.60 
(d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H), 2.27 (s, 3H). 13C NMR (151 MHz, 
DMSO- d6) δ = 164.19, 149.73, 147.86, 142.37, 138.97, 130.86, 129.90, 120.61, 
117.60, 108.54, 20.85. HRMS (ES+) calculated for C15H14N3S [M + H]
+ 268.0903, 
found 268.0905.IR ṽ = 3198.4, 2971.8, 1731.8, 1598.7, 1549.5, 1416.5 cm−1. 
N-(4-(piperidin-1-yl)phenyl)-4-(pyridin-4-yl)thiazol-2-amine, (35). 
1-(4-(piperidin-1-yl)phenyl)thiourea (20.00 mg, 0.085 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (24.00 mg, 0.085 mmol, 1.00 equiv) and EtOH 
(0.20 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (12.00 mg, 0.036 mmol, 
42%) as a pink solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ 
= 10.09 (br s, 1H), 8.60 (d, J = 4.5 Hz, 2H), 7.83 (d, J = 4.5 Hz, 2H), 7.62 (s, 1H), 
7.53 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.5 Hz, 2H), 3.05 (t, J = 5.6 Hz, 4H), 1.62 (p, J 
= 5.6 Hz, 4H), 1.51 (p, J = 5.6 Hz, 2H). 13C NMR (151 MHz, DMSO- d6) δ = 164.30, 
150.16, 147.71, 147.19, 141.20, 133.20, 119.94, 118.63, 116.96, 106.60, 50.42, 
25.45, 23.91. HRMS (ES+) calculated for C19H21N4S [M + H]
+ 337.1481, found 
337.1482. IR ṽ = 2932.2, 1731.8, 1598.7, 1510.0, 1229.4 cm−1. 
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N-(4-morpholinophenyl)-4-(pyridin-4-yl)thiazol-2-amine, (36).  
1-(4-morpholinophenyl)thiourea (84.50 mg, 0.36 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (100.00 mg, 0.36 mmol, 1.00 equiv) and EtOH 
(0.50 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (36.00 mg, 0.11 mmol, 
30%) as a pink solid without further purification. 1H NMR (600 MHz, DMSO-d6) δ 
= 10.13 (br s, 1H), 8.60 (d, J = 5.3 Hz, 2H), 7.83 (d, J = 5.3 Hz, 2H), 7.70-7.47 (m, 
3H), 6.97 (d, J = 8.2 Hz, 2H), 3.91 – 3.56 (m, 4H), 3.18 – 2.88 (m, 4H). 13C NMR 
(151 MHz, DMSO-d6) δ = 164.59, 150.57, 148.11, 146.72, 141.59, 134.13, 120.34, 
118.96, 116.53, 107.12, 66.60, 49.60. HRMS (ES+) calculated for C18H19N4OS [M 
+ H]+ 339.1274, found 339.1275. IR ṽ = 2967.0, 1736.6, 1598.7, 1510.0, 1235.2 
cm−1. 
N-(4-fluorophenyl)-4-(pyridin-4-yl)thiazol-2-amine, (37).  
Commercially available 1-(4-fluorophenyl)thiourea (0.10 g, 0.59 mmol, 1.00 equiv), 
4-(2-bromoacetyl)pyridin-1-ium bromide (0.17 g, 0.59 mmol, 1.00 equiv) and EtOH 
(0.81 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.14 g, 0.52 mmol, 88%) 
as a brown solid without further purification.1H NMR (600 MHz, DMSO-d6) δ = 
10.61 (br s, 1H), 8.85 (d, J = 5.9 Hz, 2H), 8.33 (d, J = 5.9 Hz, 2H), 8.21 (s, 1H), 7.78 
(dd, J = 8.8, 4.7 Hz, 2H), 7.26 – 7.15 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ = 
164.16, 157.42 (d, J = 238.2 Hz), 147.51, 146.03, 144.13, 137.50, 122.12 (d, J = 22.1 
Hz), 119.02, 115.94 (d, J = 5.3 Hz). HRMS (ES+) calculated for C14H11FN3S [M + 
H]+ 272.0652, found 272.0654. IR ṽ = 3000.7, 2967.0, 1736.6, 1549.5, 1505.2, 
1214.9 cm−1.  
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4-(pyridin-4-yl)-N-(4-(trifluoromethyl)phenyl)thiazol-2-amine, (38). 
Commercially available 1-(4-(trifluoromethyl)phenyl)thiourea (78.40 mg, 0.36 
mmol, 1,00 equiv), 4-(2-bromoacetyl)pyridin-1-ium bromide (100.00 mg, 0.36 
mmol, 1.00 equiv) and EtOH (3.00 mL) were added to a microwave vial. The vial 
was sealed, warmed to 100 °C and stirred under microwave irradiation (Biotage 
Initiator) for 30 min. After cooling to r.t., the solid was filtered, washed with EtOH 
and with saturated satd. aq. NaHCO3 and concentrated in vacuo to give the desired 
compound (65.00 mg, 0.20 mmol, 57%) as a yellow solid without further 
purification. 1H NMR (600 MHz, DMSO-d6) δ = 10.84 (br s, 1H), 8.64 (d, J = 8.6 
Hz, 2H), 8.07 – 7.80 (m, 5H), 7.72 (d, J = 8.6 Hz, 2H). 13C NMR (151 MHz, DMSO-
d6) δ = 163.07, 150.49, 148.05, 144.48, 141.18, 126.71, 125.54 (d, J = 265.5 Hz), 
121.04 (d, J = 32.2 Hz), 120.32, 116.97, 109.15. HRMS (ES+) calculated for 
C15H11F3N3S [M + H]
+ 322.0620, found 322.0622. IR ṽ = 2932.2, 1736.6, 1603.5, 
1535.1 cm−1. 
N-(4-methoxyphenyl)-4-(pyridin-4-yl)thiazol-2-amine, (39).  
1-(4-methoxyphenyl)thiourea (0.060 g, 0.36 mmol, 1.00 equiv), 4-(2-
bromoacetyl)pyridin-1-ium bromide (0.100 g, 0.36 mmol, 1.00 equiv) and EtOH 
(0.49 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., the solid was filtered, washed with EtOH and with saturated satd. aq. NaHCO3 
and concentrated in vacuo to give the desired compound (0.050 g, 0.19 mmol, 54%) 
as a brown solid without further purification.1H NMR (600 MHz, DMSO-d6) δ = 
10.29 (br s, 1H), 8.74 (d, J = 6.0 Hz, 2H), 8.13 (d, J = 6.0 Hz, 2H), 7.95 (s, 1H), 7.65 
(d, J = 8.5 Hz, 2H), 6.96 (d, J = 8.5 Hz, 2H), 3.74 (s, 3H). 13C NMR (151 MHz, 
DMSO-d6) δ = 164.56, 154.65, 146.87, 146.72, 145.03, 134.58, 121.29, 119.20, 
114.59, 111.03, 55.52. HRMS (ES+) calculated for C15H14N3OS [M + H]
+ 284.0852, 
found 284.0853. IR ṽ = 3266.8, 2946.7, 1593.9, 1229.4 cm−1. 
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2-bromo-1-(4-chlorophenyl)ethanone, (40).  
To a stirred solution of 1-(4-chlorophenyl)ethan-1-one ( 0.754 g, 4.88 mmol, 1.00 
equiv) in EtOAc (70.00 mL), CuBr2 was added ( 1.31 g, 5.85 mmol, 1.20 equiv). The 
solution was stirred at reflux for 18 h. After cooling to r.t, the mixture was filtered. 
The filtrate was washed with satd. aq. Na2S2O3, dried over Na2SO4, filtrate and 
concentrated in vacuo. Purification by silica gel column chromatography (100% 
hexanes) afford the desired compound (0.323 g, 1.38 mmol, 28%) as a white solid. 
1H NMR (600 MHz, CDCl3) δ = 7.94 (d, J = 8.6 Hz, 2H), 7.48 (d, J = 8.6 Hz, 2H), 
4.41 (s, 2H). 1H NMR (600 MHz, CDCl3) δ = 7.94 (d, J = 8.6 Hz, 2H), 7.48 (d, J = 
8.6 Hz, 2H), 4.41 (s, 2H). 
N1-(4-(4-chlorophenyl)thiazol-2-yl)- N4, N4-diethylbenzene-1,4-diamine, (47). 
1-(4-(diethylamino)phenyl)thiourea (0.106 g, 0.48 mmol, 1.00 equiv), 2-bromo-1-
(4-chlorophenyl)ethan-1-one (0.111 g, 0.48 mmol, 1.00 equiv) and EtOH (0.50 mL) 
were added to a microwave vial. The vial was sealed, warmed to 100 °C and stirred 
under microwave irradiation (Biotage Initiator) for 30 min. After cooling to r.t., 
EtOAc was added and the organic extract was washed with satd. aq. NaHCO3 (x1), 
with brine (x1), dried over Na2SO4, filtered and concentrated in vacuo to afford the 
desired compound (0.113 mg, 0.32 mmol, 66%) as a white solid.1H NMR (600 MHz, 
DMSO-d6) δ = 9.84 (br s, 1H), 7.90 (d, J = 8.7 Hz, 2H), 7.49 – 7.42 (m, 4H), 7.26 
(s, 1H), 6.69 (d, J = 8.7 Hz, 2H), 3.29 (q, J = 7.0 Hz, 4H), 1.07 (t, J = 7.0 Hz, 6H). 
13C NMR (151 MHz, DMSO-d6) δ = 164.78, 148.87, 143.39, 133.63, 131.81, 130.52, 
128.63, 127.35, 119.82, 112.74, 102.37, 43.95, 9.52, 12.49. HRMS (ES+) calculated 
for C19H21ClN3S [M + H]
+ 358.1139, found 358.1137. IR ṽ = 3187.8, 2971.8, 
1741.4, 1613.2, 1559.2, 1514.8 cm−1. 
N1,N1-diethyl- N4-(4-(4-fluorophenyl)thiazol-2-yl)benzene-1,4-diamine, (48). 
1-(4-(diethylamino)phenyl)thiourea (0.103 g, 0.46 mmol, 1.00 equiv), commercially 
available 2-bromo-1-(4-fluorophenyl)ethan-1-one (0.100 mg, 0.46 mmol, 1.00 
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equiv) and EtOH (0.50 mL) were added to a microwave vial. The vial was sealed, 
warmed to 100 °C and stirred under microwave irradiation (Biotage Initiator) for 30 
min. After cooling to r.t., EtOAc was added and the organic extract was washed with 
satd. aq. NaHCO3 (x1), with brine (x1), dried over Na2SO4, filtered and concentrated 
to afford the desired compound (0.060 mg, 0.17 mmol, 38%) as a grey solid without 
further purification. 1H NMR (600 MHz, CD3OD) δ = 7.87 (dd, JS = 5.8, 2.2 Hz, 
2H), 7.42 (d, J = 8.8 Hz, 2H), 7.13 – 7.09 (m, 2H), 6.87 (s, 1H), 6.80 (d, J = 8.7 Hz, 
2H), 3.34 (q, J = 7.5 Hz, 4H), 1.14 (t, J = 7.1 Hz, 6H). 13C NMR (151 MHz, DMSO-
d6) δ = 163.54 (d, J = 353.4 Hz), 160.76, 149.05, 143.33, 131.40, 130.59, 127.60 (d, 
J = 8.1 Hz), 119.76, 115.43 (d, J = 21.4 Hz), 112.73, 101.24, 43.94, 12.47. HRMS 
(ES+) calculated for C19H21FN3S [M + H]
+ 342.1435, found 342.1433. IR ṽ = 3198.4, 
2976.6, 1741.4, 1608.3, 1520.6, 1210.1 cm−1. 
N1,N1-diethyl- N4-(4-phenylthiazol-2-yl)benzene-1,4-diamine, (49). 
1-(4-(diethylamino)phenyl)thiourea (0.141 g, 0.63 mmol, 1.00 equiv), commercially 
available 2-bromo-1-phenylethan-1-one (0.126 g, 0.63 mmol, 1.00 equiv) and EtOH 
(0.6 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., EtOAc was added and the organic extract was washed with satd. aq. NaHCO3 
(x1), with brine (x1), dried over Na2SO4, filtered and concentrated in vacuo to afford 
the desired compound (0.077 mg, 0.24 mmol, 38%) as a white solid. 1H NMR (600 
MHz, DMSO-d6) δ = 9.82 (br s, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.47 (d, J = 8.3 Hz, 
2H), 7.41 (t, J = 7.3 Hz, 2H), 7.29 (t, J = 7.3 Hz, 1H), 7.18 (s, 1H), 6.69 (d, J = 7.3 
Hz, 2H), 3.28 (q, J = 6.8 Hz, 4H), 1.06 (d, J = 7.3 Hz, 6H). 13C NMR (151 MHz, 
DMSO-d6) δ = 165.00, 150.50, 143.71, 135.17, 131.05, 129.00, 127.85, 126.04, 
120.13, 113.16, 101.90, 44.34, 12.87. HRMS (ES+) calculated for C19H22N3S [M + 
H]+ 324.1529, found 324.1528. IR ṽ = 3173.3, 2971.8, 2932.2, 1741.4, 1510.0, 
1264.1 cm−1.   
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4-(2-((4-(diethylamino)phenyl)amino)thiazol-4-yl)benzonitrile, (50).  
1-(4-(diethylamino)phenyl)thiourea (0.100 g, 0.45 mmol, 1.00 equiv), commercially 
available 4-(2-bromoacetyl)benzonitrile (0.100 g, 0.45 mmol, 1.00 equiv) and EtOH 
(0.50 mL) were added to a microwave vial. The vial was sealed, warmed to 100 °C 
and stirred under microwave irradiation (Biotage Initiator) for 30 min. After cooling 
to r.t., EtOAc was added and the organic extract was washed with satd. aq. NaHCO3 
(x1), with brine (x1), dried over Na2SO4, filtered and concentrated to afford the 
desired compound (0.154 mg, 0.44 mmol, 98%) as a pale orange solid. 1H NMR (600 
MHz, DMSO-d6) δ = 8.13 (d, J = 8.1 Hz, 2H), 8.01 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 
8.1 Hz, 2H), 7.83 (d, J = 8.5 Hz, 2H), 7.75 (s, 1H), 3.58 – 3.44 (m, 4H), 1.05 (t, J = 
7.0 Hz, 6H). 13C NMR (151 MHz, DMSO-d6) δ 162.85, 148.17, 141.92, 138.47, 
132.82, 130.30, 126.33, 123.75, 119.10, 117.48, 109.62, 107.96, 52.37, 9.96. HRMS 
(ES+) calculated for C20H21N4S [M + H]
+ 349.1481, found 349.1484. IR ṽ = 3050.8, 
2632.4, 2218.7, 1741.4, 1608.3, 1510.0 cm−1. 
N1,N1-diethyl- N4-(4-(4-methoxyphenyl)thiazol-2-yl)benzene-1,4-diamine, (51). 
1-(4-(diethylamino)phenyl)thiourea (0.146 g, 0.66 mmol, 1.00 equiv), commercially 
available 2-bromo-1-(4-methoxyphenyl)ethan-1-one (0.150 g, 0.66 mmol, 1.00 
equiv) and EtOH (0.80 mL) were added to a microwave vial. The vial was sealed, 
warmed to 100 °C and stirred under microwave irradiation (Biotage Initiator) for 30 
min. After cooling to r.t., the solid was filtered, washed with EtOH and with H2O 
and concentrated in vacuo to give the desired compound (0.060 g, 0.17 mmol, 26%) 
as a white solid without further purification. 1H NMR (600 MHz, CD3OD) δ = 7.78 
(d, J = 8.6 Hz, 2H), 7.48 – 7.40 (m, 2H), 6.94 (d, J = 8.6 Hz, 2H), 6.88 – 6.80 (m, 
2H), 6.75 (s, 1H), 3.82 (s, 3H), 3.37 – 3.33 (m, 4H), 1.14 (t, J = 7.0 Hz, 6H).13C 
NMR (151 MHz, DMSO-d6) δ = 164.51, 158.71, 149.92, 143.26, 130.74, 127.69, 
126.97, 119.69, 113.94, 112.78, 99.34, 55.15, 12.48. HRMS (ES+) calculated for 
C20H24N3OS [M + H]
+ 354.1635, found 354.1633. IR ṽ = 3173.3, 2971.8, 2932.2, 
1736.6, 1608.3, 1514.8, 1249.7 cm−1. 
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N1,N1-diethyl- N4-(4-(pyridin-2-yl)thiazol-2-yl)benzene-1,4-diamine, (52). 
1-(4-(diethylamino)phenyl)thiourea (0.119 g, 0.53 mmol, 1.00 equiv), commercially 
available 2-bromo-1-(pyridin-2-yl)ethan-1-one hydrobromide (0.150 g, 0.53 mmol, 
1.00 equiv) and EtOH (0.80 mL) were added to a microwave vial. The vial was 
sealed, warmed to 100 °C and stirred under microwave irradiation (Biotage Initiator) 
for 30 min. After cooling to r.t., Et2O was added and the resulting precipitate was 
filtered, washed with Et2O and with satd. aq. NaHCO3 and concentrated in vacuo to 
give the desired compound (0.130 g, 0.40 mmol, 75%) as a brown solid without 
further purification. 1H NMR (600 MHz, CD3OD) δ = 8.55 (d, J = 4.3 Hz, 1H), 8.13 
(d, J = 7.8 Hz, 2H), 8.00 – 7.89 (m, 3H), 7.53 (s, 1H), 7.48 – 7.39 (m, 1H), 7.36 (d, 
J = 4.3 Hz, 1H), 3.71 – 3.55 (m, 4H), 1.17 (t, J = 7.1 Hz, 6H). 13C NMR (151 MHz, 
DMSO-d6) δ = 177.07, 162.93, 151.30, 149.46, 148.78, 138.23, 129.45, 123.62, 
123.04, 120.82, 117.69, 52.64, 10.15. HRMS (ES+) calculated for C18H21N4S [M + 
H]+ 325.1481, found 325.1482. IR ṽ = 3242.7, 3045.1, 2971.8, 1593.9, 1514.8, 
1338.4 cm−1. 
N1,N1-diethyl-N4-(4-(pyridin-3-yl)thiazol-2-yl)benzene-1,4-diamine, (53).  
1-(4-(diethylamino)phenyl)thiourea (79.50 mg, 0.36 mmol, 1.00 equiv), 
commercially available 2-bromo-1-(pyridin-3-yl)ethan-1-one hydrobromide (100.00 
mg, 0.36 mmol, 1.00 equiv) and EtOH (0.50 mL) were added to a microwave vial. 
The vial was sealed, warmed to 100 °C and stirred under microwave irradiation 
(Biotage Initiator) for 30 min. After cooling to r.t., satd. aq. NaHCO3 was added and 
the mixture was extracted with EtOAc (x2). The combined organic extracts were 
washed with brine (x1), dried over Na2SO4, filtered and concentrated to give the 
desired compound (40.00 mg, 0.12 mmol, 35%) as a light brown solid without further 
purification. 1H NMR (600 MHz, DMSO-d6) δ = 9.87 (br s, 1H), 9.10 (s, 1H), 8.49 
(d, J = 4.6 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.48 – 7.42 (m, 3H), 7.36 (s, 1H), 6.70 
(d, J = 8.9 Hz, 2H), 3.30 (q, J = 6.8 Hz, 4H), 1.07 (t, J = 7.0 Hz, 6H). 13C NMR (151 
MHz, DMSO-d6) δ = 165.16, 148.29, 147.22, 146.97, 143.44, 132.73, 130.41, 
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130.35, 123.74, 119.93, 112.70, 103.11, 43.92, 12.46. HRMS (ES+) calculated for 
C18H21N4S [M + H]
+ 325.1481, found 325.1484. IR ṽ = 2967.0, 2922.6, 1736.6, 
1549.5, 1514.8, 1264.1 cm−1. 
N-(4-(diethylamino)phenyl)hydrazinecarbothioamide, (55). 
To a stirred solution of compound 54 (0.30 g, 1.45 mmol, 1.00 equiv) in EtOH (1.90 
mL), hydrazine hydrate (0.09 mL, 1.45 mmol, 1.00 equiv) was added. The solution 
became warm (a precipitate formed during the addition). The solution was stirred for 
30 min at r.t. Then, the precipitate was filtered, washed EtOH and concentrated in 
vacuo to give the desired compound (0.30 g, 1.27 mmol, 87%) as a white solid 
without further purification. 1H NMR (600 MHz, DMSO-d6) δ = 9.32 (brs, 1H), 8.84 
(br s, 1H), 7.23 (d, J = 8.7 Hz, 2H), 6.58 (d, J = 8.7 Hz, 2H), 4.67 (br s, 2H), 3.30 (q, 
J = 7.0 Hz, 4H), 1.07 (t, J = 7.0 Hz, 6H). 13C NMR (151 MHz, DMSO-d6) δ = 172.81, 
145.11, 127.48, 126.06, 111.29, 43.93, 12.59. HRMS (ES+) calculated for 
C11H18N4SNa [M + Na]
+ 261.1144, found 261.1146. 
N1,N1-diethyl-N4-(5-(pyridin-4-yl)-1,3,4-thiadiazol-2-yl)benzene-1,4-diamine, 
(56). 
To a solution of compound 55 (0.15 mg, 0.63 mmol, 1.00 equiv) in dry dioxane (3.50 
mL), isonicotinic acid (0.076 g, 0.63 mmol, 1.00 equiv) was added. The solution was 
heated at 90 °C and at this temperature POCl3 was added dropwise. After 3 h stirring 
the reaction was cooling to r.t. Then, satd. aq. NaHCO3 was added until pH = 7 and 
the mixture was extracted with EtOAc (x2). The combined organic extracts were 
washed with brine (x1), dried over Na2SO4, filtered and concentrated in vacuo. 
Purification by preparative TLC (70% EtOAc in hexanes) provided the desired 
compound as a brown solid. 1H NMR (600 MHz, DMSO-d6) δ = 10.32 (s, 1H), 8.66 
(d, J = 5.9 Hz, 2H), 7.76 (d, J = 5.9 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 6.69 (d, J = 
8.0 Hz, 2H), 3.31 (q, J = 5.9 Hz, 4H), 1.07 (t, J = 7.0 Hz, 6H). 13C NMR (151 MHz, 
DMSO- d6) δ = 167.36, 153.69, 150.66, 144.34, 137.57, 129.38, 121.07, 120.45, 
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112.42, 43.91, 12.51. HRMS (ES+) calculated for C17H19N5SNa [M + Na]
+ 348.1253, 
found 348.1255. IR ṽ = 2917.8, 1736.6, 1520.6 cm−1. 
N1,N1-diethyl-N4-(5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)benzene-1,4-diamine, 
(57). 
To a stirring solution of compound 55 (0.080 g, 0.34 mmol, 1.00 equiv) in 
dichloromethane (3.50 mL) isonicotinic acid (0.041 g, 0.34 mmol, 1.00 equiv), EDCI 
hydrochloride (0.190 g, 1.00 mmol, 3.00 equiv) and TEA (0.28 mL, 2.00 mmol, 6.00 
equiv) were added in order. The solution was stirred for 12 h at r.t. The mixture was 
diluited with dichloromethane and the organic extract was washed with H2O, dried 
over Na2SO4, filtered and concentrated in vacuo. Purification by preparative TLC 
(70% EtOAc in hexanes) provided the desired compound as a pale yellow solid. 1H 
NMR (600 MHz, DMSO-d6) δ = 10.39 (br s, 1H), 8.76 (d, J = 4.5 Hz, 2H), 7.78 (d, 
J = 4.5 Hz, 2H), 7.38 (d, J = 8.6 Hz, 2H), 6.70 (d, J = 8.6 Hz, 2H), 3.29 (q, J = 6.8 
Hz, 4H), 1.06 (t, J = 6.9 Hz, 6H). 13C NMR (151 MHz, DMSO-d6) δ = 161.24, 
155.91, 150.92, 143.81, 131.06, 127.17, 119.66, 119.19, 112.72, 43.99, 12.53. 
HRMS (ES+) calculated for C17H20N5O [M + H]
+ 310.1662, found 310.1664. IR ṽ = 
2971.8, 2932.2, 1741.4, 1628.6, 1514.8 cm-1. 
6.5.2. X-ray crystallography 
The single crystal X-ray diffraction studies were carried out on a Bruker Kappa 
APEX-II CCD diffractometer equipped with Mo Kα radiation (λ = 0.71073).  
Crystals of the subject compound were grown by dissolving approximately 5mg of 
sample in 3 drops of dimethyl sulfoxide, which was then vapor diffused with 
dichloromethane over one week. A 0.480 x 0.150 x 0.160 mm piece of a green block 
was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas 
stream at 100.0 K using ϕ and  scans. Crystal-to-detector distance was 40 mm using 
variable exposure time (4s) with a scan width of 0.70°. Data collection was 100% 
complete to 53° in . A total of 10847 reflections were collected covering the indices, 
 Design, synthesis and evaluation of N-aryl-2-aminothiazole derivatives as potential leads 
for the treatment of hereditary multiple exostoses 
191 
-9 ≤ h ≤ 11, -12 ≤ k ≤ 12, -13 ≤ l ≤ 13. 3483 reflections were found to be symmetry 
independent, with a Rint of 0.0290.  Indexing and unit cell refinement indicated a 
primitive, triclinic lattice. The space group was found to be P-1. The data were 
integrated using the Bruker SAINT software program and scaled using the SADABS 
software program. Solution by direct methods (SHELXL) produced a complete 
phasing model consistent with the proposed structure. A summary of the crystal data 
and structure refinement is presented in the tables below. 
Table 1. Crystal data and structure refinement for compound 6. 
Identification code 415 
Empirical formula C18H20N4S 
Formula weight 324.44 
Temperature/K 100.0 
Crystal system Triclinic 
Space group P-1 
a/Å 9.2551(13) 
b/Å 10.2414(15) 
c/Å 10.4509(14) 
α/° 82.199(4) 
β/° 66.091(4) 
γ/° 64.841(4) 
Volume/Å3 818.9(2) 
Z 2 
ρcalcg/cm3 1.316 
μ/mm-1 0.203 
F(000) 344.0 
Crystal size/mm3 0.48 × 0.16 × 0.15 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.268 to 53.474 
Index ranges -9 ≤ h ≤ 11, -12 ≤ k ≤ 12, -13 ≤ l ≤ 13 
Reflections collected 10847 
Independent reflections 3483 [Rint = 0.0290, Rsigma = 0.0301] 
Data/restraints/parameters 3483/0/210 
Goodness-of-fit on F2 1.034 
Final R indexes [I>=2σ (I)] R1 = 0.0361, wR2 = 0.0872 
Final R indexes [all data] R1 = 0.0439, wR2 = 0.0924 
Largest diff. peak/hole / e Å-3 0.46/-0.28 
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Table 2. Fractional Atomic Coordinates (×104) and Equivalent 
Isotropic Displacement Parameters (Å2×103) for compound 6. Ueq is 
defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom X y z U(eq) 
S1 6273.8(5) 4890.4(4) 6007.8(4) 16.20(11) 
N1 13152.6(19) 988.7(16) 7766.9(16) 28.8(3) 
N2 6900.8(16) 4172.5(12) 8270.7(12) 12.7(3) 
N3 3948.0(16) 5466.9(14) 8694.9(13) 16.6(3) 
N4 -1734.8(16) 8195.4(13) 7067.6(13) 15.4(3) 
C1 11591(2) 1147.0(17) 8729.7(18) 23.7(4) 
C2 10040(2) 2008.4(16) 8582.3(16) 17.6(3) 
C3 10079.0(19) 2767.8(15) 7365.4(15) 14.9(3) 
C4 11696(2) 2627.9(17) 6364.0(17) 20.4(3) 
C5 13166(2) 1740.2(19) 6612.7(19) 28.0(4) 
C6 8477.1(19) 3659.0(15) 7130.6(15) 13.5(3) 
C7 8399(2) 3954.6(16) 5849.7(16) 16.6(3) 
C8 5626.3(19) 4841.6(15) 7833.2(15) 13.1(3) 
C9 2564.7(19) 6141.2(16) 8212.8(15) 14.5(3) 
C10 2268(2) 7470.6(16) 7586.9(16) 16.8(3) 
C11 852.4(19) 8159.4(16) 7211.8(15) 16.2(3) 
C12 -347.3(18) 7547.3(15) 7471.4(14) 12.6(3) 
C13 -25.8(19) 6206.3(15) 8113.7(15) 14.6(3) 
C14 1412.2(19) 5515.4(15) 8455.6(15) 15.1(3) 
C15 -1993(2) 9528.1(16) 6310.9(16) 18.7(3) 
C16 -2848(2) 10894.7(17) 7228.1(19) 26.1(4) 
C17 -3128.7(19) 7696.6(16) 7580.0(16) 15.6(3) 
C18 -4264(2) 8028.3(17) 9130.5(16) 19.9(3) 
 
 
 
Table 3. Anisotropic Displacement Parameters (Å2×103) for compound 6. The 
Anisotropic displacement factor exponent takes the form: -
2π2[h2a*2U11+2hka*b*U12+…]. 
Atom U11 U22 U33 U23 U13 U12 
S1 14.0(2) 21.7(2) 12.44(18) 0.47(13) -7.10(14) -4.86(15) 
N1 18.6(8) 29.1(8) 35.5(8) 3.4(6) -15.3(7) -2.9(6) 
N2 11.6(6) 13.4(6) 13.7(6) 1.1(4) -6.5(5) -4.2(5) 
N3 11.4(6) 24.1(7) 11.3(6) 1.1(5) -5.4(5) -3.8(5) 
N4 13.4(6) 15.6(6) 20.0(6) 5.3(5) -9.5(5) -6.9(5) 
C1 22.3(9) 22.2(8) 25.2(8) 3.4(6) -13.5(7) -4.4(7) 
C2 15.7(8) 16.8(7) 18.5(7) -1.0(6) -7.2(6) -4.0(6) 
C3 14.3(7) 12.9(7) 18.0(7) -3.3(5) -7.6(6) -3.5(6) 
C4 16.5(8) 22.1(8) 19.2(8) 0.8(6) -5.8(6) -5.9(6) 
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C5 13.2(8) 31.8(9) 31.7(9) -0.1(7) -7.1(7) -3.7(7) 
C6 13.4(7) 12.2(6) 15.2(7) -0.9(5) -5.8(6) -4.8(5) 
C7 12.2(7) 20.1(7) 15.1(7) -1.1(6) -5.0(6) -4.2(6) 
C8 14.5(7) 13.3(7) 13.1(7) 0.6(5) -6.2(6) -6.2(6) 
C9 11.1(7) 18.3(7) 11.4(7) -1.4(5) -5.1(6) -2.5(6) 
C10 13.3(7) 19.9(7) 19.0(7) 1.7(6) -6.3(6) -8.6(6) 
C11 14.3(7) 15.0(7) 18.9(7) 4.7(6) -6.6(6) -6.6(6) 
C12 10.9(7) 13.8(7) 12.1(6) -0.2(5) -4.4(6) -3.9(5) 
C13 13.6(7) 15.0(7) 16.7(7) 1.2(5) -6.3(6) -7.0(6) 
C14 15.0(7) 13.4(7) 14.7(7) 2.4(5) -5.9(6) -4.3(6) 
C15 17.0(8) 18.5(7) 21.9(8) 6.6(6) -10.6(6) -7.2(6) 
C16 24.1(9) 19.9(8) 36.8(10) 1.9(7) -14.8(8) -8.6(7) 
C17 12.8(7) 15.5(7) 21.3(7) 1.6(6) -8.8(6) -6.3(6) 
C18 16.0(8) 19.7(8) 21.8(8) 0.6(6) -5.3(6) -7.3(6) 
       
 
 
Table 4. Bond Lengths for compound 6. 
Atom Atom Length/Å   Atom Atom Length/Å 
S1 C7 1.7292(16)   C3 C4 1.394(2) 
S1 C8 1.7532(14)   C3 C6 1.475(2) 
N1 C1 1.339(2)   C4 C5 1.384(2) 
N1 C5 1.338(2)   C6 C7 1.356(2) 
N2 C6 1.3905(19)   C9 C10 1.394(2) 
N2 C8 1.3171(18)   C9 C14 1.390(2) 
N3 C8 1.3457(19)   C10 C11 1.387(2) 
N3 C9 1.4305(18)   C11 C12 1.414(2) 
N4 C12 1.3807(19)   C12 C13 1.4105(19) 
N4 C15 1.4588(18)   C13 C14 1.384(2) 
N4 C17 1.4622(19)   C15 C16 1.520(2) 
C1 C2 1.389(2)   C17 C18 1.520(2) 
C2 C3 1.393(2)         
       
 
 
Table 5. Bond Angles for compound 6. 
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C7 S1 C8 88.67(7)   C6 C7 S1 110.57(11) 
C5 N1 C1 116.11(14)   N2 C8 S1 114.83(11) 
C8 N2 C6 110.01(12)   N2 C8 N3 123.84(13) 
C8 N3 C9 123.52(12)   N3 C8 S1 121.33(11) 
C12 N4 C15 120.99(12)   C10 C9 N3 121.45(14) 
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C12 N4 C17 120.55(12)   C14 C9 N3 119.69(13) 
C15 N4 C17 117.75(12)   C14 C9 C10 118.71(13) 
N1 C1 C2 124.13(15)   C11 C10 C9 120.85(14) 
C1 C2 C3 119.00(15)   C10 C11 C12 121.14(13) 
C2 C3 C4 117.39(14)   N4 C12 C11 121.95(13) 
C2 C3 C6 121.36(14)   N4 C12 C13 121.04(13) 
C4 C3 C6 121.24(14)   C13 C12 C11 116.96(13) 
C5 C4 C3 119.07(15)   C14 C13 C12 121.33(14) 
N1 C5 C4 124.28(16)   C13 C14 C9 120.99(13) 
N2 C6 C3 119.58(12)   N4 C15 C16 114.74(13) 
C7 C6 N2 115.91(13)   N4 C17 C18 114.70(12) 
C7 C6 C3 124.38(14)           
 
 
 
Table 6. Hydrogen Atom Coordinates (Å×104) and 
Isotropic Displacement Parameters (Å2×103) for 
compound 6. 
Atom X y z U(eq) 
H3 3687.4 5460.66 9603.74 20 
H1 11541.46 637.75 9566.28 28 
H2 8968.36 2079 9300.33 21 
H4 11787.51 3134.77 5522.93 24 
H5 14256.06 1659.08 5918.71 34 
H7 9375.16 3685.05 4985.68 20 
H10 3046.27 7910.61 7414.94 20 
H11 685.49 9057.64 6772.95 19 
H13 -812.14 5768.5 8315.68 18 
H14 1614.27 4599.54 8862.42 18 
H15A -2714.56 9607.42 5793.12 22 
H15B -853.94 9464.7 5611.57 22 
H16A -2925.54 11730.95 6636.8 39 
H16B -2155.33 10825.11 7757.86 39 
H16C -4013.26 11009.04 7880.64 39 
H17A -2611.22 6639.08 7396.44 19 
H17B -3870.01 8147.76 7037.58 19 
H18A -4903.72 9075.78 9306.12 30 
H18B -3536.23 7647.78 9677.16 30 
H18C -5084.32 7575.09 9407.72 30 
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Refinement model description 
Number of restraints - 0, number of constraints - unknown. 
Details: 
1. Fixed Uiso 
 At 1.2 times of: 
  All C(H) groups, All C(H,H) groups, All N(H) groups 
 At 1.5 times of: 
  All C(H,H,H) groups 
2.a Secondary CH2 refined with riding coordinates: 
 C15(H15A,H15B), C17(H17A,H17B) 
2.b Aromatic/amide H refined with riding coordinates: 
 N3(H3), C1(H1), C2(H2), C4(H4), C5(H5), C7(H7), C10(H10), C11(H11), C13(H13), 
 C14(H14) 
2.c Idealised Me refined as rotating group: 
 C16(H16A,H16B,H16C), C18(H18A,H18B,H18C) 
This report has been created with Olex2, compiled on 2018.04.26 svn.r3504 for OlexSys.  
 
6.5.3. Physicochemical properties determination 
pKa -value determination by potentiometric titration 
In this approach, an automated potentiometric titration technique using the Sirius T3 
system is applied. Typically, 3 titration experiments are performed with a varying 
mixture of aqueous to organic media (typical mixtures contain approx. 45, 50 and 
55% of organic solvent). As the amount of organic solvent affects the measured pK-
values only so called apparent pKa-values (psKa) are obtained. The pure aqueous 
pKa can be deduced by extrapolation of the psKa values to 0% organic solvent using 
the so called Yasuda & Shedlovsky extrapolation. Standard deviation for this type of 
pKa-value determination is in the range of ± 0.1 log unit for all measured 
compounds. 
pH-dependent lipophilicity profile determination by potentiometric titration 
For compounds with ionisable groups the partition coefficient between an organic 
solvent and an aqueous phase depends strongly on the pH of the aqueous media. A 
full pH-dependent lipophilicity profile can be measured using also the Sirius T3 
equipment. Prerequisite for this technique is the knowledge of the ionization 
behaviour (pKa -values) of the respective compound, e.g. measured ideally also 
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using the Sirius T3 equipment. In this approach the apparent partition coeffcient is 
determined by performing potentiometric titrations experiments similarly to the ones 
described above except that an organic solvent is used which is immiscible with the 
aqueous phase. The partition coeffcient between n-octanol and aqueous media is 
collected. The pH-dependent partition coeffcient can be deduced from the observed 
shifts of the apparent psKa-values in comparison to the pure aqueous pKa-values. 
Standard deviation for this type of log P – value determination is in the range of ± 
0.1 log unit for all measured compounds. 
Solubility determination by Chasing Equilibrium Solubility method 
The kinetic and thermodynamic solubilities were measured by the potentiometric 
Chasing Equilibrium Solubility method.5 The substance was dissolved and titrated 
until a precipitate of neutral species was formed. Under this condition, the compound 
is supersaturated with respect to the neutral species solubility. The solution was then 
back titrated until the substance started dissolving again. The state with dissolving 
substance is denoted as subsaturation. The change between the subsaturated and 
supersaturated state was repeated several times to determine the substance 
thermodynamic solubility by interpolation. The intrinsic solubility was calculated 
using the principles of mass and charge balance at the pH where the equilibrium of 
the system was reached. 
6.5.4. Biological assay 
Compound Treatment and FGF2 Binding 
Wild-type CHO cells (ATCC CCL-61) were grown in F12 growth medium 
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 μg mL−1 of 
streptomycin sulfate, and 100 units per mL of penicillin G. Cells were plated at 
30,000 cells/well in 6-well plates and let adhere overnight. The media was replaced 
with specific concentrations of each compound (0, 5, 10, or 15 µM) diluted in 
complete F12 media and incubated for 3 days at 37°C. Next, the media was removed, 
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cells were lifted with Cell Dissociation Buffer (Gibco) and washed twice with cold 
PBS buffer (+ 0.1% BSA). Biotinylated FGF2 (1.25 nM, Peprotech) was added and 
incubated for 30 min on ice. Cells were washed, and bound biotinylated protein was 
detected by using streptavidin-PE-Cy5 (1:1000, BD Biosciences) and flow 
cytometry (FacsCalibur, BD Biosciences). Raw data was interpreted using FlowJo 
Analytical Software (Tree Star Inc.). Protein binding was quantified by the geometric 
mean of the fluorescence intensity. These values were plotted and further analyzed 
using GraphPad Prism v5.0. 
Stock solutions were made for each compound in DMSO (10 mM). For each 
experiment, the stock solutions were diluted first to 10 mM DMSO, then the 
appropriate serial dilutions were made in complete F12 media. Stock solutions were 
made and stored in glass containers at −20 °C. 
35S04 Radiolabeling Experiments 
Wild-type CHO cells were plated at 30,000 cells/well in 6-well plates and let adhere 
overnight. The media was replaced with 10 µM of each compound diluted in F12 
media (+10% FBS, 100 units/mL penicillin G) and radiolabeled for 3 days by 
supplementing the media also with 10 µCi/ml Na[35S]O4 (PerkinElmer Life Science). 
The media was collected to analyze secreted GAGs and cells were washed in PBS 
and incubated in 0.05% trypsin-EDTA to lift the cells and release cell surface 
proteoglycans. Cell pellets were lysed in 0.1N NaOH and used to measure protein 
concentration by BCA assay. Secreted GAG chains were extracted from the collected 
media and from cell surface GAGs through exhaustive digestion with Pronase 
(Sigma-Aldrich) in phosphate-buffered saline at 37 °C for 16 h followed by anion-
exchange chromatography (DEAE-Sephacel, GE Healthcare). All preparations were 
desalted by gel filtration (PD-10, GE Healthcare). Total GAG amount was quantified 
from the media and cell surface fractions by taking an aliquot and measuring 
radioactivity by scintillation counting.  
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Heparan sulfate (HS) and chondroitin sulfate (CS) in the secreted media and on 
the cell surface were quantified by digestion with 2 milliunits of heparin lyases I, II, 
and III for 16 h at 37 °C in 240 μl of buffer containing 40 mM ammonium acetate 
and 3.3 mM calcium acetate, pH 7.0, or for 16 h at 37 °C with 20 milliunits of 
chondroitinase ABC (AMSBio) in 100 μl of buffer containing 50 mM Tris and 50 
mM sodium chloride, pH 8.0. Following digestion, GAGs were purified by an 
additional anion-exchange chromatography (DEAE-Sephacel) and desalting (PD-
10) step prior to quantification of radioactivity by scintillation counting. Results are 
expressed as [35S]O4 counts per microgram of protein quantified by Pierce BCA 
protein assay (Thermo Fisher). 
 
6.5.5. Appendix 
1H NMR (DMSO-d6) of compound 6 
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Report for multiset pKa determination of compound 6 
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Report for multiset pH-metric logP determination of compound 6 
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Report for solubility determination of compound 6 
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7.1. Conclusions and outlook 
During my PhD program, I have exploited various methods of organic synthesis 
(i.e. click chemistry, multicomponent reactions and traditional chemistry) for the 
discovery of small molecules of therapeutic relevance. In particular, several 
ambitious medicinal chemistry programs for targeting unconventional and not yet 
drugged targets and diseases have been undertaken and presented in this thesis. 
Primarily, in Chapter 3, a novel class of compounds able to finely tune the SOCE 
mechanism that include both positive and negative modulators have been developed 
using a click chemistry approach. In addition, a SAR study focused on a selected 
inhibitor led to the identification of two promising molecules, 23 and 31 (Figure 1), 
that (a) do not display cytotoxicity up to 100 µM, (b) are able to reduce SOCE in the 
low micromolar range, (c) do not display activity on voltage-operated calcium 
channels (VOCC), TRPV1 and TRPM8 channels, (d) are more hydrolytically and 
metabolically stable in respect to the parent compound 1S.  
 
 
Figure 1. Chemical structures of Pyrtriazoles 23 and 31. 
Promisingly, compounds 23 and 31 were shown to be effective in restoring 
calcium entry to control levels ex vivo in myotubes of muscle biopsies from patients 
affected by TAM, while compound 31 proved to be effective in an animal model of 
acute pancreatitis. Administration of 31 showed a reduction of edema and 
inflammation in pancreatic tissues. Moreover, a transgenic mouse model displaying 
one of the mutations behind TAM disease is being characterized and a Pyrtriazole 
compound will be selected for in vivo studies. Overall, these results pave the way for 
the treatment of human disorders characterized by aberrant SOCE activity. Ongoing 
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studies in our laboratory are aimed at proving the reliability of this kind of approach, 
demonstrating that the isosteric replacement of the arylamide substructure with the 
a 1,4-disubstituted 1,2,3-triazole ring can be applied to other classes of SOCE 
inhibitors reported in the literature and, at the same time, can lead to the identification 
of compounds that do not display the ester moiety.  
Regarding the development of IDO1 inhibitors for cancer immunotherapy, 
described in Chapter 4, starting from a common isocyanide intermediate, we 
exploited the Passerini and the Ugi multicomponent reactions to develop a small 
library of inhibitors that target IDO1. Unfortunately, despite the most active 
compounds (6n and 7g, Figure 2) display activities at the sub-micromolar level and 
a full biocompatibility, a significant discrepancy between the enzymatic and the 
cellular inhibition was observed, suggesting that the low cell permeability might be 
related to imidazothiazole scaffold owned by this class of compounds.  
 
 
Figure 2. Chemical structures of imidazothiazole compounds 6n and 7d. 
Nevertheless, molecular docking studies suggest that the presence of an additional 
pocket, that we named C, in the active site of the enzyme might be exploited in the 
design of IDO1 inhibitors. This discovery provides a new direction for future 
developments. Indeed, this information was integrated in a structure-based virtual 
screening that has allowed us to identify a promising hit 1, bearing a benzimidazole 
scaffold, with an IC50 value against IDO1 in a cell-based assay of 16 nM (Figure 3).  
From the SAR study performed by synthesizing a small library of 24 analogues, 
compound 60 emerged with an inhibitory activity against IDO1 in a cell-based assay 
comparable to the hit (Figure 3).  
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Figure 3. Chemical structure of the hit 1 and structural analogue 60. 
 
Promisingly, a computational analysis showed that that pocket C is also present 
in the active site of IDO2 and TDO and that this class of molecules might be 
accommodated in all these three dioxygenases active site. This is of high 
significance, as the development of dual/pan IDO1/IDO2/TDO inhibitors might 
deepen efficacy, limit acquired resistance to IDO1 blockade and reduce autoimmune 
side effects of immunotherapy. Therefore, studies addressed to evaluate the 
selectivity of the selected compounds, depicted in Figure 3, over IDO2 and TDO are 
ongoing in our laboratory. Yet, their metabolic profile will be investigated, with the 
aim of selecting the most promising compound and evaluating it in in vivo proof-of-
concept studies. 
 Lastly, a project aimed at identifying compounds that enhance HS formation as 
a therapeutic strategy to prevent initiation or retard the growth of exostoses in HME 
disease has been performed. In particular, a screening of a compound library of 
~57,000 molecules in a phenotypic assay that monitors HS levels on the plasma 
membrane of CHO cells identified a promising hit from the N-aryl-2-aminothiazoles 
class. Preliminary SAR and SPR studies have been conducted to (a) confirm/validate 
the biological activity; (b) identify new biologically active analogues; and (c) 
determine key physicochemical properties of representative compounds of interest. 
The SAR study, which was based on the synthesis and evaluation of a focused library 
of 23 derivatives, identified two analogues, 33 and 35 (Figure 4), with comparable 
activity as the primary hit. Characterization of selected physicochemical properties, 
such as pKa, logD7.4, and water solubility of the most promising compounds suggests 
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that compounds of this type may be considered promising starting points towards the 
development of probes suitable for in vivo testing. Ongoing studies are directed 
towards the expansion of the SAR studies and the identification of a preferred 
candidate compound for in vivo proof-of-concept studies. In addition, future studies 
will be focused on the identification of the biological target(s) of 415 and related 
compounds.  
 
Figure 4. Chemical structure of the hit compound 415 and structural analogues 33 and 35. 
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